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Summary 
Trematodiases affect more than 250 million people worldwide, while the economic impact through veterinary 
infections is also colossal. Treatment options are however limited to two main drugs, triclabendazole for the liver 
fluke Fasciola hepatica, and praziquantel (PZQ) for the rest of the trematodes including schistosomes, the 
etiological agent of bilharziosis. Furthermore, the kinetic disposition of PZQ is hardly studied in diseased patients 
and lacking in pre-school children, where the burden of schistosomiasis is already high. The aim of the present 
thesis is to provide pharmacokinetic and pharmacological studies to understand the modalities of PZQ disposition 
in patients. Additionally, the efficacy of two novel synthetic peroxide lead candidates are evaluated against F. 
hepatica in sheep and supported by a pharmacokinetic (PK) study.  
We first validated an analytical method to assess the PK profile of the synthetic peroxides OZ78 and MT04 in 
sheep plasma and bile. After an intramuscular administration of a 100 mg/kg dose to groups of 5 sheep naturally 
infected with F. hepatica, we observed a good fasciocidal efficacy for the peroxide candidate MT04, while the 
other candidate, OZ78, failed to display any activity. The PK study did not reveal a higher kinetic disposition for 
MT04 than for OZ78, but highlights problems in drug absorption. The presence of both peroxide candidates in 
sheep bile at 6 h post-treatment does not rule out a direct drug action on the worm tegument.  
We recorded a high antischistosomal activity for the R enantiomer of PZQ against S. mansoni adults and NTS in 
vitro with IC50 values below 0.04 µg/ml. The S form displayed a very limited effect in vitro. It produced in vivo 
an important and transient shift of the worms to the liver but at 24 h after S-PZQ administration, the worms had 
returned to the mesenteric veins. The R forms of the main metabolites in mice and humans, cis- and trans-4-OH, 
exhibited a moderate activity. In vivo, mice harbouring adult S. mansoni were cured with a 200 mg/kg dose, half 
of the curative dose required with racemic PZQ. Treatment with a 800 mg/kg dose of S-PZQ failed to display a 
significant effect.  
In order to undertake PK studies, we validated an enantioselective method for PZQ and its main metabolite, R-
trans-4-OH-PZQ, in blood, plasma and dried blood spots (DBS) using an analytical range from 0.01 to 2.5 µg/ml 
for R- and S-PZQ and from 0.1 to 25 µg/ml for the metabolite. The comparison of blood, plasma and DBS samples 
simultaneously withdrawn from 9 patients infected with the liver fluke Opisthorchis viverrini and treated with 3x 
25 mg/kg PZQ allowed us to evaluate the potential of DBS as unique sampling method in future PK trials. Due 
to the high affinity of PZQ for plasma albumin, samples using whole blood displayed slightly lower concentrations 
of the parent enantiomers than plasma measurements. This difference is however small and within an acceptable 
range. For the metabolite, plasma concentrations did not display significant differences to blood or DBS levels. 
Therefore, DBS was validated as an alternative to plasma sampling. The PK profile of the 9 patients investigated 
in this study was discussed on the basis of plasma PK data. We observed plasma AUCs of 1.1, 9.0 and 188.7 
µg/ml*h and half-lives of 1.1, 3.3 and 6.4 h for R-PZQ, S-PZQ and R-trans-4-OH, respectively. Maximal plasma 
concentrations of 0.2, 0.9 and 13.9 µg/ml for R-PZQ, S-PQZ and R-trans-4-OH peaked at 7 h for PZQ enantiomers 
and 8.7 h for the metabolite. The high levels of the R form of the main metabolite of PZQ do not rule out its 
participation in the opisthorchicidal effect of the drug.  
In conclusion, we identified MT04 as a potential fasciocidal candidate. We also generated precise in vivo and in 
vitro data on the sensitivity of S. mansoni to PZQ enantiomers and confirmed that the eutomer of PZQ is its R-
form. The LC-MS/MS method for praziquantel enantiomers allows to use DBS in future clinical trials, therefore 
enabling the sampling of children and the planning of larger PK trials. Finally, we presented the first PK values 
of PZQ enantiomers and its main metabolite in patients suffering from opisthorchiasis.  
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1.1 Trematode biology and life cycle 
Trematodes, together with cestodes and monogenes, 
are part of the phylum Platyhelminthes. They are 
characterised by the adoption of molluscs as 
intermediate hosts and are further divided into two 
subclasses, the Apidogastrea and the Digenea. While 
the former is mainly composed of fish parasites, the 
latter constitutes the largest group of internal 
metazoan parasites with around 18’000 species and 
are present in all the classes of vertebrate hosts (Cribb 
et al., 2003; Olson et al., 2003).  
The life cycle of digenetic trematodes has typical 
features. First, the eggs produced by adult worms 
embryonate, releasing miracidia that infect molluscs, 
in particular gasteropodes. In this first intermediate 
host, they undergo one or several cycles of asexual 
reproduction and eventually infect a second 
intermediary host. Access to the definitive host is 
mediated either by active penetration of free-
swimming cercaria or by passive ingestion of encysted 
cercariae (metacercariae) (Cribb et al., 2003; 
Kostadinova and Perez-del-Olmo, 2014).  
Digenetic trematodes also share distinctive 
morphological traits. They possess two suckers: an 
oral sucker and a ventral one, also called acetabulum. 
Excluding schistosomes, most of the trematodes are 
hermaphroditic. Their digenetic tegument is syncytial 
and contains vesicles that might be involved in the 
renewal of the tegument in case of damage. Digenes 
have a digestive caecum, either syncytial or cellular, 
which secretes a wide range of proteolytic enzymes. 
The excretory system is composed of protonephridia 
(flame cells) that remove the metabolic waste, such as 
urea, uric acid or ammonia, through an excretory pore, 
usually at the posterior end of the worm. Waste 
products can also be eliminated via diffusion through 
the tegument (Beaumont and Cassier, 1973; 
Kostadinova and Perez-del-Olmo, 2014).  
1.1.1 Food-borne trematodes 
Food-borne trematodes comprise parasites of great 
veterinary and human importance, such as the liver 
flukes (Fasciola spp., Opisthorchis spp., Clonorchis 
sinensis), the intestinal flukes (Echinostoma spp., 
Fasciolopsis buski, the family Heterophyidae) and the 
lung flukes (Paragonimus spp.). The two species of 
interest in the frame of this thesis are F. hepatica and 
O. viverrini. While infection with O. viverrini occurs 
by the consumption of raw fish, F. hepatica 
metacercariae can be ingested by the consumption of 
water plants or contaminated water. Liver flukes dwell 
in the biliary ducts of the definitive host and can 
survive there for up to 25 years (Keiser and Utzinger, 
2009). 
 
Fig. 1 The life cycle of Opisthorchis viverrini and Fasciola hepatica: the adult fluke in the bile ducts produces eggs that embryonate to 
miracidia. They infected a gasteropode, which will later shed cercariae that will encyst as metacercariae in fish or plants. 
	 3  
The genus Fasciola comprises two major species of 
human and veterinary interest, F. hepatica and F. 
gigantica, easily differentiated by their morphology. 
F. hepatica is shorter and stocky, with a length of 3 
cm, while F. gigantica is even longer (5 cm) but 
narrower. O. viverrini adult worms are smaller, ca. 1 
cm, and can be distinguished from O. felineus and C. 
sinensis by the morphology of the testes. However, 
microscopic discrimination of the eggs from the two 
co-endemic species O. viverrini and C. sinensis is 
problematic (Kaewkes, 2003; Keiser and Utzinger, 
2009; Mas-Coma, Valero and Bargues, 2014). Adult 
liver flukes display a tegument covered by a 
glycocalyx that can reach a thickness of 20 nm in F. 
hepatica (Threadgold, 1976). The composition of the 
glycocalyx might be the reason to the PZQ higher 
resistance of F. hepatica and to some extent of 
Paragonimus spp (Andrews et al., 1983). Liver flukes 
are generally considered as blood-feeding parasites, as 
blood can be found in their gut content (Todd and 
Ross, 1966; Sukhdeo, Sangster and Mettrick, 1988). 
The exact composition of their diet is however not 
known and might be more varied than initially 
anticipated (Dawes, 1963). For example, the genome 
of O. viverrini revealed that it is equipped to digest not 
only blood but also bile components, mainly lipids, 
and cholangiocytes (Young et al., 2014). A major 
difference between F. hepatica and O. viverrini is how 
they reach the biliary ducts. F. hepatica juveniles feed 
extensively on liver parenchyma, while O. viverrini 
arrives to the liver by the ampulla of Vater (Sripa et 
al., 2010), hence eliciting a much lower immune 
reaction from the host (Bae et al., 2013).  
1.1.2 Schistosomes  
Schistosomes, or blood flukes, are the only non-
hermaphroditic trematodes. The elongated male 
measures around 1 cm and forms a groove, the 
gynecophoral canal, in which the female is nested. The 
pairing of the worms is essential, because females 
reach full maturity only in close contact with males. 
Paired schistosomes produce in Asian species up to 
thousand eggs per day, which are evacuated via the 
faeces or the urine. The first intermediate host is a 
gasteropode that will release free-swimming 
cercariae, able to actively penetrate the skin of the 
definitive host, mostly humans. Immature worms 
travel to the lungs and then finish their development in 
the portal vein. Worm pairs will finally settle in the 
mesenteric or perivesicular veins, where they can live 
more than 10 years (Utzinger and Keiser, 2004; 
Gryseels et al., 2006)
 
Fig. 2 The life cycle of Schistosoma mansoni: the adult fluke in the mesenterial veins produces eggs that will pass through the vein epithelia 
and liver, out to the intestinal tract. Once expelled with the faeces, the eggs will embryonate to miracidia. They infected a gasteropode, which 
will later shed cercariae that will actively penetrate the skin of the definitive host. 
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To optimise nutrient absorption and manipulation of 
host defences, schistosomes developed a highly 
specialised tegument, fundamentally different from 
the food-borne trematode tegument. The schistosome 
double lipid bilayer is also described as a simple 
plasma membrane covered by a membranocalyx or 
heptalaminated tegument and is not present in 
cercariae (Hockley, 1972). The absorption of glucose 
through the tegument is facilitated by numerous 
glucose transporters. Schistosomes actually consume 
every 5 h the equivalent of their own dry weight in 
glucose (Faghiri et al., 2010; Da’dara et al., 2012). 
Their high requirements in amino acids are met by the 
digestion of erythrocytes, mediated by a battery of 
cathepsin enzymes. Erythrocytes will also supply the 
parasite with erythrocyte-derived antigens to be 
displayed on the worm surface to avoid immune 
response (Saunders, Wilson and Coulson, 1987; Han 
et al., 2009). 
	 5  
1.2 Epidemiology and clinical aspects  
1.2.1 Fascioliasis 
Fascioliasis is a zoonosis occurring in a vast variety of 
mammal hosts, such as sheep, pigs, buffaloes, horses, 
camels, rabbits or rodents and is linked to intensive 
farming activities. F. hepatica is present worldwide, 
while the repartition of F. gigantica seems to be 
limited to Asia and Africa (Toledo, Esteban and Fried, 
2012; Mas-Coma, Valero and Bargues, 2014). 
Fascioliasis affects more than 2 million people, a 
number certainly underestimated (Fürst, Keiser and 
Utzinger, 2012; Mas-Coma, Valero and Bargues, 
2014). In humans, the consumption of contaminated 
water or water plants on which metacercariae encyst is 
the cause of the infection (Mas-Coma, Valero and 
Bargues, 2014).  
The first phase of the disease is asymptomatic and can 
vary between a few weeks to months. The acute phase 
corresponds to the migration of immature flukes 
through the hepatic parenchyma and is characterized 
by allergic reactions, abdominal pain, fever, vomiting 
or diarrhoea. During the chronic phase, adult worms 
induce biliary cholitis, jaundice, bile duct hyperplasia, 
inflammation, and cholangitis accompanied with 
biliary obstruction. Haemorrhages into the bile duct 
are also common and can lead to severe anaemia and 
even death, especially in sheep and young cattle (Sripa 
et al., 2010; Mas-Coma, Valero and Bargues, 2014).
Fig. 3 The distribution of fascioliasis in 2014 (scheme from the World Health Organization, 2015) 
 
1.2.2 Opisthorchiasis 
The liver fluke O. viverrini infects more than 8 million 
people principally in Thailand, Lao PDR and 
Cambodia, with its focal point in the lower Mekong 
basin (Sithithaworn and Haswell-Elkins, 2003; Fürst, 
Keiser and Utzinger, 2012). The prevalence is highly 
variable between regions and can rise up to more than 
80% in school children (Lovis et al., 2010). Also, 
cases of reinfection are important, with prevalence 
rates attaining their original level only one year after 
treatment (Upatham et al., 1988; Organization, 2015). 
The infection occurs by the consumption of raw or 
undercooked fish, a common practice in regions where 
the use of fermented fish is part of many traditional 
dishes. For example, koi pla, a dish made of thin cut 
raw fish mixed with spices, vegetables and lemon 
juice, is very popular among fishers and farmers 
(Grundy-Warr et al., 2012). This strong cultural 
behaviour at the basis of infection is enhanced by the 
high prevalence of infected fish. Also, cats and dogs 
have been identified as reservoirs, and are therefore 
maintaining the infection cycle close to human homes 
despite the global effort of sanitation (Sithithaworn et 
al., 2012). The disease in its chronic state can be 
devastating: periductal fibrosis, bile duct hyperplasia, 
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jaundice, choleocystitis, and cholangiocarcinoma with 
consecutive renal failure (Sripa, 2003; Sripa et al., 
2011). O. viverrini and the other Asian liver fluke C. 
sinensis are identified since 1994 as type-1 
carcinogens (Andrews, Sithithaworn and Petney, 
2008).  
Fig. 4 The distribution of opisthorchiasis in 2014 (scheme from the World Health Organization, 2015) 
 
1.2.3 Schistosomiasis  
There are worldwide more than 200 million people 
suffering from schistosomiasis and more than 700 
million at risk of infection (Steinmann et al., 2006; 
Utzinger et al., 2012). Three main schistosome species 
are of epidemiological and clinical importance: S. 
mansoni, found in Africa, the Arabian Peninsula and 
South America, S. haematobium in Africa and the 
Arabian Peninsula, and S. japonicum in China, the 
Philippines and Indonesia. The other two species 
parasitizing humans are S. intercalatum, restricted to 
west and central Africa, and S. mekongi in the Mekong 
basin (Utzinger and Keiser, 2004; Gryseels et al., 
2006). S. haematobium is responsible of urinary 
schistosomiasis. The adult worms live in the veins 
around the urinary bladder, and the eggs on their way 
out produce inflammation and ulcerations of the 
bladder wall. Chronic patients will display fibrosis and 
calcification of the bladder. Infections with S. 
haematobium are also an established risk factor for 
bladder cancer. The other schistosome species dwell 
in the mesenteric veins with eggs migrating either 
through the liver and inducing liver fibrosis and 
hepatomegaly, or through the intestinal wall 
generating inflammations and mucosal lesions 
(Gryseels et al., 2006). Genital schistosomiasis, 
caused by S. haematobium and S. mansoni, is linked 
to an enhanced risk of transmitting other sexual 
infections, such as HIV (Gryseels et al., 2006; 
Kjetland et al., 2006).  
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Fig. 5 The distribution of schistosomiasis in 2014 (scheme from the World Health Organization, 2015) 
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1.3 Chemotherapy against trematodes 
1.3.1 Current drugs 
Praziquantel (PZQ), first designed as a potential 
tranquilizer, rapidly became the major drug against 
trematode infections (Leopold et al., 1978; Cioli and 
Pica-Mattoccia, 2003). It has been the pillar of 
schistosomiasis mass drug administration for over 30 
years: for example in 2013, 181 million tablets were 
donated to assure schistosomiasis control (World 
Health Organization, 2015). The dose recommended 
against schistosomes is 40 mg/kg (World Health 
Organization, 2006). PZQ is also the drug of choice 
against clonorchiasis, opisthorchiasis and 
paragonimasis, while F. hepatica is completely 
refractory to the treatment (Cioli and Pica-Mattoccia, 
2003; Keiser, Duthaler and Utzinger, 2010). Adverse 
events after treatment with PZQ are mild and limited 
to the first 24 h post-administration, with the intensity 
of infection probably playing a role in their advent. 
Due to its excellent safety profile, PZQ can be 
administered to pregnant and lactating women (Cioli 
and Pica-Mattoccia, 2003). Its mode of action is still 
not completely unravelled, but seems to involve the 
Ca2+ channels of the worm (Doenhoff, Cioli and 
Utzinger, 2008). The main drawback of PZQ is its 
complete lack of activity against juvenile 
schistosomes. PZQ susceptibility occurs in cercariae 
and in schistosomula until their 2nd week of maturation 
in the mouse. Three- and four-week juveniles are 
refractory, while adults from the 6th week on are again 
fully susceptible to the drug (Sabah et al., 1986). 
Therefore, to achieve a complete worm burden, a 
second line of treatment a few weeks later is 
recommended (Utzinger et al., 2000; Utzinger and 
Keiser, 2004). Cases of treatment failure have been 
observed, but it is uncertain whether they arise from 
worms developing resistance to PZQ or from an 
incomplete elimination of juvenile worms (Doenhoff, 
Cioli and Utzinger, 2008).  
PZQ is a chiral drug extensively metabolised by the 
liver enzyme CYP4503A4 (Li et al., 2003). The R- 
enantiomer is mainly converted to the 
monohydroxylated R-trans-4-OH in humans, while S-
PZQ generates a wider variety of metabolites (Lerch 
and Blaschke, 1998; Meier and Blaschke, 2001). R-
PZQ is commonly considered to retain the 
antischistosomal activity of the drug (Wu et al., 1991; 
Staudt et al., 1992; Liu et al., 1993). S-PZQ, on the 
other hand, would be responsible of most of the 
adverse events (Wu et al., 1991) and the extremely 
bitter taste of the racemic formulation (Meyer et al., 
2009; Olliaro, Delgado-Romero and Keiser, 2014). 
There is a strong incentive to develop a paediatric 
formulation for PZQ to target pre-school children, 
who are currently excluded from mass drug treatments 
against schistosomiasis (World Heatlh Organization, 
2006; Stothard et al., 2013; Mutapi, 2015). PZQ 
treatment is to date available for a price of around 0.20 
USD; hence, a final price of 0.40 USD for the 
enantiomeric formulation is an ideal goal that is still to 
be met (Woelfle et al., 2011).  
 
 
Fig. 6 The enantioselective metabolism of PZQ with the chiral centre highlighted with a circle 
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The fasciocidal drug triclabendazole is routinely used 
in veterinary medicine but is currently only registered 
in four countries for human use (Egypt, Ecuador, 
Venezuela and France). Triclabendazole displays 
activity against both immature and mature worms, but 
its spectrum is restricted to fascioliasis and eventually 
paragonimiasis. Successful treatment with 
triclabendazole is achieved in humans with an oral 
dose of 10 mg/kg that can be repeated in heavy 
infection cases (Keiser and Utzinger, 2009). 
Resistance has been reported since the mid-1990s in 
veterinary medicine in Australia and more recently in 
several countries of Western Europe as well 
(Fairweather, 2009). Bithionol is another marketed 
fasciocidal drug, but its use has been restricted to 
particular cases of triclabendazole failure because of 
its lengthy treatment (Keiser and Utzinger, 2009).  
Other schistocidal drugs, as oxamniquine or 
metrifonate, have been abandoned with the advent of 
PZQ. Oxamniquine presented the major disadvantage 
to be active only against S. mansoni. Hence, its was 
mainly used in Brazil (Utzinger and Keiser, 2004; 
Danso-Appiah et al., 2008). Metrifonate, on the other 
hand, is only active against S. haematobium. These 
drugs might however be interesting in combination 
chemotherapy (Kramer et al., 2014). 
1.3.2 Alternative treatment candidates 
Artemisinin, a sesquiterpene lactone containing a 
peroxidic group, is a molecule extracted from the 
leaves of the shrub Artemisia annua. This plant was 
known in the traditional Chinese pharmacopoeia for 
its therapeutic effect against fevers since 340 AD, and 
specifically for treating malarial fevers since 1596. 
The isolation and identification of the active 
compound in 1972 confirmed its broad antimalarial 
efficacy, even against chloroquine-resistant parasites. 
To optimise its antimalarial activity, the semi-
synthetic analogues artemether and the water-soluble 
artesunate have been produced and successfully 
tested, although displaying a higher toxicity than 
artemisinin itself (Klayman, 1985; White, 2008). Due 
to high production prices, the treatment with semi-
synthetic artemisinins remains above the financial 
means of many patients, who could already hardly 
afford chloroquine treatment. Also, long treatment 
schedules make patient compliance difficult (White, 
2008). Most of the antimalarial activity of artemisinin 
is centred on the peroxidic bond, which is supposed to 
react with iron during haemoglobin digestion to 
produce reactive oxygen species (Vennerstrom et al., 
2004; Jefford, 2007). Therefore, fully synthetic 
peroxide analogues were tested (Vennerstrom et al., 
2004; Jefford, 2007), of which the trioxolane OZ439 
was successfully brought to a first-in-man trial at a 
single oral dose (Moehrle et al., 2013). 
Fig. 7 Chemical structures of arteminisin (A), the semi-synthetic artemisinins artemether (B) and artesunate (C), and the synthetic peroxides 
OZ78 (D), OZ418 (E) and MT04 (F) 
A  
 
B  
 
C  
 
D  
 
 
 
E
 
 
 
 
F  
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The high antimalarial potency of semi-synthetic 
artemisinins and synthetic peroxides lead researchers 
to investigate its activity against other parasites. For 
example, the trioxolane ozonids OZ78 and OZ418 
exhibited encouraging effects in rodents against 
juvenile and adult Schistosoma spp (Xiao et al., 2007; 
Xiao, Mei and Jiao, 2011; Keiser et al., 2012; Xue et 
al., 2014). Scaffold optimisations are currently under 
way to improve and stabilise schistocidal activites 
(Cowan et al., 2015). OZ78 was also successfully 
tested in rats harbouring F. hepatica, E. caproni and 
C. sinensis (Keiser et al., 2006; Keiser, Xiao, et al., 
2007; Keiser et al., 2007). The fasciocidal effect of 
OZ78 seemed however to be limited to rats, since 
subcutaneous or oral treatment of infected sheep did 
not achieve any worm burden reduction (Keiser et al., 
2008). Combination chemotherapies with PZQ and 
tribendimidine were explored in C. sinensis, but the 
same combinations with semi-synthetic artemisinins 
still show comparatively better results (Keiser and 
Vargas, 2010). Recently, the synthetic tetraoxane 
MT04 displayed even higher fasciocidal effects than 
OZ78 in vitro and in vivo in rats (Kirchhofer et al., 
2011).  
 
 
Tribendimidine, a derivative of amidantel, was 
synthesized in China in 1983, where it is approved for 
human use against soil-transmitted helminths 
(Utzinger and Keiser, 2004; Xiao et al., 2013). It 
displayed a high efficacy against C. sinensis and O. 
viverrini in rodents. However, it was not active against 
S. mansoni and F. hepatica (Keiser, Shu-Hua, et al., 
2007). In the frame of a phase 2a clinical trial, school 
children infected with O. viverrini were treated with 
the standard dose of PZQ or tribendimidine at the 
recommended oral dose for treating soil-transmitted 
helminths. The cure rates were similar, if not higher, 
for tribendimidine than for PZQ (Soukhathammavong 
et al., 2011). Phase 2b trials for opisthorchiasis are 
ongoing. Infections with C. sinensis were also 
successfully cured in adults with tribendimidine, and 
here again, the effects of PZQ and tribendimidine was 
equivalent. Moreover, tribendimidine-treated patients 
seemed to suffer less adverse events (Qian et al., 
2013). In nematodes, tribendimidine acts on the 
acetylcholine receptor family, in a similar manner as 
the other nematocidal drugs levamisole and pyrantel. 
However, tribendimidine is still active against 
levamisole-resistant phenotypes, most likely since it 
can activate a different population of acetylcholine 
receptors than levamisole (Buxton et al., 2014). 
 
A
 
 
B 
 
C 
Fig. 8 Chemical structures of tribendimidine (A) and its two most significant metabolites dADT (B) and adADT (C) 
 
Mefloquine was also first developed as a potent 
antimalarial until its antischistosomal activity was 
discovered in 2008. In contrast to PZQ, it is active 
against both juvenile and adult schistosomes. In an 
exploratory open-label trial, children co-infected with 
S. mansoni and S. haematobium were successfully 
treated with a combination of mefloquine and 
artesunate (Keiser et al., 2010; Xiao, 2013). 
Arylmethanol analogues, as enpiroline, also exhibited 
favourable effects in vitro and in vivo against S. 
mansoni (Ingram, Ellis and Keiser, 2012). 
Mefloquine, however, does not display activity 
against F. hepatica and C. sinensis (Keiser, Duthaler 
and Utzinger, 2010). Significant worm burden 
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reductions were observed in hamsters infected with O. 
viverrini (Keiser, Duthaler and Utzinger, 2010), but a 
clinical trial in humans failed to confirm an 
opisthorchicidal activity (Soukhathammavong et al., 
2011). The mode of action of mefloquine against 
trematodes is not clear, but the drug seems to inhibit 
haeme aggregation (Ingram, Ellis and Keiser, 2012) 
and to interfere with the glycolysis pathway 
(Manneck, Keiser and Muller, 2012).  
 
A  B  
Fig. 9 Chemical structures of mefloquine (A) and one of its analogues, enpiroline (B) 
 
Other trematocidal drug candidates might emerge 
from screening among drugs developed for another 
purpose, not only among malaria candidates but also 
against other protozoan infections. For example, 
nitazoxanide, a drug treating Cryptosporidium spp. 
and Giardia intestinalis infections displayed 
interesting fasciocidal activities. Similarly, screening 
among veterinary drugs might be the source of new 
trematocidal compounds that could be developed for 
human use. Drug repurposing can also venture as far 
as cancer drugs. These libraries provide an enormous 
panel of different scaffolds that can later be optimised 
to specifically target parasites. For example, 
nilutamide, an antiandrogen used to cure prostate 
cancer, displayed effects against S. mansoni juveniles. 
Also, miltefosine, a drug initially treating mammarian 
cancer, showed activity against S. haematobium and is 
approved to treat leishmaniasis (Panic et al., 2014). 
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1.4 Pharmacokinetic methods 
The PK analyses included in the present thesis were 
all performed on a LC-MS/MS instrumentation and 
were validated according to the FDA guidelines for 
analytical method validation. A short introduction to 
these methods is therefore not superfluous. The LC-
MS/MS system is an excellent tool for the 
quantification of drug concentrations in biofluids. 
Depending on their composition and the type of 
mobile phases carrying the sample, HPLC columns 
retain the molecule of interest while washing out most 
of the biological contaminants. By changing the 
concentration of the mobile phases, the analyte will 
elute at a specific time and will be carried on to the 
MS. The principle of mass spectrometry is to select 
particles with a defined molecular weight using 
magnetic or electric fields. Since molecules in the MS 
are only distinguished according to their mass, the 
cleaner from contaminants the sample is, the more 
robust will be the analysis. A more precise molecular 
identification is possible with tandem MS (MS/MS). 
MS/MS spectrometers, after selecting for the mass of 
interest, will use a collision gas to break the molecule 
at its weaker chemical bounds and quantify the 
fragments produced. Fragmentation patterns are 
specific to chemical structures. Therefore, in the 
eventuality that a contaminant displays the same 
original mass as the molecule of interest, they can be 
segregated according to their fragmentation patterns.  
 
 
Fig. 10 Scheme of a MS/MS: declustering (DP) and focusing (FP) potentials direct the beam of molecules to the first quadrupole (Q1), where 
a first mass segregation occurs. The selected molecules continue to the collision chamber where an optimised collision energy (CE) fragments 
the parent molecule. The fragments of desired mass are then selected for in the second quadrupole (Q3) and the cell exit potential (CXP) 
guides them to the detector. 
 
 
Further modifications of the instrumentation can be 
performed to maximise analyte signals, as for example 
column switching. This system allows to load the 
sample on a first, and usually shorter, 
chromatographical column and to wash the sample 
from contaminants before eluting the analytes to the 
main HPLC column for chromatographical separation. 
The advantage of this method is to provide the main 
HPLC column with analytes virtually free from matrix 
contaminants. In the frame of this thesis, it was 
especially useful for analysing bile samples, and in the 
case of PZQ to protect as much as possible the chiral 
column from contaminants.  
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Fig. 11 Scheme of a typical column switching system on a 10-port valve: in green, the loading phase of the trapping column (sketched with a 
grey rectangle) with respective mobile phases; in orange, the elution phase to the chiral column. The dark orange panel on the time program 
shows the scanning time of the MS. 
 
The validation of an analytical method should follow 
defined steps to ensure measurements as precise as 
possible, especially when performing extensive PK 
studies. The first obvious control is the stability of the 
analytes. The stability in the original matrix (plasma 
or blood) at storage temperature and time until 
analysis needs to be documented, as well as stability 
during the extraction procedure (bench-top stability), 
during several rounds of sample freezing and thawing 
and in the autosampler, while the sample batch is 
being analysed. The second crucial point is the 
selectivity of the method for the analyte. If, when 
analysing blank samples, a signal for the analyte is 
detected, the method needs to be adapted in a way that 
it will not interfere with analysis. The sensitivity of the 
method is important and needs to be tailored to the use 
of the method (quantify trace elements or diagnose 
toxicity cases). The calibration line should be linear in 
the range of concentrations expected in the samples to 
be analysed. The accuracy of the method is evaluated 
by using quality control (QC) samples prepared to 
known concentrations and measured as normal 
clinical samples. The original concentration of QC 
samples is then compared to the one calculated from 
the calibration line. The precision of the method is 
assessed by re-measuring samples on different days 
and comparing how much they differ. The last step is 
to estimate how much of the analyte is lost during the 
sample extraction procedure, termed extraction 
recovery, and how much of the matrix contaminants 
are interfering with the analyte signal recorded, the 
relative recovery. The evaluation of recovery provides 
useful information on the robustness of the method 
and allows identifying weak points to be improved. 
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1.5 Goal and Objectives 
Trematode infections represent an important burden in 
terms of global health and economic impact, and are 
tightly linked to poverty. Resistance is threatening the 
efforts to control trematodiases, and alternative drugs 
lacking. Moreover, few studies on anthelmintic drug 
disposition in target patients are available, although 
widely distributed in mass chemotherapy programs. 
The main goal of the present thesis is to contribute to 
an amelioration of the treatment options against 
trematodes, by investigations on lead peroxide 
candidates and on the standard drug praziquantel.  
 
 
 
The following objectives were considered:  
1. Validate an LC-MS/MS method to analyse the synthetic peroxide drugs OZ78 and MT04 in sheep 
plasma and bile, and elucidate their pharmacokinetic profile after a single intramuscular dose of 
100 mg/kg (Chapter 2) 
2. Investigate the effects of PZQ enantiomers and its main metabolites on S. mansoni adults and 
NTS by in vitro assays, microcalorimetry and in vivo in mice (Chapter 3) 
3. Develop and validate an enantioselective method for R-PZQ, S-PZQ and the main metabolite R-
trans-4-OH in plasma, blood and DBS (Chapter 4) 
4. Elucidate the PK profile of O. viverrini infected patients in blood, plasma and DBS, and validate 
DBS as sampling technique for future PK trials with PZQ (Chapter 5) 
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Abstract  
Fasciolosis is a parasitosis caused by the food-borne trematode Fasciola spp. of major veterinary significance. 
Triclabendazole is the first line treatment in humans and animals but cases of resistance are spreading worldwide. 
The synthetic peroxides OZ78 and MT04 are lead compounds for the treatment of fasciolosis. In the present study 
we investigated the efficacy and drug disposition following a single intramuscular dose of 100mg/kg OZ78 and 
MT04 in sheep harbouring a natural Fasciola hepatica infection. A liquid chromatography and tandem mass 
spectrometry (LC-MS/MS) method was developed and validated to quantify plasma and bile concentrations of 
both compounds. Plasma samples were analysed with an accuracy for OZ78 and MT04 from 91 to 115% and a 
precision lower than 8.9%. Bile samples displayed an accuracy between 92 and 101% and a precision up to 12.7%. 
Bile samples were collected at 0 and 6 h post-administration. Plasma mean peak concentration was 11.1 µg/ml at 
1.5 h for OZ78 and 4.8 µg/ml at 4.2 h for MT04. Mean AUC of OZ78 and MT04 was 6698 and 3567 µg´min/ml, 
respectively. Bile concentration at 6 h post-treatment was 1.0 µg/ml for OZ78 and 1.4 µg/ml for MT04. Treatment 
with OZ78 showed no effect on egg burden and adult worm counts in vivo, whereas MT04 displayed a significant 
egg count reduction of 98.5% and a worm burden reduction of 92%. In conclusion, our study reveals an excellent 
activity of MT04 against F. hepatica in naturally infected sheep and a first insight into its PK behaviour.
1. Introduction 
Fasciolosis is a major zoonosis of livestock in 
temperate regions and is responsible of an annual 
estimated economical loss of US$3 billion 
(Fairweather, 2005). This parasitosis is caused by the 
liver flukes Fasciola hepatica and Fasciola gigantica, 
and is responsible for morbidity and mortality, 
including weight loss, jaundice, hepatomegaly and 
biliary cholic. Triclabendazole is the drug of choice in 
both livestock and humans and is highly active against 
all the parasite stages (Keiser and Utzinger, 2009). 
Resistance against triclabendazole has been observed 
in Australia since 1995 and is now recorded in several 
European countries (Fairweather, 2009). This 
situation is critical and new fasciocidal drugs are 
urgently needed.  
Synthetic peroxides, such as ozonide (1,2,4-
trioxolane) OZ277, have been synthesized in the late 
1990s in the frame of antimalarial research as 
alternatives to artemisinin derivatives (Vennerstrom et 
al., 2004). The screening of libraries of structural 
analogues has generated other interesting antimalarial 
candidates and ozonide OZ439 successfully 
completed phase I trials in healthy human volunteers 
(Moehrle et al., 2013). In the past few years, the 
ozonides have also been studied against a range of 
helminths and OZ78 revealed activity against diverse 
trematode species, such as F. hepatica, Echinostoma 
caproni (Keiser et al., 2006), Clonorchis sinensis 
(Keiser et al., 2007), Schistosoma mansoni and 
Schistosoma japonicum (Xiao et al., 2007; Xiao, Mei 
and Jiao, 2011). Additionally, its toxicological profile 
has been proven acceptable in vitro and in rats and the 
drug has good pharmacokinetic properties 
(Vennerstrom et al., 2004). In F. hepatica infections, 
OZ78 achieved elimination of juvenile and adult 
worms in rats with a single oral dose of 100 mg/kg 
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(Keiser et al., 2006). In vitro, adult F. hepatica was 
affected at concentrations of 10-100 µg/ml OZ78 
(Keiser et al., 2006; Halferty et al., 2009). Incubation 
for 48 h at a concentration of 100 µg/ml of OZ78 
produced significant tegumental damages and 
displayed an impact on vitelline and testis follicles on 
adult worms (Halferty et al., 2009).  
Recently, additional dispiro 1,2,4-trioxanes and 
1,2,4,5-tetraoxanes were synthesized and tested in F. 
hepatica infected rats. Among those, the tetraoxane 
MT04 displayed a higher activity than OZ78 against 
F. hepatica, especially against adult worms (Wang et 
al., 2011). A single 50 mg/kg oral dose of MT04 
achieved a complete burden reduction in F. hepatica 
infected rats. Furthermore, the onset of action for 
MT04 was observed to occur between 18 and 24 h, in 
contrast to 24-72 h for OZ78 (Kirchhofer et al., 2011).  
The goal of the present study was to test the efficacy 
of MT04 in sheep harbouring a natural F. hepatica 
infection. For comparison, one group of sheep was 
treated with OZ78. In previous experiments (Keiser et 
al., 2010), OZ78 showed no activity in sheep at a 
single dose of 50mg/kg given orally and 
subcutaneously. Since a recent investigation on the 
fasciocidal properties of artemether and artesunate 
demonstrated an increased efficacy when the drugs 
were administered intramuscularly to sheep (Keiser et 
al., 2008), we opted for a single intramuscular dose of 
100 mg/kg for both compounds. We also refined and 
validated an existing LC-MS/MS method for OZ78 
and MT04 (Kirchhofer, Keiser and Huwyler, 2010) 
with the purpose to study their drug disposition in 
plasma and bile.  
Table 1 LC-MS/MS parameters for the detection of OZ78, MT04 
and the internal standard OZ352 
Parameter OZ 78 MT 04 OZ 352 
Source temperature 
[°C] 400 400 400 
Nebulizer gas [L/min] 12 12 12 
Curtain gas [L/min] 7 7 7 
Declustering potential 
[V] -56 -61 -61 
Focusing potential [V] -230 -230 -220 
Collision energy [V] -24 -20 -26 
Cell exit potential [V] -15 -11 -5 
Entrance potential [V] -10 -10 -10 
Ion spray voltage [V] -4200 -4200 -4200 
Polarity of analysis  negative negative negative 
Mass and transitions 
[m/z] 321®277 337®153 336®291 
 
2. Materials and methods  
2.1. Chemicals and reagents  
OZ78, MT04 and OZ352 (internal standard, IS) were 
provided by Prof. J. Vennerstrom of the College of 
Pharmacy, University of Nebraska Medical Center 
(Omaha, USA). Their chemical structures are depicted 
in Fig. 1. Acetonitrile, ethanol and methanol of HPLC 
grade were purchased from Sigma-Aldrich (Buchs, 
Switzerland). Ammonium formate of HPLC grade 
was obtained from Fluka Analytical (Buchs, 
Switzerland). Ultrapure water was produced with a 
Millipore Milli-Q water purification system. The 
solution used for the intramuscular application of 
OZ78 and MT04 was prepared with 20 ml Lipoid S 
100 (Lipoid AG, Steinhausen, Switzerland), 10 ml 
ethanol, 30 ml NMP (N- methylpyrrolidone 
Ph.Eu./CAS 70142-34-6) and Arlasolve DMI 
(dimethylisosorbide/CAS 5306-85-4) ad 100 ml. 
Blank sheep plasma was obtained from the local 
slaughterhouse (Basel, Switzerland).  
2.2. LC-MS/MS equipment and conditions  
The LC-MS/MS method developed here was adapted 
from Kirchhofer and colleagues (Kirchhofer, Keiser 
and Huwyler, 2010) for the analysis of OZ78 and 
MT04 in both plasma and bile. The HPLC system 
(Shimadzu, Kyoto, Japan) included two LC-20AD 
pumps, a CTC HTS PAL autosampler (CTC 
Analytics, Zwingen, Switzerland), and an online DG-
3310 degasser (Sanwa Tsusho, Tokyo, Japan). 
Chromatographic separation for plasma samples was 
accomplished at 25°C and 0.3 ml/min flow using a 
Kinetex XB-C18 column (50 mm × 4.6 mm, 2.6 µm, 
Brechbühler AG, Schlieren, Switzerland) combined 
with a Phenomenex security guard cartridge 
(Brechbühler). The solvent gradient was defined as 
follows: 0-1 min: 30% B; 1-4 min: 30-95% B; 4-9 min: 
95% B; 9-10 min: 95-30% B; and 10-11 min: 30% B, 
where A was 20 mM ammonium formate in ultrapure 
water and B pure acetonitrile. To avoid contamination 
of the mass spectrometer, the flow between the HPLC 
and the MS was interrupted during 0-4 and 8-11 min 
of each run using a six-port switching valve (VICI 
Valco Instruments, Schenkon, Switzerland).  
For the analysis of bile samples, the analytical column 
was combined with a trapping column (Halo C18, 
4.6mm×5mm, Sertec Electronics, Olten, Switzerland). 
The column switching system operated with the 
following solvent gradient: 0-1 min: 30% B, 0.3 
ml/min flow through the trapping column (sample 
loading) and 1ml/min through the analytical column 
(column wash); 1–4 min: 30-95% B, 0.3 ml/min flow 
through the trapping and analytical column (sample 
elution of the trapping column and loading onto the 
analytical column); 4-8min: 95% B (sample elution); 
8-11 min: 30% B (column regeneration); and injection 
loop: 20 µl. In the first minute, the trapping column 
was washed with a flow of 1 ml/min.  
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An API 3000 tandem mass spectrometer (AB Sciex, 
Framingham, USA) equipped with a turbo ion spray 
source operating in the negative ionization mode was 
used for the MS/MS analyses. The applied mass 
transitions and the MS parameters are summarized in 
Table 1. Instrument control and data analyses were 
performed using the Analyst 1.5 software (AB Sciex, 
2008).
 
A B C 
 
 
 
332.4 g/mol 338.4 g/mol 336.4 g/mol 
 
Fig. 1 Chemical structures of OZ78 (A), MT04 (B) and OZ352 (C, internal standard) 
 
2.3. Standard, quality control and internal standard 
preparation  
Stock solutions (OZ78 and MT04, 0.5 mg/ml) were 
prepared in acetonitrile. Working solutions of OZ78 
and MT04 were obtained by serial dilution of stock 
solutions with pure water:acetonitrile 1:1 (v/v) to 
concentrations ranging from 300 to 6 µg/ml. The 
internal standard (IS) working solution was prepared 
at a concentration of 1 µg/ml of OZ352 in acetonitrile 
(Keiser et al., 2010).  
2.4. Plasma sample preparation  
Plasma calibration samples were freshly prepared by 
spiking blank plasma samples with the working 
solutions to reach final concentrations of 20, 10, 4, 2, 
1 and 0.4 µg/ml of OZ78 and MT04, where 0.4 µg/ml 
was the lower limit of quantification (LLOQ). Quality 
control (Qc) samples were obtained by spiking blank 
plasma derived from 4 different sheep to final 
concentrations of 15, 3, 0.75 and 0.4 µg/ml (high, 
medium, low and LLOQ concentrations). To adjust for 
matrix effects, calibration, Qcs and PK samples to be 
measured were further diluted 1:1 with the plasma 
used for the calibration samples.  
Plasma samples were extracted using Phree 96 well 
plate kits (Phenomenex, Brechbühler) allowing an 
efficient filtering and removal of both proteins and 
phospholipids in one step. First, 400 µl IS was 
dispensed in each well. Then 100 µl of each plasma 
sample was added. The plates were agitated and 
centrifuged at 500 × g and 10°C for 5 min (5804 R 
centrifuge, Vaudaux-Eppendorf AG, Switzerland). 
Five microliters of the filtrate was used for the LC-
MS/MS analysis.  
2.5. Bile sample preparation  
Calibration and Qc samples (n = 4) were prepared for 
each single bile sample with the corresponding blank 
sample from the same animal collected at time T = 0. 
Calibration, Qcs and samples to be measured were 
diluted with one volume of mobile phase A. Extraction 
was performed by adding 400 µl IS to 100 µl sample 
followed by mixing in a thermomixer (Thermomixer 
Comfort 1.5ml, Vaudaux-Eppendorf) for 10 min at 
10°C. Samples were then centrifuged (5424 R 
centrifuge, Vaudaux-Eppendorf) at 21,130 × g and 
10°C for 10 min. 20 µl of the supernatant was used for 
the LC-MS/MS analysis.  
2.6. Method validation  
The LC-MS/MS method was validated with respect to 
selectivity, linearity, precision, accuracy, and 
recovery. Selectivity was tested by running 15 blank 
PK plasma and 16 bile samples extracted with pure 
acetonitrile to test for potential interferences with 
endogenous substances. The calibration curves were 
established using the internal standard method by 
plotting concentrations vs. peak-area ratios of the 
analytes to the IS. Accuracy and precision of the 
method was assessed by analysing Qc samples 
covering the calibration range (LLOQ, low, middle 
and high concentrations). Precision was determined 
using the coefficient of variation, and the accuracy 
estimated as the percentage ratio of the measured 
concentration to the nominal concentration. The 
uniformity of the extraction recovery (partial 
recovery) within the calibration range was evaluated 
by comparing three samples spiked before and after 
the extraction at low, medium and high 
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concentrations. Similarly, suppressive or enhancive 
effects of the biological matrix (matrix effects) were 
quantified by comparing organic solvents or the 
biological matrix spiked with defined amounts of 
analytes (Table 2). The stability of each analyte has 
been reported elsewhere (Kirchhofer, Keiser and 
Huwyler, 2010).  
2.7. Study design and sample collection  
The drug trial in sheep was conducted between June 
and July 2012 in a farm located in the Campania 
region of southern Italy with a known history of 
fasciolosis. The study had received clearance from the 
Centre for Veterinary Service of the University of 
Naples Federico II (Ref. no. 99/12), which is the 
central ethical committee for the control of animal care 
in field trials. Treatment as well as blood and bile 
collections was performed by accredited veterinarians. 
Fifteen sheep with moderate infections (based on 
faecal egg burden) with F. hepatica were selected on 
the study farm. At days -2, -1 and 0 before treatment, 
sheep were weighted and their faecal egg burden 
estimated with the FLOTAC technique using zinc 
sulphate as flotation solution (Cringoli et al., 2010). 
Based on egg counts three equal groups (n = 5/group) 
were formed: controls, OZ78 treated and MT04 
treated sheep. Sheep treated with OZ78 or MT04 
received a single dose of 100 mg/kg drug 
intramuscularly. Drug was dissolved in as little solvent 
as possible and total injection volume did not exceed 
15 ml.  
Before treatment, 15-30 ml blood was collected from 
the jugular vein from each sheep using 10 ml EDTA-
coated vacutainers (BD, Belliver Industrial Estate, 
Plymouth, UK). At t = 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 
and 24 h post-treatment, 5 ml blood samples were 
drawn from treated sheep. Bile samples (10 ml) were 
collected prior to and 6 h post-treatment by direct 
puncture of the gall bladder of each treated sheep and 
transferred to 4.5ml Nunc Cryotubes (Sigma–
Aldrich).  
Blood samples were cooled and centrifuged within 1 h 
at a nearby laboratory to obtain plasma. Plasma and 
bile samples were transported on dry ice and stored at 
-80°C until assayed. At days 19, 20 and 21 post-
treatment, the faecal egg counts were again 
determined. At day 21, all the sheep were transported 
to the local slaughterhouse and euthanized. The livers 
were dissected to collect and count the flukes in the 
veterinary facility of the CREMOPAR in Eboli.
Table 2 Accuracy and precision of quality control samples of OZ78 and MT04 measured in plasma and bile 
 Analytes Nominal concentration [ng/ml] 
Concentration measured 
[ng/ml]a 
Accuracy 
[%]b 
Precision 
[%]c 
Plasma 
OZ 78 
15000 13710 91.4  5.0 
3000 3171  105.7  5.6 
750 863  115.1  3.8 
400 438  109.4  0.6 
MT 04 
15000 14051 93.7  4.1 
3000 3121 105.1 8.9 
750 795 106.0  3.6 
400 432 108.1  8.2 
Bile 
OZ 78 
15000 15073 100.5  7.4 
3000 2968 100.9 7.3 
750 706 92.2 9.4 
400 385 92.3 12.7 
MT 04 
15000 14668 97.8 3.5 
3000 2998 99.9 3.5 
750 749 99.8 4.1 
400 407 101.7 4.4 
a Mean of measured concentrations in 4 quality control samples 
b The accuracy is calculated as the percentage ratio of the measured concentration to the nominal concentration 
c The precision is the percentage ratio of the standard deviation to the measured concentration 
2.8. Statistical analysis  
Geometric means were calculated for individual F. 
hepatica egg counts and arithmetic means and 
medians with respective ranges were used to 
characterize adult worm burdens. Stata (version 12.1, 
StataCorp, TX, USA) was used for the statistical 
analyses. The difference in geometric means of egg 
counts pre- and post-treatment was compared between 
control and treated groups with a Student’s t-test 
allowing for unequal variances. For worm burdens, 
medians of control group were compared to medians 
in treated groups using the Wilcoxon-Mann-Whitney 
test. To assess differences in concentrations of OZ78 
and MT04 in bile 6 h after treatment, an unpaired t-test 
allowing for unequal variances was performed. 
Differences in means and medians were considered to 
be significant at the 0.05 level.  
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2.9. Pharmacokinetic analyses  
On the basis of the LC–MS/MS measurements, the 
following PK parameters for plasma were calculated:  
Cmax  maximal plasma concentration 
Tmax time to reach Cmax
AUC  area under the curve, from 0 to 24 h 
T1/2 elimination half-life 
Cmax and Tmax of OZ78 and MT04 were observed 
values derived from the plasma concentration time 
profile. AUC and T1/2 were calculated with the 
software WinNonlin (Version 5.2, Pharsight 
Corporation, USA) using non-compartimental 
analysis. The elimination half-life was defined as: T1/2 
= ln2/l, where l was determined by performing a 
regression of the natural logarithm of the 
concentration values during the elimination period
Fig. 2 Chromatograms of blank vs. LLOQ, QC 2, and PK sample t= 1 h in plasma 
3. Results  
3.1. Method validation  
T0 plasma and bile blanks were analysed to detect 
endogenous matrix components producing interfering 
peaks at the analyte retention time (Figs. 2 and 3). The 
bile average of noise and LLOQ signals, however, 
varied greatly in intensities between individuals. Mean 
plasma relative recovery was 82.75 ± 3.25% for OZ78 
and 86.58 ± 4.52% for MT04. The total recovery 
observed for plasma was 83.83 ± 4.95% for OZ78 and 
82.83 ± 3.97% for MT04.  
The calibration lines were linear over the range of 0.4-
20 g/ml with a coefficient of correlation (R2) above 
0.99 for plasma and bile. Accuracy and precision at the 
four Qc concentrations for plasma and bile are 
summarized in Table 2. The accuracy for plasma 
ranged from 91 to 115%, with a precision between 0.6 
and 8.9%. In bile samples, an accuracy between 92 and 
101% and a precision of 3.5 to 12.7% was determined.  
3.2. Efficacy of OZ78 and MT04  
Table 3 summarizes the effects of OZ78 and MT04 on 
the faecal egg burden. Geometric mean egg counts of 
OZ78 and MT04 before treatment were 90.8 and 92.3 
eggs per gram of faeces (EPG), respectively. The 
infection intensity ranged between 42 and 215.3 EPG 
for OZ78 and between 54 and 160.1 EPG for MT04. 
Between the start and the end of the study, EPG counts 
of the control group showed a statistically non-
significant difference of 10.2% in EPG geometric 
means. The OZ78 treated group similarly displayed a 
 Blank vs. LLOQ signals QC 2 (3 µg/ml) PK sample t = 1 hour 
O
Z 
78
 
   
M
T 
04
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statistically non-significant EPG reduction of 49% 
with a single intramuscular dose of 100 mg/kg. 
However, at the same dose and administration route, 
we found for MT04 a highly significant EPG reduction 
of 98.5% after the treatment (p-value = 0.001).  
The effects of OZ78 and MT04 on total adult worm 
burden are presented in Table 4. The mean F. hepatica 
burden in the control group was 5 worms. In the OZ78 
treated group, on average 7.8 worms were recovered. 
In MT04 treated sheep, the mean worm burden was 
0.4, which translates to a statistically significant worm 
burden reduction of 92%.
Table 3 F. hepatica faecal egg counts of control and OZ78- or MT04-treated sheep: mean group and individual egg counts pre- and post-
treatment and respective percentage egg reductions 
Treatment group 
Individual sheep 
Pre-treat. means (SD)a 
Individual EPG values 
Post-treat. means (SD)b 
Individual EPG values 
Mean egg reduction (%) 
Individual egg reduction (%) T
c P-value 
Control 60.0 (37.1) 53.9 (30.5) 10.2   
1 46.4 (15.9) 52.4 (12.7) 0   
2 31.2 (9.2) 11.0 (3.5) 64.8   
3 55.5 (19.3) 52.9 (8.5) 4.7   
4 42.3 (15.1) 97.0 (24.0) 0   
5 124.5 (89.6) 56.2 (21.5) 54.8   
OZ 78 90.8 (72.0) 46.3 (28.8) 49.0 -1.26 0.12 
6 42 (0.0) 28.7 (4.6) 31.6   
7 86.5 (19.3) 74.2 (10.3) 14.2   
8 43.4 (9.2) 23.0 (8.9) 47.0   
9 215.3 (21.6) 81.1 (25.0) 62.3   
10 66.9 (15.1) 24.3 (9.1) 63.7   
MT 04 92.3 (42.3) 1.4 (1.3) 98.5 -3.10 0.01 
12 59.8 (6.0) 2.8 (1.4) 95.3   
13 99.5 (12.5) 2.5 (2.0) 97.5   
14 54.3 (13.0) 0 (0.0) 100   
15 160.1 (40.3) 1.6 (0.6) 99   
16 87.9 (18.6) 0 (0.0) 100   
a Geometric mean (SD) of EPG data from day -2 to 0 post-treatment 
b Geometric mean (SD) of EPG data from day 19 to 21 post-treatment 
c T score obtained from the unpaired t-test 
3.3. Pharmacokinetics of OZ78 and MT04 in plasma 
and comparative bile data  
The plasma concentration-time profiles of OZ78 and 
MT04 are presented in Fig. 4 and corresponding PK 
parameters are summarized in Table 5. OZ78 and 
MT04 were both observed in plasma over 24h post-
treatment. The OZ78 mean peak concentration of 11.1 
µg/ml was reached after 1.5 h. MT04 displayed a peak 
concentration of 4.8 µg/ml at 4.2h. The mean AUC for 
OZ78 and MT04 was 6698 and 3567 µg´min/ml, 
respectively. Elimination half-life was 13.1 and 13.3 h 
for OZ78 and MT04, respectively.  
The concentration of each compound was measured in 
bile 6h after treatment. Mean concentrations of 1.0 ± 
1.0 µg/ml OZ78 and 1.4 ± 0.6 µg/ml for MT04 were 
determined in bile fluids. We also detected a non-
significant tendency (p-value = 0.561) of MT04 to be 
more concentrated than OZ78 in bile (Fig. 5). 
 
Table 4 F. hepatica worm burdens (WB) of control and OZ78- or MT04-treated sheep: cure rates, group mean values and medians with ranges 
and worm burden reductions 
Treatment group Cure rate (%)a Mean WB (SD) Median WB (range) Total WB reduction (%) Zb P-value 
Control 0 5 (4.2) 4 (1-12) - - - 
OZ 78 0 7.8 (3.1) 7 (5-12) 0 -1.485 0.14 
MT 04 60 0.4 (0.5) 0 (0-1) 92 2.463 0.01 
a Percentage number of animals cleared from F. hepatica 
b Z score obtained from Wilcoxon-Mann-Whitney test 
 
Table 5 Pharmacokinetic parameters of OZ 78 and MT 04  
Treatment group Cmax (µg/ml) Tmax (h) AUC (µg´min/ml) T1/2 (h) 
OZ 78 11.1±5.1 1.5±0.9 6698.6±1634.2 13.1±6.1 
MT 04 4.8±4.0 4.2±2.0 3567.5±2739.1 13.3±3.8 
Cmax: maximal concentration; Tmax: time of peak concentration; AUC: area under the curve; T1/2: time of half-life 
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4. Discussion  
4.1. Method validation  
The LC–MS/MS method used here was adapted from 
Kirchhofer, Keiser and Huwyler, 2010 to allow the 
analysis the analytes in bile. In addition, the covered 
concentration range was extended to 400-20,000 ng, 
which made the dilution of highly concentrated 
samples unnecessary. The overall sample handling 
time was shortened by simplifying the extraction 
procedure (acetonitrile extraction instead of 
evaporation and reconstitution in solvent) and the 
analytical runs were reduced from 14 to 11 min. The 
sensitivity and selectivity of our method was 
considered to be satisfactory, since the desired LLOQ 
of 400 ng/ml was achieved with a signal to noise ratio 
of 4:1. The recovery of analytes in plasma was high 
(>82%). However, different types of interfering matrix 
effects were observed between bile obtained from 
different sheep. We overcame this problem by 
establishing an individual calibration curve for each 
animal using blank bile obtained prior to the 
administration of drug. A precision of ±15% (LLOQ: 
±20%) and an accuracy between 85 and 115% (LLOQ: 
80–120%) was accepted in our study.  
4.2. Efficacy and PK profile of OZ78 and MT04  
The treatment with 100 mg/kg OZ78 by intramuscular 
injection had no effect on a moderate natural F. 
hepatica infection in sheep. This result echoes the 
unsuccessful outcomes of our previous study in sheep 
which had been experimentally infected with F. 
hepatica and treated orally or subcutaneously with 
50mg/kg OZ78 (Keiser et al., 2010). Hence, doubling 
the dosage and changing the route of administration 
did not result in increased fasciocidal activity. On the 
other hand, at the same dosage and administration 
route, MT04 displayed a very good activity against 
chronic F. hepatica infection, achieving significant 
egg and worm burden reductions of 98.5 and 92.0%, 
respectively.  
When comparing PK parameters of OZ78 and MT04, 
the time to reach the maximal plasma concentration 
(Tmax) was 1.5 h for OZ78 and 4.2 h for MT04 with 
mean peak concentrations of 11.1 and 4.8 µg/ml, 
respectively. Elimination half-life did not differ 
between compounds and is approximately 13 h. 
However, oily and lipid formulations may lead to 
depot effects in muscle tissues, and since it has been 
shown that OZ78 and MT04 are rapidly eliminated in 
sheep (Keiser et al., 2010), absorption is most likely 
rate-limiting. Thus, the long T1/2 observed here may be 
indicative of a prolonged absorption of drug.  
OZ78 plasma maximal peak concentration and AUC 
values are higher, almost double, than those of MT04. 
Considering the lack of fasciocidal activity of OZ78 
compared to MT04, the latter result is surprising. A 
high concentration of OZ78 in plasma is therefore not 
sufficient to guarantee a fasciocidal effect in sheep. 
The difference in fasciocidal activity between the two 
related compounds is certainly inherent to their 
chemical structures. MT04 is characterized by a 
tetraoxane moiety, while OZ78 is a trioxolane 
derivative. MT04 thus has an additional peroxide 
bond, which might explain the higher activity. A 
previous study by Wang and colleagues (Wang et al., 
2011) investigated a wide library of dispiro peroxides 
against F. hepatica. Besides the observation that 
spiroadamantane and carboxymethyl structures were 
required for fasciocidal efficacy, they noticed that 
trioxane and tetraoxane peroxides displayed a higher 
efficacy than corresponding trioxolanes. It seems thus 
that the peroxide bond is not the only element 
influencing efficacy but also that the 6-membered 
heterocycle (trioxane and tetraoxane) might offer 
advantages over the 5-ring structure (trioxolane). 
Moreover, it was observed that tetraoxanes had a 
better stability in red blood cells over corresponding 
trioxanes and trioxolanes (O’Neill et al., 2010).  
The drug disposition profiles of OZ78 and MT04 were 
monitored over a period of 24 h. The Cmax and Tmax 
determined here for a single OZ78 dose of 100 mg/kg 
were not different from the parameters observed in a 
previous study in sheep using a 50 mg/kg 
subcutaneous dose (Keiser et al., 2010). The AUC 
found here is 50% smaller compared to the AUC 
observed at 50 mg/kg subcutaneous dose. It is 
surprising that the administration of a double dose is 
not reflected in a higher AUC. The elimination half-
life on the other hand is much longer in our study than 
with the subcutaneous smaller dose. This difference 
might be explained by the administration route: a 
higher dose injected intramuscularly might diffuse 
more slowly due to a depot type effect, releasing the 
drug over time and in proportion to muscular activity. 
This depot effect could therefore be reflected by a 
smaller Cmax and a longer elimination half-life. Thus, 
differences in drug bioavailability between the 
intramuscular and subcutaneous administration routes 
are likely due to differences in absorption from the 
injection site.  
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Fig. 3 Chromatograms of blank vs. LLOQ signals in bile samples from 8 sheep 
 
Excellent fasciocidal activity was detected at a single 
oral dose of 100 mg/kg OZ78 in rats (Kirchhofer et al., 
2011). However, as mentioned above, no activity was 
observed in experimentally F. hepatica infected sheep 
at a dose of 50mg/kg (Keiser et al., 2010) or at a higher 
dose, as observed here. In contrast to sheep, 
compounds in rats with a molecular weight >300 are 
well excreted into bile (Smyth and Haslewood, 1963; 
Abou-El-Makarem et al., 1967; Toutain, Ferran and 
Bousquet-Melou, 2011). This difference with respect 
to biliary excretion of drugs could explain the 
discrepancy between the activity of OZ78 in rats and 
sheep. Following the unexpected low activity in sheep, 
a PK study with OZ78 and MT04 was conducted in 
uninfected rats. It was observed that Cmax, Tmax and T1/2 
did not significantly differ between sheep and rat. The 
AUC however was increased by a factor five in rats, 
which might explain the discrepancy of fasciocidal 
activity between both animal species. However, using 
uninfected rats might not reflect at best PK parameters 
observed in infected animals, and repeating the 
experiment in infected rats might allow generation of 
more fine-tuned hypotheses.  
Besides PK measurements in plasma, we examined the 
concentration of OZ78 and MT04 in sheep bile 6h 
after treatment. The drug concentration in bile is of 
high interest because it mirrors the direct environment 
of the fluke. OZ78 and MT04 were less concentrated 
in bile than in plasma at the same time point. We also 
observed a trend towards higher concentrations of 
MT04 than OZ78 in bile. It is possible that MT04 
undergoes greater biliary excretion, thus displaying a 
higher concentration than OZ78 in bile and therefore 
revealing a higher efficacy against F. hepatica. 
However, to be able to draw a final conclusion on drug 
disposition in bile, the collection of additional sheep 
bile samples would have been required, which was not 
possible in the setup of the present study  
The exact mechanism of action of peroxides against F. 
hepatica or other trematodes is not known. In malaria, 
peroxides are dependent upon haemoglobin digestion, 
leading to the formation of reactive intermediates 
including reactive oxygen species (Vennerstrom et al., 
2004; Jefford, 2007; Kořený, Oborník and Lukeš, 
2013). F. hepatica dwells in biliary canals but feeds, 
as malaria, on red blood cells from the neighbouring 
biliary blood vessels. Peroxides might therefore also 
interact with the digestion process of F. hepatica. 
Keiser and Morson (Keiser and Morson, 2008) 
compared mortality and tegumental damage of F. 
hepatica in vitro between normal medium plus OZ78 
and medium plus OZ78 supplemented with haemin. 
They observed that tegumental damage caused by 
OZ78 was more pronounced in the medium 
supplemented with haemin, but no change in mortality 
rate was recorded. It is likely that the presence of iron 
is not necessary for OZ78 action. Also, specimens 
treated in vitro with OZ78 displayed damages in the 
mid-body (no haemin) or anterior (haemin 
supplemented) regions, while parasites recovered 
from treated rats showed substantial damage to the 
posterior region. It is clear that in vitro conditions are 
not sufficient to mimic the in vivo effect of peroxides. 
Another study compared the uptake of albendazole, 
fenbendazole and triclabendazole by F. hepatica when 
adding bile in the incubation medium (Alvarez, 
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Mottier and Lanusse, 2004). They observed that the 
detergent properties of bile decreased the absorption 
of these drugs by the parasite. The properties of bile 
might also modify the lipophilicity of peroxides and 
possibly enhance their diffusion. It would therefore be 
useful to study OZ78 and MT04 in vitro in the 
presence of sheep and rat bile salts to assess the 
diffusion of peroxides in the parasite, as well as to 
specify their mechanism of action.  
Fig. 4 Pharmacokinetic profiles in plasma of OZ 78 (a) and MT 04 (b) following a single intramuscular dose of 100mg/kg 
 
 
 
Fig. 4 Concentration of OZ 78 and MT 04 in bile 6 hours after 
treatment 
5. Conclusion  
The present study was conducted in sheep naturally 
infected by F. hepatica. Although field experiments 
might display different outcomes due to various 
factors (e.g. co-infections), the conditions of the sheep 
in this preliminary study are often encountered by 
farmers and field veterinarians. In contrast to OZ78, 
the tetraoxane MT04 shows better anthelminthic 
activity in sheep despite a lower drug concentration in 
plasma. Both peroxides were observed to be excreted 
in similar concentrations in bile, which does not 
explain their difference in efficacy. The result found 
with MT04 is encouraging and further experiments in 
sheep under controlled conditions and using a larger 
sample size should therefore be conducted. Efficacy of 
MT04 should also be assessed against juvenile worms. 
 
a 
 
 
b 
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Additionally, biliary excretion of MT04 and fluke 
uptake mechanism should be investigated in more 
detail to clarify its mechanism of action.  
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Abstract 
A racemic mixture of R and S enantiomers of praziquantel (PZQ) is currently the treatment of choice for 
schistosomiasis. Though the S enantiomer and the metabolites are presumed to contribute only a little to the 
activity of the drug, in-depth side- by-side studies are lacking. The aim of this study was to investigate the in vitro 
activities of PZQ and its main metabolites, namely, R- and S-cis- and R- and S-trans-4-hydroxypraziquantel, 
against adult worms and newly transformed schistosomula (NTS). Additionally, we explored the in vivo activity 
and hepatic shift (i.e., the migration of the worms to the liver) produced by each PZQ enantiomer in mice. Fifty 
percent inhibitory concentrations of R-PZQ, S-PZQ, and R-trans- and R-cis-4-hydroxypraziquantel of 0.02, 5.85, 
4.08, and 2.42 µg/ml, respectively, for adult S. mansoni were determined in vitro. S-trans- and S-cis- 4-
hydroxypraziquantel were not active at 100 µg/ml. These results are consistent with microcalorimetry data and 
studies with NTS. In vivo, single 400-mg/kg oral doses of R-PZQ and S-PZQ achieved worm burden reductions 
of 100 and 19%, respectively. Moreover, worms treated in vivo with S-PZQ displayed an only transient hepatic 
shift and returned to the mesenteric veins within 24 h. Our data confirm that R-PZQ is the main effector molecule, 
while S-PZQ and the metabolites do not play a significant role in the antischistosomal properties of PZQ.	
1. Introduction 
Schistosomiasis or bilharzia is caused by blood flukes 
of the genus Schistosoma and is part of the group of 
neglected tropical diseases affecting more than 207 
million people in tropical areas (Steinmann et al., 
2006; Utzinger et al., 2011; Colley et al., 2014).  
The exclusive treatment to date for schistosomiasis is 
praziquantel (PZQ), which was discovered in the 
1970s by Merck and Bayer. PZQ is administered as a 
racemic mixture of R and S enantiomers in tablets of 
600 mg. The recommended dosage to treat 
schistosomiasis is 20 mg/kg three times in 1 day, and 
since PZQ does not act on juvenile worms, follow-up 
treatment 4 to 6 weeks later is strongly advised 
(Gryseels et al., 2006). In preventive chemotherapy 
programs, PZQ is administered as a single 40-mg/kg 
dose to at-risk populations (Organization, 2006). PZQ 
undergoes significant first-pass metabolism through 
the liver enzyme cytochrome P450 (CYP) 3A4 and to 
a lesser extent through 1A2 and 2C19 (Li et al., 2003). 
R-PZQ is metabolized at a much higher rate than S-
PZQ. R-PZQ is transformed mainly into cis- and trans-
hydroxypraziquantel (4-OH-PZQ), while S- PZQ is 
converted to other monohydroxylated metabolites. In 
rat liver microsomes, the main metabolite is cis-4-OH-
PZQ (Lerch and Blaschke, 1998; Meier and Blaschke, 
2001), while in humans it is trans-4-OH-PZQ (Melo et 
al., 2005).  
The difference in the antischistosomal activity of each 
PZQ enantiomer has been known since 1983 
(Andrews et al., 1983), and several studies have 
observed greater activity of R-PZQ than of S-PZQ in 
vitro and in vivo (Tanaka et al., 1989; Xiao and Catto, 
1989a; Staudt et al., 1992). A clinical trial with 
Schistosoma japonicum-infected patients also 
recorded a higher efficacy of R-PZQ than of racemic 
PZQ at the same dosage (Wu et al., 1991; Xu et al., 
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1994). Additionally, treatment with R-PZQ resulted in 
fewer adverse events than the standard treatment (Wu 
et al., 1991). However, since higher drug 
concentrations in plasma and slightly longer half-lives 
are achieved with the metabolites than with PZQ 
(Lima et al., 2011), it is possible that the metabolites 
contribute to the antischistosomal activity of PZQ. The 
efficacy of racemic trans-4-OH-PZQ was evaluated in 
vitro by Staudt and colleagues (Staudt et al., 1992), 
who observed similar antischistosomal properties of 
the trans metabolite and R-PZQ against adult worms.  
In this study, we comparatively assessed the in vitro 
activities of R-PZQ, S-PZQ, and the metabolites cis- 
and trans-4-OH-PZQ against adults and newly 
transformed schistosomula (NTS). Drug effects were 
evaluated by using both microscopic readouts and 
isothermal microcalorimetry. Since the metabolites 
are also chiral molecules, we evaluated for the first 
time the in vitro efficacy of the respective R and S 
enantiomers. We also studied the in vivo activity of 
each parent enantiomer in mice and estimated the 
hepatic shift of the worms after each treatment.  
2. Materials and methods 
2.1 Mice and infection  
All in vivo experiments were performed at the Swiss 
Tropical and Public Health Institute (Basel, 
Switzerland) and followed Swiss and cantonal animal 
welfare regulations (license no. 2070). Female NMRI 
mice (age, 3 weeks; weight, ca. 14 g) were purchased 
from Charles River (Sulzfeld, Germany) or Harlan 
Laboratories (Blackthorn, United Kingdom). The 
animals were allowed to adapt for 1 week under 
controlled conditions (22°C, 50% humidity, 12 h of 
light, and free access to water and a rodent diet) before 
experimental handling.  
NMRI mice were infected subcutaneously with 80 to 
100 cercariae, as previously described (Keiser, 2009).  
2.2 Drugs and media 
RPMI 1640 medium (Life Technologies, Carlsbad, 
CA) supplemented with 5% heat-inactivated fetal calf 
serum (iFCS), penicillin (100 U/ml; Life 
Technologies), and streptomycin (100 µg/ml; Life 
Technologies) was used for adult schistosome in vitro 
and microcalorimetry experiments. For NTS in vitro 
culture, medium 199 (Life Technologies) 
supplemented with iFCS and antibiotics was used.  
Racemic PZQ was purchased from Sigma-Aldrich 
(Buchs, Switzerland). Enantiomers of PZQ and cis- 
and trans-4-OH-PZQ were acquired from Merck 
Serono (Darmstadt, Germany) and synthesized by 
Matthew Todd (University of Sydney, Sydney, 
Australia) (Woelfle et al., 2011). Racemic cis- and 
trans-4-OH-PZQ were obtained from Gilles Gasser 
(University of Zurich, Zurich, Switzerland) (Patra et 
al., 2013). For in vitro studies, each compound was 
dissolved in dimethyl sulfoxide (DMSO; Fluka, 
Buchs, Switzerland) at a concentration of 10 mg/ml. 
For in vivo studies, the drugs were dissolved in 7% 
(vol/vol) Tween 80 and 3% (vol/vol) ethanol before 
oral treatment.  
2.3 In vitro studies 
NTS were obtained from cercariae by mechanical 
transformation (Keiser, 2009). Six to 12 h later, the 
schistosomula (100 NTS/well) were incubated in flat-
bottom 96-well plates (BD Falcon) containing the 
drug solution in medium at 1.2, 3.7, 11.1, 33.3, and 
100 µg/ml. Control NTS were incubated with the 
highest concentration of drug solvent used in the 
assays (2% DMSO). The plates were incubated at 
37°C in 5% CO2 for 72 h, and compound activity was 
microscopically assessed by using a motility scale 
ranging from 3 (normal activity) to 0 (no activity and 
granularity present) (Manneck, Haggenmüller and 
Keiser, 2009).  
To test the effect of each compound on adult worms, 
the drugs were diluted in medium in flat-bottom 24-
well plates (BD Falcon) at concentrations ranging 
from 0.01 to 10 µg/ml for racemic PZQ and R-PZQ 
and from 0.4 to 100 µg/ml for S-PZQ and the 
metabolites. Control wells consisted of drug-free 
medium with 2% DMSO. At 7 to 8 weeks post-
infection, S. mansoni-infected mice were euthanized 
with CO2 and dissected and adult worms were 
collected from the hepatic portal and mesenteric veins. 
Four to 6 worms of both sexes were deposited in each 
well and incubated at 37°C. After 4 and 72 h, the worm 
condition was microscopically evaluated on a scale of 
3 (normal activity and no tegumental alteration) to 0 
(dead, highly granulated) (Keiser, 2009). To test the 
recovery of adult worms following a short exposure to 
S-PZQ, we incubated adult worms in medium with 
100, 200, 300, or 400 µg/ml S-PZQ for 1 or 2 h and 
next transferred them to drug-free medium for up to 
72 h. These motility values at 72 h were compared to 
the values of worms incubated in S-PZQ for 72 h and 
control worms incubated in drug-free medium. Fifty 
percent inhibitory concentrations (IC50s) and IC90s 
were determined with CompuSyn software by using 
the motility values obtained at different dosages. The 
eudysmic ratio (Testa and Trager, 1990) was 
calculated as follows: eudysmic ratio IC50distomer/ 
IC50eutomer, where the eutomer, the active 
enantiomer, is R-PZQ and the distomer is S-PZQ.  
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2.4 Isothermal microcalorimetry  
The microcalorimetry experiments were performed in 
triplicate on a 48-channel isothermal microcalorimeter 
(TAM48; TA Instruments, New Castle, DE). First, 
glass ampoules were filled with 2,900 µl of medium 
and four worms of both sexes were added to each vial. 
Ampoules were then placed in the channels for the 
equilibration phase. Twelve hours later, 100 µl of a 
prewarmed drug solution prepared in medium was 
injected with a 1-ml syringe (BD Plastipak, Becton, 
Dickinson S.A., Madrid, Spain). End concentrations 
reached 0.04, 0.2, and 1 µg/ml for racemic and R-PZQ 
and 1, 5, and 50 µg/ml for S-PZQ and the metabolites. 
Ampoules containing schistosomes in the presence of 
DMSO alone (final concentration of 2%) served as 
negative controls, while ampoules containing dead 
worms, obtained by dipping them in 70% ethanol for 
5 min and rinsing them in a medium solution, served 
as positive controls. Schistosome motility data derived 
from noise amplitudes were recorded for 5 days and 
analyzed with R software and Excel (Manneck et al., 
2011). The noise amplitudes produced by worm 
movements and metabolism decay exponentially as 
the worms die, until they reach the background noise 
level recorded in the dead-worm positive controls. The 
intersection of both curves determines the endpoint of 
worm motility (Manneck et al., 2011).  
2.5 In vivo studies 
At 49 days post-infection (chronic S. mansoni 
infection), groups of three to six mice were treated 
orally with 400 mg/kg racemic PZQ, 400 or 800 mg/kg 
S-PZQ, or 100, 200, or 400 mg/kg R-PZQ. At 14 days 
post-treatment, the mice were euthanized and 
dissected. The worms in the veins and liver were sexed 
and counted (Xiao et al., 2007). Mean worm burdens 
of treated mice were compared to those of untreated 
mice, and worm burden reductions (WBRs) were 
determined. IC50s and eudysmic ratios were calculated 
as described above. The hepatic shift was investigated 
as follows. Groups of five mice infected with adult 
schistosomes were treated with 400 mg/kg S-PZQ, 
400 mg/kg racemic PZQ, or 200 mg/kg R-PZQ. After 
30 min, 1 h, 4 h, 24 h, and 7 days, one mouse in each 
group was euthanized and dissected and the worm 
burdens in its veins and liver were evaluated.  
Statistical tests were performed with Stata (version 
12.1; StataCorp LP, College Station, TX). Differences 
in worm burdens were assessed by using an unpaired 
t-test and allowing for unequal variances by 
comparing the control groups with the treated groups. 
The significance threshold was set at a P-value of 0.05.  
Table 1 Calculated in vitro IC50sand IC90s of racemic and 
enantiomeric PZQ and 4-OH metabolites against adult S. mansoni 
at 4 and 72 h postincubation  
a Extrapolated value determined by CompuSyn.  
b NA, not active at 100 µg/ml.  
3. Results  
3.1 In vitro studies 
Table 1 summarizes the in vitro IC50 and IC90 of 
racemic and optically pure PZQ and 4-OH-PZQ 
metabolites against adult S. mansoni after 4 and 72 h 
of incubation. R-PZQ displayed the highest activity, 
with an IC50 of 0.04 µg/ml after 4 h of incubation. The 
IC50 of R-PZQ after 72 h was half of the value for the 
racemic mixture, while the IC50 of S-PZQ was higher 
by a factor 100. The IC50s of the metabolites at 72 h 
showed the same pattern; the R conformation was 
twice as active as the racemic form, while no activity 
of the S metabolites at 100 µg/ml was detected. When 
the activities of the cis and the trans configurations 
were compared, the cis metabolites displayed slightly 
better activity than trans metabolites but the IC50s of 
the metabolites were nevertheless much higher than 
that of racemic PZQ. The eudysmic ratio of PZQ in 
vitro at 72 h post-exposure was estimated at 293.  
The antischistosomal activity of S-PZQ following 
short-term incubation is depicted in Fig. 1. Worms 
incubated for 1 or 2 h in high concentrations of S-PZQ 
recovered almost completely and displayed high 
motility values (1.25 to 2.5) after 3 days, in contrast to 
worms incubated for a full 72 h in S-PZQ, which did 
not score above 0.5.  
 IC50(µg/ml) IC90 at 
72 h 
(µg/ml) 
Eudysmic 
ratio Compound 4 h 72 h 
Rac-PZQ 0.1 0.05 0.4  
R-PZQ 0.04 0.02 0.04 
293 
S-PZQ 5.7 5.9 17.9 
Rac-trans-4-OH-
PZQ 16.7 7.9 3694
a 
R-trans-4-OH-PZQ 13.4 4.1 58.4 
S-trans-4-OH-PZQ NAb NA NA 
Rac-cis-4-OH-PZQ 15.8 4.8 81.4 
R-cis-4-OH-PZQ 4.5 2.4 48.7 
S-cis-4-OH-PZQ NA NA NA 
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Fig. 1: Motility values of adult worms (n=4-6, in triplicate) after 1 h (Ú) or 2 h () incubation in S-PZQ followed by incubation in drug-free 
medium until 72 h, compared with adults incubated 72 h in S-PZQ (l) and controls 72 h in drug-free medium (dashed line).  
The results of the in vitro assays against NTS are 
displayed in Table 2. The IC50 of R-PZQ was 
estimated at 0.03 µg/ml. S- PZQ showed markedly 
lower activity, with an IC50 of 40.0 µg/ ml. The 
eudysmic ratio calculated against NTS was 1,196. The 
IC50s of the trans metabolites were determined as 133 
and 28.5 µg/ml for the racemic and R derivatives, 
respectively, while the cis form of the R enantiomer 
showed moderate activity (IC50 of 34.3 µg/ml).  
Table 2 IC50 and IC90 values of racemic and enantiomeric PZQ and 
4-OH metabolites against NTS 72 h post-incubation in vitro 
 IC50 at 72 h (µg/ml) 
IC90 at 72 h 
(µg/ml) 
Eudysmic 
ratio 
Rac-PZQ 1.5 34.5  
R-PZQ 0.03 18.8 
1196 
S-PZQ 40.0 522.5a 
Rac-trans-4-OH-
PZQ 133.1
a 5852.2a 
R-trans-4-OH-
PZQ 28.5 747.4
a 
S-trans-4-OH-PZQ NAb NA 
Rac-cis-4-OH-
PZQ 911.1
a 2448837a 
R-cis-4-OH-PZQ 34.3 1161.8a 
S-cis-4-OH-PZQ NA NA 
a Extrapolated value determined by CompuSyn.  
b NA, not active at 100 µg/ml.  
3.2 Isothermal microcalorimetry 
The worm motility endpoints after PZQ enantiomer 
and metabolite treatments are summarized in Table 3. 
With R-PZQ, worm motility ceased in the first 3 h 
post-injection at concentrations as low as 0.04 µg/ml, 
while the same effect was observed for racemic PZQ 
only at 0.2 µg/ml. Worms exposed to the racemic and 
R metabolites at a concentration of 1 µg/ml did not 
display a decrease in motility. For racemic and R-cis-
4-OH-PZQ, the motility endpoints at 5 µg/ml were 
estimated, as depicted in Fig. 2, as 96.7 and 3 h post-
injection, respectively. Racemic trans-4-OH-PZQ was 
not active at 5 µg/ml, but R-trans-4-OH-PZQ 
produced a motility endpoint of 75 h post-injection.  
Table 3 Endpoints of worm motility in hours post-injection (SD) 
determined by noise amplitudes for different concentrations of 
racemic and enantiomeric PZQ and 4-OH metabolites 
 0.04 µg/ml 0.2 µg/ml 1 µg/ml 
Rac-PZQ > 120 < 3 < 3 
R-PZQ < 3 < 3 < 3 
S-PZQ > 120 > 120 > 120 
 1 µg/ml 5 µg/ml 50 µg/ml 
Rac-trans-4-OH-PZQ > 120 > 120 < 3 
R-trans-4-OH-PZQ > 120 75 (5) < 3 
S-trans-4-OH-PZQ > 120 > 120 > 120 
Rac-cis-4-OH-PZQ > 120 96.7 (16.1) < 3 
R-cis-4-OH-PZQ > 120 < 3 < 3 
S-cis-4-OH-PZQ Not tested Not tested > 120 
At a very high concentration of the racemic and R 
metabolites of 50 µg/ml, the motility of worms 
stopped within 3 h. None of the S derivatives 
interfered with worm motility after incubation for 5 
days at 50 µg/ml. 
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Fig. 2 Example of heat production recorded by microcalorimetry: rac cis-4-OH and R-cis-4-OH-PZQ at 5 µg/ml and S-cis-4-OH-PZQ at 50 
µg/ml 
3.3 In vivo studies 
In Table 4, the WBRs after different single oral doses 
of R- and S-PZQ are presented. Racemic PZQ 
produced a WBR of 94.1% at 400 mg/kg, while no 
significant effect was observed at 100 mg/kg. R-PZQ 
showed a WBR of 52% at 100 mg/kg and WBRs of 
98% at 200 and 400 mg/kg. S-PZQ displayed a low 
WBR of 19.6% at 800 mg/kg. When the worm burdens 
at 400 mg/kg were compared, there were significant 
differences between racemic PZQ and R-PZQ and the 
control group (P-values < 0.001). There was no 
statistically significant difference between the worm 
burdens of controls and those of S-PZQ-treated mice 
(P=0.68). The 50% effective doses (ED50s) of R- and 
S-PZQ were 95.4 and >1,000 mg/kg, respectively, and 
the corresponding eudysmic ratio was >10.  
The observed hepatic shift obtained with PZQ 
enantiomers for a single mouse per time point is 
illustrated in Fig. 3. Racemic PZQ acted rapidly; at 30 
min post-treatment, only a few living worms were still 
observed in the mesenteric veins, while from 1 h 
onward, all of the worms were found dead in the liver. 
Treatment with R-PZQ at half the dose of racemic 
PZQ produced fairly similar effects. Living worms in 
veins, however, were observed until 4 h post-
treatment. In contrast, treatment with S-PZQ resulted 
in a high number of dead worms in the liver at 30 min 
post-treatment, after which the number of worms 
killed decreased over time, and after 4 h post-
treatment only a small number of worms were found 
dead. At the 4-h examination point, all of the worms 
had migrated to the liver following treatment with S-
PZQ. By 24 h post-treatment, the majority of the 
worms had returned to the mesenteric veins.  
Table 4 Total and female worm burden reduction (WBR) obtained 
with racemic PZQ, R-PZQ and S-PZQ at different dosages in mice 
harboring adult S. mansoni 
Dose No. of mice  
WBR [%] 
(SD) 
ED50 
(mg/kg) 
Rac PZQ    
400 mg/kg 4 94.1 (8.6) 
246.5 
100 mg/kgb 6 15 (9.5) 
R-PZQ    
400 mg/kg 3 100.0 (0) 
95.4 200 mg/kg 6 98.1 (2.3) 
100 mg/kg 6 52.0 (30.8) 
S-PZQ    Eudysmic ratio 
800 mg/kg 6 19.6 (22.2) 
3066777a 32136 
400 mg/kg 4 18.0 (21.4) 
a Extrapolated value determined by CompuSyn 
b Data from Keiser, Manneck and Vargas, 2011
 37 
 
Fig. 3 In vivo hepatic shift after treatment with rac PZQ 400 mg/kg, R-PZQ 200 mg/kg or S-PZQ 400 mg/kg: number of worms alive in the 
mesenteric veins (white), alive in the liver (dashed) and dead in the liver (black) 
 
 
4. Discussion 
In the framework of a public-private partnership 
including Merck Serono, Astellas Pharma, the Swiss 
Tropical and Public Health Institute, and TI Pharma, 
efforts are ongoing to develop a pediatric formulation 
of PZQ. The project is currently in the preclinical 
phase, and in this work, we have for the first time 
conducted thorough side-by-side in vitro and in vivo 
studies with PZQ enantiomers and metabolites that 
will aid the development process.  
Our data show that the antischistosomal activity is 
driven mainly by the R configuration. We observed 
that R-PZQ and the R-hydroxylated metabolites reveal 
100- and 1,000-fold higher activities than their S 
counterparts in vitro. The racemic compounds display 
IC50s twice as high as those of their respective R 
configurations. Note that the IC50s observed against 
NTS were much higher than those against adults, 
which is in line with previous findings (Xiao, Catto 
and Webster, 1985; Ingram et al., 2012). Nevertheless, 
R enantiomers are again more active than S 
conformations against NTS.  
Microcalorimetry findings are consistent with our 
IC50s determined microscopically against adults in 
vitro. The loss of motility produced by R-PZQ at 0.04 
and 0.2 µg/ml and by racemic PZQ between 0.04 and 
0.2 µg/ml correlates nicely with the IC50s (0.02 and 
0.05 µg/ml, respectively). As observed in the in vitro 
microscopic assays, S-PZQ is not active at 1 µg/ml. 
Microcalorimetric measurements confirmed that the 
R-cis and R-trans forms are the active metabolites 
(e.g., with the R-cis and R-trans forms at 5 µg/ml, a 
loss of motility was observed at 96.7 and 75 h post-
injection, respectively). These observations are in 
agreement with our IC50 data (2.4 and 4.1 µg/ml for 
the R-cis and R-trans forms, respectively) based on 
microscopic viability scores.  
A similar pattern was observed in vivo. A single oral 
dose of 400 mg/kg of racemic PZQ shows activity 
similar to that of R-PZQ at 200 mg/kg. In contrast, 
treatment with S-PZQ at 800 mg/kg did not result in a 
significant WBR and none of the treated mice were 
cured.  
Dissection of mice at different time points after 
treatment allowed us to investigate the hepatic shift 
caused by PZQ and its enantiomers. The hepatic shift 
of worms into the liver had been characterized earlier 
for PZQ, as well as for several other drugs, including 
mefloquine (Keiser et al., 2009), artemether (Xiao and 
Catto, 1989b), oxamniquine (Foster and Cheetham, 
1973), or older antischistosomal drugs (Buttle and 
Khayyal, 1962). Treatment with the racemate and R-
PZQ efficiently immobilized or killed the majority of 
the worms, which were carried by blood flow to the 
liver, where they disintegrated over time. In contrast, 
treatment with S-PZQ killed only a few worms. 
Worms migrated to the liver and returned to the 
mesenteric veins 24 h post-treatment. The typical 
translocation of the worms into the liver might be 
explained by a loss of grip on the mesenteric vein wall 
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due to the chemical action of the compound, and when 
the therapeutic effect ceases, they migrate back to the 
mesenteric veins (Buttle and Khayyal, 1962). The 
return of worms to the mesenteric veins has been 
described for subtherapeutic doses or inefficient 
compounds (Bueding and Fischer, 1970). The 
transient hepatic shift observed in S-PZQ-treated mice 
is therefore strong additional evidence of its 
inefficacy.  
In order to place our in vitro findings in context, we 
have summarized the pharmacokinetic (PK) 
parameters of R-PZQ, S-PZQ, and the R-trans and S-
trans enantiomers obtained in humans (Lima et al., 
2011) in Table 5. The maximal concentration (Cmax) of 
R-PZQ (0.16 µg/ml) is 8 and 4 times as high as its IC50 
(0.02 µg/ml) and IC50 (0.04 µg/ml) at 72 h and still 4 
times as high as its IC50 (0.04 µg/ml) at 4 h. Besides, 
the high ratio of the area under the curve (AUC) to the 
IC50 of 43.5 of R-PZQ might also describe its excellent 
antischistosomal activity. On the other hand, the 
concentrations of S-PZQ and the R-trans enantiomer 
in plasma do not exceed the calculated IC50 calculated 
in our work at any time (IC50s approximately 11 and 3 
times as high as the Cmax, respectively). Though the 
AUC of the R-trans metabolite is much higher than 
those of R-PZQ and S-PZQ, the AUC/IC50 ratio is only 
2.1. Furthermore, our in vitro recovery experiments 
with S-PZQ, even at concentrations up to 700 times its 
Cmax (Lima et al., 2011), demonstrated that the worms 
were still alive and recovered from 2 h of exposure. As 
mentioned before, the S-trans metabolite is not active 
at 100 µg/ml.  
Published PK data for the cis metabolite are not yet 
available, but in light of its high IC50 compared to that 
of R-PZQ, it is also unlikely that it significantly 
contributes to the antischistosomal activity of PZQ.  
Changes in the activity of CYP enzymes can 
dramatically change the PK parameters of PZQ and 
thereby its therapeutic activity. For example, co-
administration of CYP 3A4 inducers such as 
dexamethasone dramatically reduces plasma PZQ 
levels in patients with neurocysticercosis (Vazquez, 
Jung and Sotelo, 1987; Na-Bangchang, Vanijanonta 
and Karbwang, 1995; Li et al., 2003). Albendazole is 
an inhibitor of CYP enzymes, and when it is 
administered concomitantly with PZQ, plasma R-PZQ 
levels are increased (Lima et al., 2011). The 
expression of CYP is also modulated during chronic 
schistosomiasis, with markedly lower activity in 
infected mice, probably resulting from the immune 
response to the infection (Gotardo et al., 2011). 
Interestingly, resistant isolates of S. mansoni do not 
inhibit host CYP as much as susceptible isolates do. 
This mechanism of resistance produces faster first-
pass metabolism, hence a shorter time of exposure to 
the parent drug (Botros et al., 2006). These results 
support the evidence that R-PZQ is the active 
molecule and metabolites do not have a major role in 
the activity of PZQ.
Table 5 PK parameters after an oral dose of 23.3 mg/kg in human volunteersa: maximal concentration (Cmax), time to maximal concentration 
(tmax), half-life (t1/2), area under the curve (AUC), and ratio Cmax/ IC50b and AUC/IC50b 
 Cmax (µg/ml) tmax (h) t1/2 (h) AUC (µg´h/ml) Cmax/IC50 (ratio) AUC/IC50 (ratio) 
R-PZQ 0.16 2.67 1.55 0.87 8 43.5 
S-PZQ 0.52 2.55 1.46 2.99 0.09 0.5 
R-trans-4-OH-PZQ 1.31 2.72 1.70 8.80 0.31 2.1 
S-trans-4-OH-PZQ 0.78 3.05 1.91 5.60 NAc NAc 
a adapted from Lima et al., 2011 (oral dose of 23.3 mg/kg) 
b IC50 values from adults after 72 h 
c NA, not applicable (no IC50) 
 
We conclude that the activity of PZQ is based almost 
exclusively on R-PZQ and that neither S-PZQ nor the 
metabolites significantly contribute to the therapeutic 
effect. Our results favor the development of a child-
friendly formulation of R-PZQ, since an enantiopure 
formulation displays two major advantages; first, it 
would allow clinicians to reduce the dosage by half, 
and second, it would ease administration to children, 
who are bothered by the bitter taste of S-PZQ (Meyer 
et al., 2009).  
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Abstract  
Praziquantel (PZQ) is the treatment of choice against various trematode and cestode infections. To study the 
pharmacokinetics of PZQ in patients infected with the liver fluke Opisthorchis viverrini, we developed and 
validated an enantioselective liquid chromatography coupled to tandem mass spectrometry method for the analysis 
of R - and S -PZQ and its R -trans-4-OH-PZQ metabolite in human plasma, blood and dried blood spots (DBS). 
The analytes were detected in the positive mode using selected reaction monitoring (R- and S-PZQ: m/z 312.2 → 
202.2; R-trans-4-OH-PZQ: m/z 328.0 → 202.0). Prior to the chiral separation with a cellulose tris(3-chloro-4-
methylphenylcarbamate) column, the analytes were purified from matrix contaminants and concentrated on a C-
18 trapping column. The analytical range for each PZQ enantiomer was 0.01–2.5 µg/ml, and 0.1–25 µg/ml for the 
metabolite. The method met the requirements regarding precision (±15%, ±20% at the lower limit of 
quantification-LLOQ), intra- and inter-assay accuracy (85–115%, 80–120% at LLOQ), and linearity (R2 ≥ 0.998). 
The analytes were stable in stock solutions as well as in plasma, blood and DBS. For DBS, the influences of 
hematocrit and blood spot size were considered as minor. Our validation results show that the method presented 
here is precise, accurate and selective, and can be used for pharmacokinetic studies. Moreover, the enantioselective 
separation was achieved with a run time of 11.5 min and a simple sample processing method.  
1. Introduction 
Praziquantel (PZQ), a pyrazino-isoquinoline available 
as a racemic mixture of R- and S-enantiomers, is the 
drug of choice for the treatment of most trematode and 
cestode infections, including the liver fluke 
Opisthorchis viverrini, a parasite affecting more than 
8 million people in Southeast Asia. PZQ undergoes an 
important enantioselective first-pass metabolism in 
the liver, mainly through CYP450 3A4 (Li et al., 
2003). R-PZQ is mostly metabolised to R-trans-4-OH- 
PZQ in humans or R-cis-4-OH-PZQ in mice, while S-
PZQ breaks down into various mono- and di-hydroxy 
metabolites additionally to S-trans- and S-cis-4-OH-
PZQ (Lerch and Blaschke, 1998; Meier and Blaschke, 
2001; Melo et al., 2005). PZQ disposition is heavily 
dependent on the fasting state or the co-administered 
food type, as well as on the liver function level (Castro 
et al., 2000; Gotardo et al., 2011). Therefore, it is of 
primordial importance to evaluate the 
pharmacokinetics of PZQ in patients suffering from 
worm infections affecting the liver, such as 
opisthorchiasis and schistosomiasis, and relate 
treatment efficacy with dosage regimens and plasma 
concentrations.  
The dried blood spotting (DBS) technique is an useful 
alternative for the collection of pharmacokinetic (PK) 
blood or plasma samples. In short, blood drops are 
collected by pricking a patient’s finger, deposited on a 
filter paper and kept dried until analysis. This method 
provides many advantages over alternative sampling 
methods: no cold chain is required, handling and 
storage of samples are simple, and minimal blood 
withdrawal volumes are needed (Spooner, Lad and 
Barfield, 2009). The ease of sample collection allows 
handling a much larger group of patients and 
performing population PK studies in rural areas 
without clinical settings. However, the concentrations 
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measured in DBS are not necessarily equal to blood or 
plasma concentrations. For example, the drug 
concentrations in capillary blood might be different to 
that in venous blood, or the analyte might display a 
strong plasma protein binding (Emmons and Rowland, 
2010; Xu et al., 2013). To date different high-pressure 
liquid chromatography (HPLC) and liquid 
chromatography coupled to tandem mass 
spectrometry (LC–MS/MS) methods were published 
for chiral separation of PZQ enantiomers (Westhoff 
and Blaschke, 1992; Kelly, He and Stewart, 1993; Liu 
and Stewart, 1997; Polisel Jabor, Rocha and Bonato, 
1997; Lima et al., 2009), but they focused on the 
analysis of plasma samples only. The objective of this 
study was to develop a rapid, precise and accurate LC–
MS/MS method to analyze R-PZQ, S-PZQ and R-
trans-4-OH-PZQ metabolite in human plasma, blood 
and DBS. This method can be applied to future studies 
comparing PZQ concentrations in different bio-fluids 
and to support PK studies in patients in disease-
endemic countries.  
2. Materials and methods  
2.1. Chemicals and reagents  
Racemic (rac) PZQ was purchased from Sigma-
Aldrich (Buchs, Switzerland). Enantiomers of PZQ 
and cis- and trans-4-OH-PZQ (trans-4-OH) were 
obtained from Merck Serono (Darmstadt, Germany). 
As internal standard (IS), eleven-fold deuterized PZQ 
(PZQ-d11) was purchased from Toronto Research 
Chemicals (Toronto, Ontario, Canada). Chemical 
structures of PZQ, PZQ-d11 and trans-4-OH are 
displayed in Fig. 1. Acetonitrile, ethanol and methanol 
of MS grade were obtained from Carl Roth GmBH 
(Allschwil, Switzerland). Ammonium formate, 
ammonium acetate and formic acid of MS grade were 
purchased from Sigma-Aldrich (Buchs, Switzerland). 
Ultrapure water was supplied with a Millipore Milli-Q 
water purification system (Merck Millipore, 
Darmstadt, Germany). Blank human plasma and blood 
were obtained in lithium heparin-coated vacutainer 
tubes (BD, Allschwil) from the local blood donation 
centre (Basel).  
2.2. LC–MS/MS equipment and conditions  
The HPLC system (Shimadzu, Kyoto, Japan) 
consisted of four LC-20AD pumps, a CTC HTS PAL 
autosampler (CTC Analytics, Zwingen, Switzerland), 
and an online DG-3310 degasser (Sanwa Tsusho, 
Tokyo, Japan), coupled to an API 3000 triple 
quadrupole mass spectrometer (MS) (AB Sciex, 
Framingham, MA, USA) with a Turbo Ionspray 
interface. A first chromatographic separation was 
achieved at 25°C through a column trapping system 
(HALO C-18, 4.6 × 5 mm, Optimize Technologies, 
Oregon City, OR, USA) using 10 mM ammonium 
acetate and 0.15% formic acid in ultra-pure water as 
mobile phase at a flow rate of 0.3ml/min. The sample 
injection volume was set at 20 µl. After 1 min, the 
analytes were eluted via a ten-port switching valve 
(VICI Valco Intruments, Schenkon, Switzerland) from 
the trapping to the main column, a Lux Cellulose-2 
column [cellulose tris(3-chloro-4-methylphenyl-
carbamate) phase, 150 × 4.6 mm, 3 µm, Phenomenex, 
Torrance, CA, USA], for enantioselective separation. 
The elution gradient was defined as follows: 1-2 min, 
B 70-90%; 2-9.5 min, B 90%; 9.5–10 min, B 90–0%; 
10–10.5 min, B 0–70%; 11–11.5 min, B 70% with 
mobile phase A consisting of 20 mM ammonium 
formate in ultrapure water and mobile phase B of pure 
acetonitrile. The flow rate was 1.5ml/min. Carry-over 
problems were controlled by rinsing the syringe and 
the loop twice with pure water and acetonitrile - 
isopropanol (1:1, v/v) after each injection. To avoid 
contamination of the MS, a second ten-port switching 
valve (VICI Valco Instruments) was used to divert the 
effluent of the analytical column from the MS during 
0–3 and 9.5–11.5 min of each run. Due to the high 
flow rate of 1.5 ml/min, 50% of the flow was diverted 
through a splitter 
 
 
Fig. 1 Chemical structures of PZQ (A), the main metabolite trans-4-OH (B) and the internal standard PZQ-d11 (C), with the chiral centre 
designated with ✴ 
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The analytes were detected by selected reaction 
monitoring (SRM) in the positive mode. Parameters 
were optimized by direct infusion of 1 µg/ml of PZQ 
or the trans-4-OH metabolite in acetonitrile at a rate of 
10 µl/min (Harvard apparatus infusion pump 11, 
Holliston, MA, USA). Spectrometer parameters were 
as follows: nebulizer gas (N2) flow was 12 µl/min, 
curtain gas (N2) flow was 12 µl/min, source 
temperature was 400°C, ion spray voltage was 5500 
V, collision gas (N2) flow was 4 µl/min, entrance 
potential 10 V and dwell time was 300 ms. Analyst 1.5 
software package (AB Sciex) was used for instrument 
control and data collection.  
2.3. Standard, quality control and internal standard 
preparation  
Stock solutions (racemic PZQ, R-PZQ and S-PZQ: 1 
mg/ml; cis- and trans-4-OH in racemic or 
enantiomeric forms: 10 mg/ml; and IS: 1.25 mg/ml) 
were prepared in methanol and kept at -20°C. For the 
preparation of calibration and quality control (QC) 
samples, PZQ and R-trans-4-OH stock solutions were 
mixed to obtain a stock mix solution of 60 µg/ml of R- 
and S-PZQ and 600 µg/ml of R-trans- 4-OH. Working 
solutions of R-PZQ, S-PZQ and R-trans-4-OH were 
obtained by serial dilution of the stock mix solution 
with pure water – acetonitrile (1:2, v/v) to 
concentrations ranging from 0.6 to 60 and 6 to 600 
µg/ml, respectively. The extraction solution for blood 
and plasma consisted of 0.5 µg/ml IS diluted in 
acetonitrile. For DBS, the extraction solution 
containing IS was further diluted with ultrapure water 
[IS solution-water (4:1, v/v)].  
2.4. Plasma, blood and DBS sample preparation  
Calibration samples were freshly prepared and 
included in each analytical run by spiking blank 
samples with the working solutions to reach final 
concentrations of 2.5 down to 0.01 (lower limit of 
quantification-LLOQ) µg/ml for R- and S-PZQ, and of 
25 to 0.1 (LLOQ) µg/ml for R-trans-4-OH. QC 
samples were similarly obtained by spiking blank 
samples to final concentrations of 1.75, 0.175, 0.0175 
and 0.01 µg/ml (high, medium, low and LLOQ 
concentrations) for R- and S-PZQ, and to 17.5, 1.75, 
0.175 and 0.1 µg/ml for R-trans-4-OH. For plasma and 
blood QC samples, each QC concentration was 
prepared in 6 replicates from different human donors. 
DBS QC sample replicates were prepared with 6 
different hematocrit values ranging from 25 to 50% 
and the DBS calibration line with a hematocrit of 35%, 
following the procedure recommended by Koster et 
al., 2015. DBS blood samples (20 µl) were deposited 
on DMPK-C DBS cards (Whatman, GE Healthcare 
Life Sciences, Cardiff, UK) dried overnight and stored 
at room temperature in plastic bags containing silica 
gel desiccants.  
2.5. Extraction procedure  
Hundred µl of plasma or blood samples underwent 
protein precipitation with 700 µl of acetonitrile 
containing IS. The samples were vortex-mixed and 
agitated in a thermomixer for 20 min at 25°C and 
18,400 × g. DBS samples were cut out of the filter card 
with a puncher of 5mm diameter and extracted with 
300 µl of DBS extraction solution containing IS (see 
above). The filter-disks were vortex-mixed, agitated in 
a thermomixer for 20 min at 25°C, and sonicated for 
40 min. Extracts were transferred to 96-well filter 
plates (2 µm PVDF membrane, Corning Life Sciences, 
Tewksbury, MA, USA) and centrifuged at 25°C and 
1,500 × g for 10 min. The collecting plates were then 
sealed with pre-slit caps (Sepra Seals®, Thermo 
Fisher Scientific, Hudson, NH, USA) and directly 
placed in the LC–MS/MS autosampler at 10°C. 
2.6. Method validation  
The LC–MS/MS method was validated for selectivity, 
linearity, precision, accuracy, recovery and stability 
according to the Food and Drug Administration (FDA) 
guidelines for bioanalytical method validation (Food 
and Drug Administration, 1999). The selectivity of the 
method was evaluated by running blank plasma, blood 
and DBS samples to estimate eventual interferences 
with endogenous matrix components. The LLOQ was 
set in order to achieve a sufficient sensitivity with a 
minimum signal to noise peak area ratio of 5, based on 
DBS samples, which supply a limiting amount of 
blood. Carry-over effects were tested by injecting a 
blank sample after the highest sample of the 
calibration line. Calibration curves normalized with IS 
peak areas were fitted by linear regression. The 
weighting factor for the linear regression (1/x2) was 
selected to yield the lowest total error. Accuracy and 
precision of the method were assessed by analysing 
QC samples at LLOQ, low, medium and high 
concentrations. Precision was estimated using the 
coefficient of variation (CV) between 6 replicates, and 
accuracy was calculated as the percentage ratio of the 
measured concentration to the nominal concentration. 
A precision of ±15% (LLOQ: ±20%) and an accuracy 
between 85 and 115% (LLOQ: 80-120) was accepted 
in our method.  
To estimate the uniformity of the extraction procedure 
(relative recovery) within the calibration range, 
sample extracts were compared to blank extracts 
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spiked with analytes at corresponding expected 
concentrations (low, medium and high QC 
concentrations). Similarly, suppressive or enhancive 
effects of the biological matrix (matrix effects) were 
quantified by comparing the signal spiked in blank 
extract with the signal spiked in buffer [IS solution- 
water (7:1, v/v) for plasma and blood; DBS extraction 
solution for DBS]. The total recovery of the method 
was calculated as the signal in sample extracts 
compared to the signal in spiked buffer. Each 
concentration was prepared in 6 replicates from 
different human donors. The percentage recovery data 
should be constant across the calibration range.  
The short-term stability of each analyte stock solution 
was estimated by comparing signals from stock 
solutions left 6 h at room temperature with freshly 
prepared solutions. The long-term stability of stock 
solutions was evaluated between 3 month-old 
solutions stored at 4°C and freshly prepared solutions. 
The bench-top stability of plasma and blood samples 
was tested between samples left 4 h at room 
temperature and fresh samples. The freeze-thaw 
stability was similarly determined using 3 cycles of 
freezing at −80°C and thawing at room temperature. 
The stability of extracts in the autosampler was 
evaluated between extracts stored at 10°C in the 
autosampler for 72 h and freshly extracted samples.  
The hematocrit bias in DBS was estimated by 
comparing QC samples prepared with blood from 
different hematocrit values (25 to 50%), as described 
above. The effect of the blood spot size was tested by 
comparing the signals from spots of blood of 15 vs. 30 
µl.  
2.7. Application of method  
Blood, plasma and DBS sample collection was 
performed in the frame of a dose-finding study with 
tribendimidine against O. viverrini in humans in Lao 
PDR. Ethical clearance was obtained from the ethics 
committee of Basel, Switzerland (EKBB reference no. 
375/11), and from the National Ethics Committee in 
Laos. The trial is registered at Current Controlled 
Trials (ISRCTN96948551). In short, a patient was 
treated with 3 oral doses of 25 mg/kg PZQ, with the 
second and third dose administered at 4 and 8 h after 
the first treatment. Eleven blood samples were 
collected at 0, 2, 4, 6, 8, 8.5, 9, 10, 11, 12 and 24 h 
after the first treatment. About 4 ml of venous blood 
was withdrawn from the antecurbital arm vein through 
an i.v. catheter and collected in heparin-coated 
vacutainer tubes (BD). Within 30 min after sampling, 
1 ml of blood was stored in a cryotube and the 
remaining blood centrifuged to obtain plasma. Plasma 
and blood samples were transported on dry ice to 
Basel (Switzerland) where they were kept at −80°C 
until assayed. Six DBS samples were collected as well 
at 0, 4, 8, 9, 11 and 24 h post-treatment. The samples 
were taken by puncturing the middle or ring finger 
with a sterile one-way finger pricker (Accu-Check 
Safe-T-Pro Plus, Roche, Switzerland). Lithium 
heparin coated capillaries (AlereTM Cholestech 
LDX®, V=40 µl) were used to collect and deposit the 
blood on DBS cards. The cards were allowed to dry 
overnight and stored in plastic bags with desiccant at 
room temperature.  
3. Results and discussion  
3.1. Method development  
Different LC and LC–MS/MS methods were 
published for chiral separation of PZQ enantiomers in 
plasma (Westhoff and Blaschke, 1992; Kelly, He and 
Stewart, 1993; Liu and Stewart, 1997; Polisel Jabor, 
Rocha and Bonato, 1997; Lima et al., 2009). However, 
these methods present long run times of at least 20 min 
and the use of normal-phase eluents requires long 
sample preparation procedures. The aim of our study 
was therefore to develop a less time-consuming 
analytical method suitable for running a large number 
of clinical samples. Sample processing duration and 
analytical run time were therefore critical points to be 
optimized in our method. In addition, while the earlier 
methods focussed on plasma, we aimed to validate a 
method that could be used for 3 different bio-fluids, 
i.e. blood, plasma and DBS, for a future bridging 
study. The intention behind using DBS is to be able to 
perform larger scale PK studies in remote settings in 
Africa and Southeast Asia, including young children. 
DBS methods clearly have limitations of sensitivity, 
given such the small volumes of blood assayed. For 
comparison, earlier developed methods using plasma 
reached an LLOQ of 1.25 ng/ml for the parent 
enantiomers and 12.5 ng/ml for the metabolite, which 
was not possible for DBS samples. However, such 
sensitivity is not absolutely needed because of the high 
PK disposition after a standard treatment. Finally, we 
increased the upper analytical range compared to the 
previous methods to fit better to PK profiles obtained 
in patients treated with the standard dose of PZQ, and 
therefore avoid sample dilution for S-PZQ and R-
trans-4-OH.
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Table 1 Recovery of R-PZQ, S-PZQ and R-trans-4-OH at low, medium and high QC concentrations in blood, plasma and DBS (n=6) 
 Matrix Nominal conc. [µg/ml] RRE [%]a ± CV ME [%]b ± CV Total recovery [%]c ± CV 
R-
PZ
Q
 
Blood 
1.75 80.8 ± 4.9 106.2 ± 7.5 85.9 ± 6.5 
0.175 79.4 ± 9.0 105.0 ± 6.2 83.4 ± 2.3 
0.0175 86.2 ± 5.1 99.6 ± 8.3 85.9 ± 6.9 
Plasma 
0.01 99.4 ± 4.0 101.3 ± 4.9 100.7 ± 2.1 
1.75 96.5 ± 3.8 102.3 ± 3.6 98.7 ± 1.3 
0.175 93.9 ± 4.4 106.0 ± 3.8 99.5 ± 1.3 
DBS 
0.0175 81.2 ± 7.1 97.3 ± 3.8 79.0 ± 3.5 
0.01 80.2 ± 5.8 100.8 ± 2.0 80.8 ± 5.2 
1.75 84.9 ± 7.5 97.4 ± 1.4 82.7 ± 1.7 
S-
PZ
Q
 
Blood 
1.75 81.2 ± 4.4 107.9 ± 7.0 87.7 ± 5.1 
0.175 79.3 ± 8.0 106.2 ± 6.7 84.2 ± 2.8 
0.0175 86.5 ± 3.8 100.4 ± 8.6 86.8 ± 7.4 
Plasma 
0.01 98.4 ± 4.6 99.0 ± 3.8 97.3 ± 2.7 
1.75 96.4 ± 3.8 102.1 ± 3.9 98.4 ± 1.3 
0.175 94.1 ± 4.3 104.8 ± 2.7 98.6 ± 1.0 
DBS 
0.0175 80.9 ± 7.2 95.8 ± 5.3 77.5 ± 3.0 
0.01 79.1 ± 5.9 98.8 ± 3.3 78.2 ± 5.0 
1.75 84.2 ± 8.5 96.9 ± 1.5 81.6 ± 1.9 
R-
tr
an
s-
4-
O
H
 
Blood 
17.5 79.8 ± 8.2 127.0 ± 6.4 104.0 ± 6.6 
1.75 89.2 ± 9.5 123.5 ± 6.8 110.2 ± 4.5 
0.175 87.5 ± 9.8 111.8 ± 5.0 94.6 ± 6.0 
Plasma 
0.16 86.9 ± 9.6 83.3 ± 5.0 71.0 ± 13.0 
17.5 86.0 ± 8.4 85.3 ± 5.5 76.9 ± 7.8 
1.75 81.2 ± 6.3 74.4 ± 6.8 70.4 ± 4.5 
DBS 
0.175 79.2 ± 8.6 105.7 ± 5.3 83.7 ± 4.0 
0.1 79.8 ± 2.6 105.2 ± 8.0 83.9 ± 6.0 
17.5 79.6 ± 5.4 96.9 ± 5.8 77.1 ± 1.6 
a The relative recovery (RRE) is the signal in normally-extracted samples compared to the signal spiked after extraction 
b The matrix effects (ME) are the signal spiked after extraction compared to the signal spiked in buffer 
b The total recovery is the signal in normally-extracted samples compared to the signal spiked in buffer 
First, the MS parameters were optimized in the 
positive mode for PZQ, trans-4-OH and IS, and for 
each analyte the mass transition with the highest signal 
was selected. The major analyte parameters are 
summarized in the Supplementary Table T1.  
An efficient sample extraction method without 
evaporation and reconstitution was developed. For 
plasma and blood samples, a simple protein 
precipitation with acetonitrile was found to be 
satisfactory. For DBS samples, the composition of the 
extraction solution was a critical factor. The use of 
pure acetonitrile led to incomplete extraction of 
analytes, while high water content increased sample 
background, due to extraction of water-soluble 
elements of blood. The dried blood was thus partially 
dissolved using a mixture of water and acetonitrile 
containing IS (1:4, v/v), followed by sonication for 40 
min.
Table 2 Accuracy and precision obtained in DBS QC samples with hematocrit values from 25 to 50% (n=3) calculated with a calibration line 
of hematocrit 35% 
QC concentration Hematocrit [%] R-PZQ [%] ± CV S-PZQ [%] ± CV R-trans-4-OH [%] ± CV 
Low 
25 90.9 ± 5.3 89.5 ± 8.7 86.3 ± 11.3 
30 96.2 ± 8.9 91.5 ± 9.9 90.3 ± 5.8 
35 99.4 ± 2.2 96.8 ± 3.9 100.1 ± 4.4 
40 103.6 ± 0.6 103.6 ± 6.2 111.0 ± 6.3 
45 109.2 ± 2.2 108.9 ± 5.3 113.6 ± 3.3 
50 113.5 ± 2.2 111.1 ± 1.5 103.4 ± 8.8 
High 
25 97.9 ± 2.4 101.4 ± 8.5 97.9 ± 6.7 
30 100.7 ± 8.4 104.3 ± 9.8 94.8 ± 4.8 
35 110.1 ± 9.0 109.4 ± 10.3 92.6 ± 0.8 
40 109.1 ± 5.8 109.7 ± 4.6 97.8 ± 8.4 
45 111.5 ± 2.0 114.5 ± 2.2 109.8 ± 5.8 
50 114.1 ± 1.4 114.0 ± 2.1 106.4 ± 1.3 
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To purify and concentrate the analytes prior to chiral 
analysis, an in-line chromatographic separation using 
a C-18 trapping column was implemented. The 
adsorption of analytes on the trapping column was 
accomplished with an aqueous buffer. Ammonium 
acetate at 10 mM plus 0.15% formic acid displayed a 
3-fold higher signal than non-acidic buffer or pure 
water.  
The choice of the cellulose-2 column was based on the 
phase similarity to the Chiralcel OD columns used in 
previous enantioselective methods for praziquantel 
(Westhoff and Blaschke, 1992; Kelly, He and Stewart, 
1993; Polisel Jabor, Rocha and Bonato, 1997). To 
optimize run times, acetonitrile was preferred over 
methanol for the organic mobile phase to separate 
PZQ enantiomers. For the aqueous phase, 20mM 
ammonium formate was chosen. Addition of acid 
modifiers, as formic or acetic acid, had a negative 
effect on the peak shape and was therefore not advised. 
By using a flow rate of 1.5 over 0.7 ml/min, a loss of 
half of the signal was observed. However, this was 
considered as acceptable in view of a 50% run time 
gain. A gradient from 70 to 90% mobile B in 1 min 
allowed us to achieve a baseline separation of the R-
PZQ peak from the metabolite peaks. 
Since PZQ enantiomers, as well as the mono-
hydroxylated isomers cis- and trans-4-OH, have the 
same mass, their chromatographic baseline separation 
is necessary. Separation of R- and S-PZQ was 
achieved with a retention time of 5.5 and 7.5 min, 
respectively (Fig. 2). R-trans-4-OH, the main 
metabolite had the shortest retention time of 3.5 min. 
S-trans, and R- and S-cis-4-OH, which were not of 
interest, did not interfere with the analytics.  
 
Fig. 2 Chromatogram of the chiral separation of PZQ (black line) 
and cis- and trans-4-OH enantiomers (grey line) at a concentration 
of 0.6 µg/ml, and IS (dotted line) at 0.5 µg/ml 
The performance of other DBS card types, such as the 
903 Protein Saver (Whatman) and the Bond Elut DMS 
(Agilent Technologies, Santa Clara, CA, USA), was 
also evaluated compared to the Whatman DMPK-C 
cards used in the present study. Both card types from 
Whatman are made from a cellulose-based collection 
paper. The Agilent cards, on the contrary, are a non-
cellulose technology and are designed to achieve a 
better signal and reduce the hematocrit bias (Agilent, 
no date). For Agilent cards, an extraction with 
acetonitrile-water (1:1, v/v) in addition to the standard 
4:1 extraction was tested, without optimizing further 
the extraction method for this type of substrate. The 
choice of DBS paper turned out to be an important 
factor. Due to the physico-chemical properties of the 
Agilent cards, the blood drops were not spreading as 
much as on the cellulose- based cards and only a 
puncher of 3 mm diameter could be used. Both 
Whatman cards show similar signal intensities over 
the calibration line with low coefficients of variation 
(CV) (Supplementary Table T2). The Agilent cards, 
on the contrary, display much lower signals than the 
DMPK-C, and the recoveries of analytes vary with 
molecular structure and concentration tested, as 
observed by Cobb and colleagues (Cobb et al., 2013) 
for different compound families. The linearity of DBS 
with the different methods reflected the results 
observed with the signal difference, with Whatman 
903 being a good surrogate for DMPK-C, while 
Agilent cards exhibited non-linear calibration lines.  
3.2. Method validation  
The method was validated according to the guidelines 
for bio- analytical method validation of the FDA. The 
LLOQ was set at 0.01 µg/mL for R-and S-PZQ and at 
0.1 g/ml for R-trans-4-OH. The method was sensitive 
at LLOQ concentrations, with peak area ratios of 
signal-to-noise at LLOQ higher than 5:1 for all the 
analytes. The carry-over peaks were as well lower than 
5x the LLOQ signal. No co-eluting peaks from 
endogenous matrix components were observed in 
blank samples. Representative chromatograms of 
LLOQ vs. noise signals, and of a patient sample are 
depicted in the Supplementary Fig. F1, and in Fig. 3, 
respectively.  
The calibration lines consisted of 8 points (0.01, 0.025, 
0.05, 0.1, 0.25, 0.5, 1 and 2.5 µg/ml for R- and S-PZQ; 
0.1 0.25, 0.5, 1, 2.5, 5, 10 and 25 µg/ml for R-trans-4-
OH) and were characterized by correlation 
coefficients for all the analytes higher than R2= 0.998. 
The accuracy and precision of the method was 
assessed intra- and inter-assay for each analyte, as 
summarized in the Supplementary Table T3. The 
accuracy observed in all the analytes was within the 
limits of 85 and 115% (80 and 120% at LLOQ) and 
the precision level observed was not above 15% (20% 
at LLOQ).  
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Fig. 3 Representative LC-MS/MS chromatograms of trans-4-OH 
(grey line), PZQ (black line) and IS (dotted line) in plasma (A), 
blood (B) and DBS (C) of a patient treated with 3x25 mg/kg PZQ at 
2 h post-treatment 
The recovery of analytes after the extraction 
procedure, as well as eventual enhancing or 
suppressing matrix effects, and overall total recovery 
were estimated for all the analytes across the 
calibration range (Table 1). Extraction recovery and 
matrix effects were similar for R- and S-PZQ for the 
different matrices. Matrix effects for the parent 
molecule were negligible. For the metabolite, the 
extraction recovery was similar to the parent analytes 
in blood and plasma, while in DBS the recovery 
efficiency was lower. Interestingly, for R-trans-4-OH, 
the matrix effects were minimal in DBS, while 
enhancing effects could be observed in blood matrix 
and suppressive effects in plasma. The overall 
recoveries of all analytes were above 70% and 
constant across the 3 concentrations tested.  
The stability of analytes was tested in the stock 
solutions as well as in the different matrices 
(Supplementary Table T4). Our stability results of 
PZQ and the main metabolite in plasma were 
consistent with previously published studies (Ridtitid 
et al., 2002; Hanpitakpong et al., 2004; Bonato et al., 
2007; Lima et al., 2009, 2011). The analyte signals 
after 3 cycles of freezing and thawing was unchanged 
compared to fresh samples. Bench-top stability, i.e. 
the stability of analytes after 4 h at room temperature, 
was acceptable. Stability in the autosampler was not 
an issue, since extracted samples could be kept 
without variation in signal intensity for 72 h in the 
autosampler prior to analysis. Plasma and blood 
samples were stable for at least 6 months at −80°C. 
DBS samples could be kept at room temperature at 
least for 6 months without alteration of the analyte 
signals.  
The validation of a method using DBS calls for 
additional parameters to be evaluated (Spooner, Lad 
and Barfield, 2009; Xu et al., 2013). First, the blood 
hematocrit, by its influence on blood viscosity, can 
change the spread of the blood drop on the filter paper 
and consequently the recovery of analytes from DBS. 
In our study, a small hematocrit bias was observed: 
accuracy of all the analytes increased with increasing 
hematocrit. However, when using calibration 
standards with a middle-range hematocrit (i.e. 35%), 
accuracy values were within the recommended limits 
(Table 2). The DBS sampling technique might be as 
well prone to bias by repartition of the analytes over 
the spot area. Due to the physical behaviour of the drop 
depositing on the paper, the analyte might concentrate 
on the outer ring of the blood spot, leaving the 
punching area with a lower analyte concentration. The 
spread of the analytes in the blood spot was tested in 
different spot sizes. The percentage differences of 
signals obtained from spots of 30 vs. 15 µl spots 
ranged between 101.1 and 114.4% at low, medium and 
high concentrations for all the analytes. The spot size 
effect was therefore minor and we assume that all the 
analytes were uniformly distributed over the whole 
DBS spotting area.  
3.3. Method application  
The method reported here was applied to study the 
kinetic disposition of an O. viverrini-infected patient 
orally treated with 3 × 25 mg/kg PZQ. The PK profiles 
of R- and S-PZQ and R-trans-4-OH are illustrated in 
Fig. 4. The concentrations observed for R-PZQ are 
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overall lower by a factor of 2 compared to S-PZQ, with 
a Tmax at 6 h after treatment. R-trans-4-OH displays a 
slower kinetic disposition with a peak concentration 
between 8 and 8.5 h. The Cmax of the metabolite is 
almost 9 times higher than S-PZQ and almost 18-fold 
higher than R-PZQ. The Cmax of S-PZQ in our study 
is, as expected, 3-fold higher than the one reported in 
a previously published study (Lima et al., 2011) with 
healthy volunteers treated with a third of the dose used 
here (25 mg/kg vs. 3 × 25 mg/kg). R-PZQ, however, 
displays a lower Cmax than expected from the 
aforementioned article (i.e. lower than 3x the Cmax ), 
probably because we did not sample at 2.5 h, the Tmax 
recorded by Lima and colleagues. Also, the 
administration in 3 doses over 8 h instead of a single 
dose might account for the differences of PZQ 
disposition between the present study and the article 
by Lima and colleagues. For the metabolite, on the 
contrary, the Cmax observed in our study is much 
higher than expected, which might be explained with 
the different dosing regimen and the metabolite 
accumulating over time, probably due to a poor 
elimination. Blood and DBS display very similar PK 
profiles, while plasma shows a slightly higher 
disposition than blood or DBS for the parent molecule 
and slightly lower disposition for the metabolite, likely 
arising from a lower plasma affinity of the metabolite 
compared to the parent analyte. Overall, blood, plasma 
and DBS PK profiles are consistent for each analyte, 
demonstrating the applicability of our method.  
 
Fig. 4 Pharmacokinetic profiles of R-PZQ (A), S-PZQ (B) and R-trans-4-OH (C) in blood (¡), plasma (Ú) and DBS (▲) in a patient treated 
with 3x25 mg/kg PZQ 
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4. Conclusion  
The LC–MS/MS method reported here for the 
enantioselective analysis of PZQ and R-trans-4-OH 
metabolite is selective, precise and accurate. The short 
run time of 11.5 min and the simple and reproducible 
extraction methods for plasma, blood and DBS are 
valuable advantages to the analysis of a large number 
of samples. A sensitivity of 0.01 µg/ml for R- and S-
PZQ and of 0.1 µg/ml for R-trans-4-OH was achieved 
in DBS, plasma and blood. Applicability of the 
method was demonstrated by the analysis of the PK 
profile of a patient treated with 3 × 25 mg/kg PZQ over 
24 h. This method in combination with the DBS 
technique, will allow us to collect and analyze PK 
samples from clinical trials in rural areas of Africa and 
Southeast Asia.  
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Supplementary tables 
 
Table T1 MS/MS conditions optimized for each analyte 
Parameter R- and S-PZQ R-trans-4-OH PZQ-d11 
Mass and mass transitions [m/z] 312®202 328®202 323®203 
Declustering potential [V] 66 56 66 
Focusing potential [V] 240 190 240 
Collision energy [V] 25 27 25 
Cell exit potential [V] 16 16 16 
 
Table T2 DBS calibration line linearity and differences in signal intensities between the standard Whatman DMPK-C cards and other card 
types 
  Agilent (4:1)b Agilent (1:1) Whatman 903 (4:1) 
R
-P
ZQ
 Mean differencea [%] ± CV 31.4 ± 19.6 50.0 ± 16.4 101.6 ± 10.1 
Linearity (R2) 0.9837 0.9959 0.9994 
S-
PZ
Q
 Mean difference [%] ± CV 33.3 ± 63.4 18.4 ± 14.2 104.5 ± 6.6 
Linearity (R2) 0.9699 0.9720 0.9994 
R
-tr
an
s-
4-
O
H
 Mean difference [%] ± CV 41.2 ± 52.1 180.3 ± 42.5 105.3 ± 7.1 
Linearity (R2) 0.9622 0.9693 0.9995 
a Mean of the percentage ratio of the tested cards to the Whatman DMPK-C card signals across all the calibration points (n=8) 
b In brackets, the extraction solution ratio acetonitrile - water (v/v) 
 53 
Table T3 Intra- (n=6) and inter-assay (n=12) accuracya and precisionb in QC samples at LLOQ, low, medium and high concentrations 
 Matrix Nominal concentration [µg/ml] Intra-assay [%] ± CV Inter-assay [%] ± CV 
R
-P
ZQ
 
Blood 
1.75 103.8 ± 2.8 103.2 ± 3.6 
0.175 99.6 ± 5.8 97.3 ± 5.4 
0.0175 91.8 ± 8.4 91.3 ± 7.3 
0.01 102.2 ± 3.4 94.7 ± 10.9 
Plasma 
1.75 108.8 ± 4.6 103.0 ± 8.5 
0.175 102.8 ± 5.9 99.3 ± 5.8 
0.0175 106.0 ± 4.4 103.7 ± 6.0 
0.01 107.0 ± 0.6 105.2 ± 8.3 
DBS 
1.75 98.9 ± 8.6 100.0 ± 9.9 
0.175 96.0 ± 9.1 99.6 ± 7.7 
0.0175 101.6 ± 9.5 104.4 ± 8.2 
0.01 103.6 ± 14.3 102.4 ± 12.7 
S-
PZ
Q
 
Blood 
1.75 104.4 ± 2.8 103.6 ± 3.6 
0.175 100.5 ± 6.2 97.6 ± 5.7 
0.0175 96.6 ± 6.8 94.4 ± 6.7 
0.01 103.5 ± 8.1 99.2 ± 9.0 
Plasma 
1.75 108.8 ± 3.8 102.6 ± 9.2 
0.175 97.9 ± 9.2 96.3 ± 5.2 
0.0175 106.1 ± 3.8 102.9 ± 5.9 
0.01 106.4 ± 8.9 103.3 ± 9.3 
DBS 
1.75 100.9 ± 9.9 100.9 ± 10.6 
0.175 101.5 ± 6.0 99.9 ± 7.9 
0.0175 103.2 ± 7.7 101.8 ± 9.4 
0.01 100.4 ± 10.1 91.8 ± 12.7 
R
-tr
an
s-
4-
O
H
 
Blood 
17.5 104.5 ± 6.3 104.5 ± 5.7 
1.75 100.2 ± 11.4 100.0 ± 8.5 
0.175 105.0 ± 8.7 99.7 ± 10.9 
0.1 88.2 ± 3.9 96.3 ± 14.8 
Plasma 
17.5 100.0 ± 4.9 100.8 ± 4.7 
1.75 104.2 ± 5.5 105.2 ± 4.4 
0.175 97.2 ± 7.5 100.5 ± 8.6 
0.1 98.9 ± 5.6 96.1 ± 10.5 
DBS 
17.5 91.5 ± 2.0 102.0 ± 9.5 
1.75 94.5 ± 9.4 101.0 ± 9.3 
0.175 101.8 ± 8.4 108.6 ± 10.7 
0.1 100.7 ± 10.1 101.2 ± 11.6 
a The accuracy is calculated as the percentage ratio of the measured concentration to the nominal concentration 
b The precision is the percentage ratio of the standard deviation to the measured concentration 
 
Table T4 Sample stability assays (n=3) 
 Analytes QC R-PZQ [%] ± CV S-PZQ [%] ± CV R-trans [%] ± CV 
Fr
ee
ze
- 
th
aw
 Blood High 95.4 ± 9.4 99.7 ± 0.1 106.0 ± 10.6 Low 94.6 ± 1.0 101.2 ± 1.1 93.2 ± 0.5 
Plasma High 102.6 ± 8.7 100.6 ± 3.7 87.7 ± 12.1 Low 94.6 ± 1.1 91.6 ± 0.9 107.0 ± 0.8 
B
en
ch
-to
p 
Blood High 102.4 ± 9.3 101.4 ± 0.9 110.0 ± 8.8 
Low 111.2 ± 1.3 109.5 ± 0.2 100.2 ± 0.8 
Plasma High 102.9 ± 6.5 100.2 ± 1.8 105.7 ± 7.5 
Low 94.7 ± 0.9 95.8 ± 0.3 104.4 ± 0.7 
Lo
ng
-te
rm
 
(6
 m
on
th
s)
 Blood (-80°C) 
High 102.4 ± 2.4 109.9 ± 2.3 90.1 ± 5.4 
Low 86.2 ± 0.6 88.2 ± 1.2 89.6 ± 5.1 
Plasma 
(-80°C) 
High 101.6 ± 5.0 99.7 ± 2.1 88.5 ± 2.3 
Low 100.6 ± 0.9 104.8 ± 0.6 98.6 ± 0.4 
DBS 
(25°C) 
High 96.8 ± 13..4 100.0 ± 9.6 110.6 ± 11.2 
Low 89.2 ± 5.4 107.3 ± 9.8 109.0 ± 7.3 
A
ut
os
am
pl
er
 
(1
0°
C
) 
Blood High 100.0 ± 2.3 98.2 ± 1.7 87.0 ± 2.8 
Low 97.2 ± 6.9 97.8 ± 4.9 113.5 ± 8.7 
Plasma High 94.0 ± 3.9 89.5 ± 5.6 85.8 ± 5.8 
Low 88.5 ± 6.1 85.3 ± 8.0 94.2 ± 3.1 
DBS High 107.5 ± 5.3 108.9 ± 5.2 113.6 ± 5.0 Low 108.6 ± 3.7 112.1 ± 7.0 101.9 ± 2.4 
St
oc
k 
so
lu
tio
ns
 Bench-top  101.8 ± 2.8 100.0 ± 2.0 104.7 ± 0.6 
Sonication  107.5 ± 1.7 101.9 ± 1.3 101.9 ± 3.2 
3 months  93.5 ± 8.3 93.7 ± 8.1 91.5 ± 13.5 
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Supplementary figures 
 
 
Fig. F1 Chromatograms of blank (grey line) vs. LLOQ (black line) signals of PZQ and trans-4-OH enantiomers in plasma (A, B), blood (C, 
D) and DBS (E, F) 
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Abstract  
Background Praziquantel (PZQ) is the treatment of choice for infections with the liver fluke Opisthorchis 
viverrini, a major health problem in Southeast Asia. However, pharmacokinetic (PK) studies investigating the 
disposition of PZQ enantiomers (R- and S-PZQ) and its main metabolite, R-trans-4-OH-PZQ, in diseased patients 
are lacking. The implementation of a dried blood spot (DBS) sampling technique would ease the performance of 
PK studies in remote areas without clinical facilities. The aim of the present study is to provide data on the 
disposition of PZQ enantiomers and R-trans-4-OH-PZQ in opisthorchiasis patients and to validate the use of DBS 
compared to plasma and blood sampling. Methodology/Principal Findings PZQ was administered to nine O. 
viverrini-infected patients at 3 oral doses of 25 mg/kg in 4 h intervals. Plasma, blood and DBS were 
simultaneously collected at selected time points from 0 to 24 h post-treatment. PK parameters were determined 
using non-compartmental analysis. Drug concentrations and areas under the curve (AUC0-24h) measured in the 3 
matrices were compared using Bland-Altman analysis. We observed plasma AUC0-24h s of 1.1, 9.0 and 188.7 
µg´h/ml and half-lives of 1.1, 3.3 and 6.4 h for R-PZQ, S-PZQ and R- trans-4-OH, respectively. Maximal plasma 
concentrations (Cmax) of 0.2, 0.9 and 13.9 µg/ml for R-PZQ, S-PQZ and R-trans-4-OH peaked at 7 h for PZQ 
enantiomers and at 8.7 h for the metabolite. Individual drug concentration measurements and patient AUC0-24hs 
displayed ratios of blood or DBS versus plasma between 79–94% for R- and S-PZQ, and between 108–122% for 
R-trans-4-OH. Conclusions/Significance Pharmacodynamic (PD) in vitro studies on PZQ enantiomers and R-
trans-4-OH-PZQ are necessary to be able to correlate PK parameters with efficacy. DBS appears to be a valid 
alternative to conventional venous sampling for PK studies in PZQ-treated patients. 
 
Author summary Opisthorchiasis, caused by the food-borne trematode Opisthorchis viverrini, affects more than 
8 million people in Southeast Asia, and in its chronic phase it might lead to cholangiocarcinoma. Praziquantel 
(PZQ) is the sole drug available to treat the disease and is administered as a racemic mixture of R and S 
enantiomers, of which R-PZQ is considered active. As PZQ is rapidly metabolized, its disposition and efficacy in 
patients might considerably vary according to disease state, sex or age. However, pharmacokinetic (PK) studies 
on the disposition of PZQ enantiomers and its main metabolite, R-trans-4-OH, in diseased patients are lacking. 
To allow the collection of PK samples in a large number of patients, we implemented a dried blood spot (DBS) 
technique, which is less invasive than venipuncture. The aim of our study is to provide first data on the disposition 
of PZQ enantiomers and the main metabolite of PZQ in opisthorchiasis patients and to validate the use of DBS 
over venous sampling. Standard PZQ treatment was administered to nine O. viverrini infected patients, and 
plasma, blood and DBS were simultaneously collected within 24 h post-treatment. We observed a 100-fold higher 
disposition of the metabolite compared to R-PZQ, which questions its role in the opisthorchidal activity of PZQ. 
DBS sampling appears to be a valid alternative to venous sampling and will be a valuable tool for future PK 
studies in PZQ-treated patients. 
 
 57 
1. Introduction  
Opisthorchiasis is caused by the trematode 
Opisthorchis viverrini, a liver fluke affecting about 8 
million people in Southeast Asia, particularly in the 
Mekong basin (Sithithaworn and Haswell-Elkins, 
2003; Fürst, Keiser and Utzinger, 2012). Infection 
occurs following consumption of raw or undercooked 
fish harboring O. viverrini metacercariae (Grundy-
Warr et al., 2012). In the early phase, the disease is 
mostly asymptomatic but in the acute stage periductal 
fibrosis and liver enlargement are common, mostly a 
result of inflammation due to worm feeding. The 
chronic stage triggers severe clinical symptoms 
including jaundice, biliary obstructions, and 
cholangiocarcinoma as a serious complication 
(Mairiang and Mairiang, 2003; Sripa, 2003; Sripa et 
al., 2010; Sayasone et al., 2012).  
Praziquantel (PZQ) is the drug of choice for 
opisthorchiasis and is manufactured as a race- mic 
mixture of R and S enantiomers. The recommended 
treatment regimen is 3 oral doses of 25 mg/kg, usually 
administered between 4 and 6 h apart (World Health 
Organization, 1995). The disposition of PZQ is highly 
influenced by the fasting state, the co-administered 
food type, as well as the liver function (El Guiniady et 
al., 1994; Castro et al., 2000). Though no studies have 
been conducted against O. viverrini yet, R-PZQ is 
considered to be the active molecule in the treatment 
of schistosomiasis, while the inactive S-PZQ is 
suspected to be responsible for the bitter taste of the 
drug and for the mild to moderate adverse events 
caused by the treatment (Wu et al., 1991; Staudt et al., 
1992; Meyer et al., 2009; Olliaro, Delgado-Romero 
and Keiser, 2014). In humans, PZQ undergoes an 
enantioselective first-pass metabolism through the 
cytochrome CYP450 3A4 isoform (Li et al., 2003) and 
is mainly transformed into the monohydroxylated 
metabolite R-trans-4-OH-PZQ (R-trans-4-OH), while 
S-PZQ is metabolized to several different 
monohydroxylated molecules (Lerch and Blaschke, 
1998; Meier and Blaschke, 2001; Melo et al., 2005). 
R-trans-4-OH displays minor anthelmintic activity, 
with an IC50 hundred times higher than R-PZQ against 
Schistosoma mansoni (Meister et al., 2014).  
The disposition of PZQ enantiomers and metabolites 
has not yet been studied in opisthorchiasis patients. In 
fact, the only pharmacokinetic (PK) study of PZQ 
involving patients with opisthorchiasis focuses on the 
racemic drug (Na Bangchang et al., 1993). 
Enantioselective disposition was performed 
exclusively in healthy volunteers with a low dose 
(Lima et al., 2011). Therefore, studies on the 
enantioselective disposition of PZQ in the diseased 
population are warranted for a better understanding of 
the modalities of drug action and disposition.  
Dried blood spot (DBS) sampling is a microsampling 
technique, involving the collection of capillary blood 
through a finger prick. The method is therefore less 
invasive compared to venipuncture. The blood drops 
are dried on a filter paper and stored at ambient 
temperature until assayed. Compared to blood or 
plasma sampling, this method does not require sample 
freezing and offers easy handling and storage, hence 
allowing the performance of PK studies in remote 
areas without clinical set-ups. Blood quantities 
withdrawn with DBS are minimal (20 µl vs. 3–4 ml for 
plasma or blood), which provides an advantage for 
research with children. Finally, the ease of sample 
collection enables including a larger number of 
patients and is therefore ideal for population PK 
studies (Spooner, Lad and Barfield, 2009; Deglon et 
al., 2013; Demirev, 2013; Xu et al., 2013). The major 
caveat when replacing plasma with DBS sampling is 
the use of a different matrix where the drug partition 
might not be equivalent (Emmons and Rowland, 2010; 
Xu et al., 2013). Validating this alternative sampling 
technique for future trials hence calls for a formal 
comparison of drug concentrations measured in 
plasma and DBS.  
The aim of our study was to elucidate for the first time 
the kinetic disposition of both PZQ enantiomers and 
its main metabolite in O. viverrini-infected patients. 
Additionally, we assessed the difference between 
concentrations determined in plasma, blood and DBS 
sampling for the analysis of PZQ PK profiles using 
Bland-Altman analysis.  
2. Materials and methods  
2.1 Chemicals and reagents  
Racemic (rac) PZQ was obtained from Sigma-Aldrich 
(Buchs, Switzerland). PZQ enantiomers as well as the 
metabolite trans-4-OH were donated by Merck Serono 
(Darmstadt, Germany). Eleven-fold deuterized PZQ 
(PZQd11, internal standard-IS) was acquired from 
Toronto Research Chemicals (Ontario, Canada). The 
chemical structures of PZQ, PZQd11 and trans- 4-OH 
are depicted in Fig 1. Acetonitrile, ethanol and 
methanol of MS grade were purchased from Carl Roth 
GmBH (Allschwil, Switzerland), and ammonium 
formate, ammonium acetate and formic acid of MS 
grade from Sigma-Aldrich (Buchs, Switzerland). 
Ultrapure water was provided using a Millipore Milli-
Q water purification system (Merck Millipore, 
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Darmstadt, Germany). Blank human plasma and blood 
were supplied in lithium heparin-coated vacutainer 
tubes (BD, Allschwil, Switzerland) from the local 
blood donation centre (Basel, Switzerland).
 
Fig. 1 Chemical structures of PZQ, the main metabolite trans-4-OH and PZQ-d11 (internal standard), with the chiral centre represented with 
a shaded circle.  
2.2 PK sample collection  
The plasma, blood and DBS sample collection was 
performed in the framework of a PK and dose-finding 
study of tribendimidine against O. viverrini in 
humans. Ethical clearance was obtained from the 
ethics committee of Northern and Central Switzerland 
(EKNZ reference no. 375/11), and from the National 
Ethic Committee for Health Research, Ministry of 
Health (MoH) of Lao PDR (reference no. 
009/NECHR). The trial is registered at Current 
Controlled Trials (ISRCTN96948551). In short, 9 O. 
viverrini-infected patients were treated with 3 oral 
doses of 25 mg/kg PZQ, with the second and third dose 
administered 4 and 8 h after the first dose, 
respectively. The trial was performed at the 
Champasak Provincial Hospital in Pakse,Lao PDR, 
and prior to treatment, a standardized food dish (rice) 
was provided to all patients. Adverse events were 
monitored at 3, 24 and 48 hours post-treatment using 
a standardized questionnaire. Prior to treatment, 
patients underwent physical examinations and 
laboratory tests, such as liver and kidney parameters 
and complete blood counts. About 4 ml of venous 
blood was collected at 0, 2, 4, 6, 8, 8.5, 9, 10, 11, 12 
and 24 h after the first dose from the antecubital arm 
vein through an intravenous catheter into EDTA-
coated vacutainer tubes (BD). Within 30 min after 
sampling, 1 ml of blood was pipetted into a cryotube 
and the remaining blood centrifuged to obtain plasma. 
Plasma and blood samples were transported on dry ice 
to Basel where they were kept at -80°C until analysis. 
DBS samples were collected at 0, 4, 8, 9, 11 and 24 h 
post-first-dose from patients 1 to 5, and at 0, 2, 6, 8.5, 
10 and 12 h post-first-dose from patients 6 to 9. The 
samples were obtained by puncturing the middle or 
ring finger with sterile one-way finger prickers (Accu-
Check Safe-T-Pro Plus, Roche, Switzerland). Lithium 
heparin coated capillaries (Alere Cholestech LDX, V 
= 40 µl) were used to collect and deposit blood on 
DMPK-C cards (Whatman, GE Healthcare Life 
Sciences, Cardiff, UK). The cards were dried 
overnight and stored in plastic bags with desiccant at 
room temperature.  
2.3 Analytical method  
The LC-MS/MS method for the analysis of R- and S-
PZQ and R-trans-4-OH and its validation for plasma, 
blood and DBS is described elsewhere (Meister et al., 
2016). Briefly, plasma and blood calibration samples 
were freshly prepared and included in each analytical 
run by spiking blank samples to reach final 
concentrations from 2.5 to 0.01 (lower limit of 
quantification-LLOQ) µg/ml for R- and S-PZQ, and of 
25 to 0.1 (LLOQ) µg/ml for R-trans-4-OH. QC 
samples were similarly pre- pared by spiking 6 
different blanks to obtain high, medium, low and 
LLOQ concentrations. For the extraction of analytes, 
100 µl of plasma or blood samples underwent protein 
precipitation with 700 µl of IS solution (500 ng/ml IS 
in pure acetonitrile), and were shaken in a 
thermomixer for 20 min at 25°C and 1400 rpm. DBS 
samples of 5 mm diameter were extracted with 300 µl 
of DBS extraction solution (IS solution: ultrapure 
water, 4:1, v/v), shaken in a thermomixer for 20 min 
at 25°C, and sonicated for 40 min prior analysis.  
A first chromatographic separation was achieved 
through a column trapping system (HALO C-18, 4.6 x 
5 mm, Optimize Technologies, OR, USA) using 10 
mM ammonium acetate and 0.15% formic acid in 
ultrapure water at a flow rate of 0.3 ml/min. After 1 
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min, the analytes were eluted from the trapping to the 
chiral column (Lux Cellulose-2 (150x4.6mm, 3µm, 
Phenomenex, CA, USA)) with an elution gradient of 
70 to 90% B, with mobile phase A consisting of 20 
mM ammonium formate in ultrapure water and mobile 
phase B of pure acetonitrile.  
2.4 Treatment efficacy and pharmacokinetic analysis  
Statistical analyses were performed with Prism 
software (GraphPad, CA, USA). Parasite egg counts 
were determined with duplicate Kato-Katz smears 
from two stool samples prior to the treatment and 
between 19 and 25 days after treatment for the 
estimation of treatment efficacy. Cure rates were 
defined as the percentage patients who were egg-
negative after treatment. The number of eggs per gram 
of stool (EPG) was evaluated by adding up the egg 
counts from the quadruplicate Kato-Katz thick smears 
and multiplying this number by a factor of six. 
Geometric mean egg counts were calculated before 
and after treatment to determine the corresponding 
percentage egg-reduction rate (ERR).  
To evaluate the reproducibility of the measurements, 
incurred sample reanalysis (ISR) was performed with 
a total of 170 samples originating from 5 patients in 
the 3 matrices (56% of total sample size). The 
percentage difference between the original and the 
reanalyzed measurement was calculated as follows:  
percentage difference = (repeat – original) ´ 
100 / mean(repeat, original)  
As acceptance criterion for ISR, at least 66.7% of the 
samples (2 out of 3) should not deviate by more than 
20%, as recommended in the European guidelines on 
bioanalytical method validation and the daft of the 
FDA guidelines (European Medicines Agency, 2011; 
Food and Drug Administration, 2013).  
PK parameters, including the area under the 
concentration-time curve (AUC0-24), the maximal 
concentration (Cmax), the time to maximal 
concentration (Tmax) and the half-life (t1/2) were 
calculated for each patient with the Excel add-in 
PKsolver (Zhang et al., 2010) using non-
compartmental analysis with the linear trapezoidal 
rule.  
2.5 Agreement between matrices  
Concordance of drug concentrations observed in blood 
or DBS compared to plasma was evaluated using 
Pearson’s correlation coefficient and Bland-Altman 
plots, with percentage ratios between the two matrices 
(blood/plasma or DBS/plasma) plotted against mean 
concentrations (Altman and Bland, 1983; Bland and 
Altman, 1986, 2012). For matrix differences in AUC 
values, Bland-Altman analysis also applied.  
The limits of agreement at 95% for the ratios were 
calculated as follows:  
limits of agreement = mean percentage ratio 
± 1.96´ standard deviation  
For the drug concentration data, the calculation of the 
limits of agreement were adapted to take into account 
multiple measurements per individuals, following the 
method described by Bland and Altman (Bland and 
Altman, 2007) using Stata software (version 12.1, 
College State, TX, USA).  
2.6 In vitro assessment of blood/plasma partition of 
PZQ  
The partitioning of PZQ between plasma and 
erythrocytes was assessed in vitro using human blood 
from the local blood donation center. Whole blood 
samples (hematocrit adjusted to 35%) were spiked in 
triplicate with the analytes of interest to reach end 
concentrations of 0.05 and 0.5 µg/ml for R- and S-PZQ 
and 0.5 and 5 µg/ml for R-trans-4-OH. The samples 
were incubated 1 h at room temperature. Hundred 
microliters of each sample were aliquoted and the 
remainder was centrifuged at 1500 g for 20 minutes to 
obtain plasma. Whole blood and plasma samples were 
extracted using acetonitrile containing IS and analyzed 
as described above. Analyte peaks were normalized 
with IS peaks and ratios of blood to plasma were 
calculated for each concentration and analyte. 
Table 1 Characteristics of participants and O. viverrini cure rates 
Median age (range)  
[years] 
Sex  
[% females] 
Median weight (range)  
[kg] 
Pre-treatment [EPG] 
geometric mean 
Post-treatment [EPG]  
geometric mean 
Cure rate  
[%] 
40 (25-46) 67 56 (40-77) 3653 0 100 
 
3. Results  
3.1 Sample collection and analysis  
A total of 91 plasma and 91 blood samples were 
collected. For DBS, 45 samples were analysed. Due to 
technical problems, five DBS samples for patient 9 
were collected at 6, 7, 8.5, 10 and 12 h post-treatment, 
and an extra venous blood sample was withdrawn at 7 
h post-treatment. To estimate the repeatability of the 
analytical measurements, an incurred sample 
reanalysis was performed. Between 88.2 and 100% of 
the samples in plasma, blood and DBS were within the 
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ISR acceptance criterion (within 20% difference). All 
samples from the 9 patients presenting obvious 
measurement errors or displaying a high discrepancy 
between matrices were reanalyzed (n = 21).  
For R-PZQ, concentrations ranged from 0.01 to 0.85 
µg/ml, to 0.90 µg/ml and to 1.08 µg/ml for DBS, blood 
and plasma, respectively. For S-PZQ, the following 
concentration ranges were observed: 0.01–1.59 µg/ml 
in DBS, 0.01–1.83 µg/ml in blood, and 0.02–2.34 
µg/ml in plasma. The metabolite R-trans-4-OH 
displayed concentrations ranging from 3.01 to 19.01 
µg/ml in DBS, 1.62 to 22.05 µg/ml in blood, and 1.41 
to 17.85 µg/ml in plasma.  
3.2 Treatment efficacy and kinetic disposition of PZQ 
in patients  
All participants were adults, 3 males and 6 females 
aged 25 to 46 years with a median weight of 56 kg 
(Table 1). Prior to treatment, 8 patients displayed 
moderate O. viverrini infections (between 1,000 and 
10,000 EPG) and 1 patient a heavy infection (13,920 
EPG). All patients were asymptomatic. Hookworm 
co-infections were present in 5 participants 
(participants 1, 4, 6, 7 and 8), while patient 2 presented 
a co-infection with the whipworm Trichuris trichiura. 
Liver and kidney parameters were in the normal range 
for all the patients. Blood counts were also normal, 
except for patient 2 who displayed slightly elevated 
white blood cell counts (11.7 ´ 103 cells/l) and a 
moderate anaemia (hemoglobin concentration = 9.2 
g/dl). All patients were treated as planned and 
tolerated the treatment well, with the exception of 
patient 2, for whom the treatment was interrupted due 
to adverse events (vomited within 30 min after the 
second dose). Between 19 and 25 days post-treatment, 
the participants were screened again for the presence 
of O. viverrini eggs in stool: all patients were cleared 
from infection, hence cured (Table 1).
 
Fig. 2 Plasma concentrations for R-PZQ (1), S-PZQ (2) and R-trans-4-OH (3) over time and across patients (patient 2 sketched with a star) 
and analyte concentrations across the 3 matrices in patient 1 
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Table 2 Median (range) of AUC0-24h, t1/2, Cmax and Tmax in plasma across 9 patients 
Analyte AUC0-24h [µg´h/ml] t1/2 [h] Cmax [µg/ml] Tmax [h] 
R-PZQ 1.1 (0.8-10.7) 1.1 (1.0-3.0) 0.2 (0.1-1.1) 7.00 (4.0-11.8) 
S-PZQ 9.0 (6.1-26.3) 3.3 (1.9-3.7) 0.9 (0.6-2.3) 7.00 (4.0-11.8) 
R-trans-4-OH 188.7 (157.2-257.4) 6.4 (4.1-7.1) 13.9 (13.1-17.9) 8.7 (8.0-12.0) 
 
Patient variability in plasma concentrations was high, 
with patient 2 displaying clearly higher concentrations 
than the other subjects, despite not taking the last dose 
(Fig 2). Median PK parameters calculated from 
plasma concentrations are summarized in Table 2. R-
PZQ displays the smallest AUC0-24h (1.1 µg/ml/h) and 
a short estimated t1/2 (1.1 h) compared to the other 
analytes. S-PZQ exhibits a nearly 5 x higher Cmax (0.9 
µg/ml) and an AUC0-24h more than 8 x higher than R-
PZQ (9.0 µg/ml/h). Both enantiomers peak at the same 
time (7 h). The main metabolite R-trans-4-OH has an 
increased exposure compared to the parent molecule. 
For example, its AUC0-24h (188.7 µg´h/ml) is 20x 
greater than S-PZQ and 170x greater than R- PZQ. 
The metabolite’s estimated t1/2 and Tmax are 6.4 h and 
8.7 h, respectively. Patient 2 displays 2–10 fold higher 
R-PZQ, S-PZQ and R-trans-4-OH AUC0-24h values 
compared to the other patients.  
3.3 Sample measurement agreement between matrices  
When comparing the analyte concentrations obtained 
in the different matrices by Pearson’s correlation 
coefficient, blood versus plasma and DBS versus 
plasma data displayed correlation coefficients above 
0.92 (all p <0.01, Table 3). The mean concentration 
curves are consistent for plasma, blood and DBS, as 
exemplified with patient 1 (Fig 2).  
The modified Bland-Altman approach for multiple 
measurements per individual was used on drug 
concentrations, although the values obtained with this 
method did not differ from the conventional approach. 
The Bland-Altman plots (Fig 3) show that percentage 
ratios were generally consistent across concentrations. 
The mean percentage ratios of R-PZQ in blood or DBS 
compared to plasma, display ratios of 79.0 and 89.6%, 
respectively (Table 3). There is therefore a tendency 
for plasma samples to have slightly higher 
concentrations of R-PZQ than blood or DBS. For S-
PZQ, the same pattern is observed, with slightly higher 
ratios than R-PZQ: 93.9 and 92.1% percentage ratios 
for blood and DBS, respectively. The metabolite R-
trans-4-OH displays on the contrary higher ratios of 
blood or DBS to plasma of 122.0 and 110.6%, 
respectively. However, the 95% limits of agreement 
(LoA) all include 100%, except for R-PZQ in the 
blood versus plasma comparison (LoA = 59–99%). 
The LoA intervals are large and range up to 55–133% 
for the parent enantiomers and 94–145% for the 
metabolite in the blood-plasma ratios. LoA are slightly 
larger for DBS-plasma ratios.  
Bland-Altman plots of AUC percentage ratios 
between plasma and blood or DBS are consistent 
across AUC values (Fig 4). The percentage ratios of 
blood or DBS to plasma for each PK parameter exhibit 
values between 80 and 120%, except in t1/2 DBS to 
plasma ratios for R-PZQ (122%) and R-trans-4-OH 
(75%, Tables 4 and 5). As for drug concentrations, the 
mean ratios of DBS or blood versus plasma tend to be 
lower than 100% for the parent enantiomers but higher 
than 100% for the metabolite. Only the t1/2 DBS to 
plasma ratios do not precisely follow this pattern, 
probably because they are calculated with 5 samples 
per patient instead of 10, driving therefore a higher 
estimation error. The LoA of the AUC ratios lie 
between 64–107% for the parent enantiomers and 87–
136% for the metabolite in the blood-plasma ratios 
with a slightly wider range for DBS-plasma ratios. As 
for drug concentration results, all the LoA include 
100%, except for R-PZQ in the blood to plasma ratio.
Table 3 Concordance of blood and DBS compared to plasma measurements, evaluated with Pearson’s correlation and percentage ratio with 
their 95% limits of agreement (LoA) 
Analyte Matrix Correlation coefficient Percentage ratioa (LoAb) [%] 
R-PZQ 
blood (n=91) 0.995 79.0 (59.1; 99.0) 
DBS (n=45) 0.994 89.6 (55.6; 123.6) 
S-PZQ 
blood (n=91) 0.963 93.9 (54.5; 133.3) 
DBS (n=45) 0.970 92.1 (44.4; 139.8) 
R-trans-4-OH 
blood (n=91) 0.948 122.0 (94.0; 145.0) 
DBS (n=45) 0.921 110.6 (77.0; 144.3) 
a The percentage ratio is computed as blood or DBS values divided by plasma measurements averaged across patients and time points and 
presented as percentage to the plasma values 
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3.4 In vitro assessment of blood/plasma partition of 
PZQ
Blood to plasma ratios were consistent across both 
concentrations measured. R-PZQ displayed ratios of 
83.1 ± 3.6 and 77.7 ± 3.9% for 0.05 and 0.5 µg/ml, 
respectively. The partition of S-PZQ in plasma was 
similar to R-PZQ, with ratios of 81.3 ± 5.4 and 74.5 ± 
1.5% for low and high concentrations, respectively. 
The metabolite R-trans-4-OH showed a partition in 
plasma higher than the parent enantiomers, with 
values of 92.0 ± 6.0 and 87.5 ± 6.2% for 0.5 and 5 
µg/ml, respectively. 
Fig. 3 Bland-Altman plots of measurement performed with blood or DBS compared to plasma values for R-PZQ, S-PZQ and R-trans-4-OH 
with mean ratio sketched with a solid line and 95% limits of agreement with dashed lines 
4. Discussion 
PZQ is the only drug available for the treatment of 
opisthorchiasis, yet surprisingly preclinical and 
clinical work including PK studies are sparse. We 
conducted for the first time a PK study in patients 
infected with O. viverrini treated with three doses of 
PZQ and studied the enantioselective drug disposition 
in blood, plasma and DBS.  
The only other PK study conducted with O. viverrini-
infected patients so far examined the kinetic 
disposition of the racemic drug after a single oral dose 
of 40 mg/kg (Na Bangchang et al., 1993). Patients 
were of similar age and weight as in our study, but 
with a higher proportion of males. The authors 
observed a Cmax for racemic PZQ of 0.9 and 1.1 µg/ml 
in early (asymptomatic) and acute (moderately 
advanced) infection, respectively which does not 
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differ from the value observed in our study, 1.1 µg/ml 
for R-and S-PZQ combined. A half-life value of 2.3 
and 3.8 h previously observed for the racemic parent 
compound in early and acute infection (Na Bangchang 
et al., 1993) is as well consistent with a half live of S-
PZQ of 3.3 h (R-PZQ is eliminated much faster, due 
to different enzymes kinetics than S-PZQ) in our 
study. Given that a dose of 40 mg/kg corresponds to 
53% of the dose administered in our trial, the AUC0-
24h range observed in our study (6.1–26.3 µg/ml) is 
closer to that previously reported for patients with 
acute opisthorchiasis (2.5–15.6 µg/ml) than that in 
patients with asymptomatic opisthorchiasis (1.6–5.0 
µg/ml) (Na Bangchang et al., 1993). This result is not 
surprising, given the disease prevalence in the region 
and the age of the patients, for which acute cases are 
expected to be frequent (Lovis et al., 2010; Sayasone 
et al., 2011, 2012).
 
Fig. 4 Bland-Altman plots of AUC values obtained from blood or DBS compared to plasma AUCs for R-PZQ, S-PZQ and R-trans-4-OH with 
mean ratio sketched with a solid line and 95% limits of agreement with dashed lines. Patient 2 is depicted with a triangle (p) 
 
We observed a high variability in analyte 
concentrations between patients. This is often 
observed in PK studies with PZQ and is likely due to 
the high first-pass metabolism of PZQ in the liver or 
gut, with the activity of CYP 450 being highly 
dependent on the health, genetic and nutritional status 
of the patient (Olliaro, Delgado-Romero and Keiser, 
2014). Multiple dosing can also add to variability, 
since differences among patients in absorption and 
elimination as well as competition/saturation effects 
are common and exacerbate each other.  
The high AUC0-24h values of the PZQ enantiomers and 
metabolite determined for patient 2 (taking only two 
doses instead of three) might be explained by several 
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factors. Firstly, this is the only patient suffering from 
a co-infection with whipworms and hookworms at 
follow up. Changes in drug metabolism due to 
immune reactions due to three co-existing parasites 
might be possible, as some immunomodulators were 
found to decrease hepatic activity (Tekwanl, Shukla 
and Ghatak, 1988; Renton, 2001). Secondly, patient 2 
displays the highest weight to height ratio (body mass 
index of 35.2 kg/m2), which could lead to an 
overestimation of the effective drug dose, as it is often 
the case in overweighed patients (Pai, 2012). Finally, 
this patient might have developed liver and intra-
hepatic bile duct pathologies, thereby altering drug 
metabolism, as observed in patients infected with 
another liver fluke, Fasciola hepatica (Tekwanl, 
Shukla and Ghatak, 1988). Although measurement of 
liver enzyme parameters and the physical examination 
did not identify this patient as a symptomatic 
opisthorchiasis case, ongoing liver pathology can not 
be ruled out (Na Bangchang et al., 1993). In fact, the 
detection of hepatic abnormalities due to 
opisthorchiasis, such as fibrosis or moderate 
hepatomegaly, is recommended to be performed via 
ultrasonography (not done in the present study), as 
liver enzymes do not seem to be a reliable indicator for 
the pathology of this disease (Mairiang and Mairiang, 
2003; Sripa et al., 2011).  
Not surprisingly, patient 2 suffered from adverse 
events during the treatment course, as high Cmax levels 
are often correlated with adverse events (Olliaro et al., 
2011). It might be worth highlighting that this patient 
as well all other study participants were cured 
following PZQ treatment. The high efficacy noticed 
with a triple dose of PZQ is in accordance with 
previous studies (Keiser and Utzinger, 2004).The 
patient with the highest infection intensity (patient 7: 
13,920 EPG at baseline) displayed parent and 
metabolite AUC0-24h values similar to the other 
patients with moderate EPG values (between 1,000 
and 10,000 EPG at baseline), hence infection intensity 
does not seem to correlate with PZQ disposition.  
The most striking result observed in the disposition of 
PZQ is the high concentration of R-trans-4-OH, 
culminating at 13.9 µg/ml. For comparison, a study 
from Lima and colleagues (Lima et al., 2011) 
conducted in healthy volunteers treated with a single 
oral dose of 25 mg/kg PZQ displayed a 10x lower Cmax 
of R-trans-4-OH. This finding, which might be 
explained with changes in metabolism due to the liver 
disease, raises the question of the role of the 
metabolite in the opisthorchicidal activity of PZQ. In 
vitro and in vivo studies should be conducted to assess 
the activities of R-and S-PZQ and R-trans-4-OH 
against O. viverrini.  
The incurred sample reanalysis revealed a proportion 
higher than 2/3 of the samples falling into the 
acceptance criterion of deviating no more than 20%. 
These results demonstrate that the measurements are 
reliable and that there are no major problems in sample 
handling, processing or analysis. The hematocrit of 
35% used for the calibration line and the 25–50% 
range of hematocrits used for the quality controls 
reflects values in our patients (mean hematocrit of 
35.5 ± 4.1%), and more generally values encountered 
in Southeast Asia. For example, in Thailand, the mean 
hematocrit in men is between 42-47% and in women 
it is between 37-39% (Tanphaichitr et al., 1980).
Table 4 Mean percentage ratios of AUC0-24h values in blood or DBS compared to plasma and lower and upper 95% limits of agreement (LoA) 
with their respective 95% confidence intervals (CI) 
 Mean ratioa [%] (CI)  Lower LoAb [%] (CI) Upper LoA [%] (CI)  
Analyte blood  DBS blood  DBS blood DBS 
R-PZQ 81.9  (76.8;86.6) 
92.5  
(82.9;102.2) 
69.6 (61.4;77.9) 68.0 
(51.3;84.7) 
94.1 (85.8;108.9) 117.1 
(100.4;133.8) 
S-PZQ 85.4  (76.8;93.9) 
87.0  
(73.2;100.7) 
63.6 (48.8;78.4) 52.0 
(28.2;75.7) 
107.2 
(92.4;122.0) 
122.0 
(98.2;145.7) 
R-trans-4-OH 111.2  (101.5;120.9) 
107.6  
(97.9;117.4) 
86.5 
(69.8;103.3) 
81.4 
(63.6;99.2) 
135.9 
(119.1;152.6) 
133.9 
(116.1;151.7) 
a The percentage ratio is computed as blood or DBS AUC0-24h values divided by plasma AUC0-24h values averaged across patients and presented 
as percentage to the plasma values. 
b The 95% limits of agreement for AUC0-24h values were calculated with the conventional Bland-Altman method. 
 
Table 5 Percentage ratios of t1/2, Cmax and Tmax in blood or DBS compared to plasma 
 t1/2 Cmax  Tmax  
Analyte blood [%] DBS [%] blood [%] DBS [%] blood [%] DBS [%] 
R-PZQ 89.4 121.6 89.4 92.0 100.0 101.0 
S-PZQ 81.8 100.0 81.8 96.5 100.0 99.4 
R-trans-4-OH 105.2 75.3 105.2 103.5 115.4 111.5 
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All the LoA intervals included 100%, indicating no 
difference between DBS or blood compared to plasma 
concentrations, except for R-PZQ in blood. The LoAs 
observed were wide, which can be explained by the 
additive measurement errors in each matrix. When 
validating a bioanalytical method, the accepted 
measurement variability is of ± 15%. This translates to 
indicative maximal LoA of 71–129% (calculated 
using the conventional Bland-Altman formula with 
SD = 15%), which is broadly similar to the results 
observed in this study. The wider LoA and confidence 
intervals for DBS-plasma compared to blood-plasma 
AUC0-24h ratios reflect the half as small sample size for 
the estimation of DBS AUC0-24hs compared to blood 
AUC0-24hs samples. In light of these observations, we 
estimate that there is a general agreement between 
matrices and that DBS is a valid surrogate to venous 
sampling.  
In the Bland-Altman comparisons of blood versus 
plasma or DBS versus plasma, R- and S-PZQ 
displayed drug concentrations and AUC0-24h 
percentage ratios of around 80% and R-trans-4-OH 
ratios higher than 100%. The higher concentrations 
observed for R- and S-PZQ when quantified in plasma 
compared to blood or DBS might arise from a very 
high affinityof the drug for plasma proteins. PZQ is 
highly protein-bound (~80%) (Olliaro, Delgado-
Romero and Keiser, 2014). Hence, red blood cells 
might have a slight diluting effect on PZQ 
concentrations, depending on the blood hematocrit 
(Emmons and Rowland, 2010). For example, 
tasquinimod, an anticancer drug characterized by a 
very high plasma binding (>98%), revealed a 
blood:plasma ratio of 66% (Isaacs et al., 2014; 
Svensson et al., 2015). This phenomenon was also 
observed in a study comparing DBS and plasma 
sampling with piperacillin and tazobactam in infants 
with DBS:plasma ratios between 50 and 60% (Cohen-
Wolkowiez et al., 2014). Therefore, our results for the 
parent enantiomers are in line with previous 
observations in drugs with high plasma affinity and 
displayed an agreement between plasma and blood or 
DBS of around 80–90%. In contrast, R-trans-4-OH did 
not follow such pattern and displayed higher 
concentrations in blood or DBS than in plasma, which 
likely indicates a lower affinity for plasma proteins 
than its parent molecule and a higher repartition in 
erythrocytes.  
The in vitro evaluation of PZQ partition between 
plasma and erythrocytes highlighted a higher affinity 
of the enantiomers to plasma, which echoes the 
observations in patients described above. Considering 
that PZQ is bound to 80% to plasma proteins (Olliaro, 
Delgado-Romero and Keiser, 2014) and that 
acetonitrile precipitation extracts both the unbound 
and bound fractions, the blood to plasma ratios 
between 75 and 83% indicate that penetration of the 
free fraction into erythrocytes is very limited to almost 
absent. On the other hand, the metabolite R-trans-4-
OH displays in vitro an almost even distribution in all 
blood compartments, while in patient samples this 
ratio is slightly more biased towards erythrocytes.  
In conclusion, we have shown that DBS is a valid 
alternative to plasma sampling for PK studies with 
PZQ. Additional studies are warranted to estimate the 
kinetic disposition of patients after different PZQ 
dosing schemes and to investigate the PK/PD 
relationship, in particular the role of R–trans-4-OH in 
the opisthorchicidal activity of PZQ.  
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6.1 Synthetic Peroxides  
6.1.1 Key findings
The first part of my project aimed to elucidate the 
pharmacokinetic profile of OZ78 and MT04 in sheep 
naturally infected with F. hepatica (Chapter 2). This 
study was the second testing of OZ78 in sheep after a 
first unsuccessful experience (Keiser et al., 2010). It 
should therefore be regarded as an additional attempt 
to overcome the loss of activity of OZ78 when 
translating the excellent rat experiments (Kirchhofer et 
al., 2011) to sheep. Briefly summarizing the results of 
this investigation, after a single intramuscular dose of 
100 mg/kg OZ78 or MT04, we observed Cmax and 
AUC values for OZ78 twice as high as those for 
MT04, as well as a much more rapid Tmax. Despite its 
superior kinetic disposition, OZ78 failed again to cure 
infections with F. hepatica, while MT04 displayed a 
good fasciocidal activity. Here, I would like to bring 
additional elements to contribute answering to the 
questions left open in Chapter 2: why do we observe 
so different efficacy outcomes for OZ78 between rat 
and sheep? Is the mode of action of these peroxides 
linked to haem detoxification or does bile play a role 
as well? And finally, is MT04 still a valid fasciocidal 
candidate?
6.1.2 Rat and sheep, what is the difference for OZ78? 
Fasciocidal activity of OZ78 is very good in rats, with 
a single oral dose of 100 mg/kg resulting in a complete 
juvenile and adult WBR, and a dose of 50 mg/kg 
displaying a WBR slightly above 50% (Kirchhofer et 
al., 2011). When translating the optimal dose from the 
rat to the sheep, it was estimated that treating sheep 
with 50 mg/kg OZ78 was sufficient if not higher than 
necessary (Keiser et al., 2010). The outcome of this 
first experiment in sheep was however disappointing; 
no noticeable differences in WB could be observed 
between treated and control sheep. Also, PK values 
observed in sheep were much lower than expected 
from the rat. For example, in uninfected rats, the Cmax 
observed in plasma was 70.1 µg/ml after an oral dose 
of 50 mg/kg OZ78. In infected sheep treated orally 
with 50 mg/kg OZ78 (corresponding to slightly more 
than a 100 mg/kg dose in rats, as previously 
mentioned), the Cmax observed in plasma was only 45.8 
µg/ml. As emphasized by Keiser et al., 2010, the 
digestive system of rats and sheep displays 
considerable differences and can account for the 
treatment failure in sheep. The keratinised rumen is 
actually not designed for a good absorption of drugs, 
which can be substantially delayed by up to 15h due to 
the slow turn-over rate of the rumen (Toutain, Ferran 
and Bousquet-Melou, 2011). In the case of OZ78, 
absorption in another part of the gut can be considered 
minimal; the Tmax and t1/2 of 1h obtained after oral 
treatment are extremely rapid and point to a ruminal 
absorption of OZ78. Drug binding to cellulose from an 
herbivorous diet can also interfere with absorption. 
Since cellulose breakdown in the sheep gut occurs only 
after 50 h (Toutain, Ferran and Bousquet-Melou, 
2011), it might explain in part the lower AUC in sheep 
compared to rat.  
Oral and subcutaneous administration routes of OZ78 
in sheep have shown drastically different PK profiles 
at 50 mg/kg dose (Keiser et al., 2010). Oral application 
was characterised by a higher Cmax and a short t1/2, 
while subcutaneous administration had a slower 
absorption rate but a longer t1/2 and a twofold AUC 
value than oral application. The slow release observed 
with subcutaneous application is certainly due to the 
oily vehicle forming a depot under the skin, as 
suggested by Keiser et al., 2010. In the second study 
in sheep reported in Chapter 2, we obtained Cmax and 
Tmax values close to and an AUC smaller for 
intramuscular administration than for subcutaneous 
application, although the dose was doubled. There are 
obviously clear problems with the absorption of the 
peroxides with intra-muscular application. The fact 
that none of the PK parameters could be enhanced by 
doubling the dose and changing the administration 
route in the second sheep experiment points to a rate-
limiting absorption. Also a significant difference to 
keep in mind regarding the two studies in sheep is the 
use of both experimental and natural infections. 
Naturally infected sheep can display a much more 
severe liver pathology consecutive to chronic 
infections, while experimentally infected sheep would 
not present such extensive bile-duct calcifications and 
abscesses. Moreover, other concurring infections in 
naturally infected sheep (observed though not 
monitored) could have affected the kinetic disposition 
of the drug even more drastically than a simple 
experimental infection with F. hepatica. The role of 
the disease severity in causing a lower drug disposition 
is not easily explained. Investigating the PK profile of 
OZ78 in rats using intramuscular application instead 
of an oral dose would certainly help assessing whether 
a rate-limiting phenomenon or another factor is 
responsible for the low PK profile observed after a 
treatment with 100 mg/kg. 
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6.1.3 Haem or bile? Do we have enough hints to guess how peroxides act on F. hepatica? 
The synthetic peroxide library was first generated to 
provide potential antimalarial drug candidates on the 
basis of the chemical structure of artemisinin, and 
more precisely on the pharmacophoric peroxide bond. 
This peroxide bond is supposed to interfere with the 
detoxification process of haem, generating free 
radicals attacking the parasite (Vennerstrom et al., 
2004; Jefford, 2007). Yet it is not only Plasmodium 
spp., but also blood-feeding parasites such as F. 
hepatica that need to deal with haem toxicity, as a by-
product of erythrocyte digestion. Indeed, synthetic 
peroxides displayed very promising results against the 
liver flukes F. hepatica (Keiser et al., 2006; Jennifer 
Keiser et al., 2007) and C. sinensis (J Keiser et al., 
2007; Keiser et al., 2009; Keiser and Vargas, 2010), 
the blood flukes Schistosoma spp. (Xiao et al., 2007) 
and the intestinal fluke E. caproni (Keiser et al., 2006; 
Kirchhofer et al., 2011). In in vitro studies with F. 
hepatica, the effects of OZ78 on the worm tegument 
were already observed in medium without haemin. The 
addition of haemin to the culture medium containing 
OZ78, although producing more tegumental damage, 
did not accelerate worm death. It was hence postulated 
that an iron-independent pathway might contribute to 
the mechanism of action in worms (Keiser and 
Morson, 2008; Halferty et al., 2009). An investigation 
of the effects of artemisinins on a yeast model reveals 
at least two mechanisms of action; the first involves 
iron, as suggested earlier, while the second directly 
targets mitochondria under non-fermentative 
conditions (Moore et al., 2011).  
The direct environment of adult F. hepatica, the bile, 
might well act in synergy with synthetic peroxides to 
damage and ultimately kill the worms. Since OZ78 had 
already displayed inefficacy against F. hepatica in 
sheep, we hypothesised that its concentration in bile 
might be not sufficient to exert a fasciocidal effect. 
Therefore, in parallel to investigating the 
pharmacokinetics of OZ78 and MT04 in sheep plasma, 
we were able to assess their presence in sheep bile at 6 
h post-treatment. We observed that their concentration 
in bile was lower than in plasma by a factor of 5 and 2, 
respectively. However, since peroxides are secreted in 
bile in measurable amounts, a synergistic influence of 
bile on peroxide activity could not be ruled out. In a 
pilot project aiming to gain more insight into the mode 
of action of peroxides, we compared the in vitro 
fasciocidal effects of OZ78 and MT04 in presence of 
bile (5%) or haem-containing elements, as haemin and 
haemoglobin, at 80 µg/ml (unpublished observations). 
Peroxide concentration was set at 10 µg/ml, a value 
close to the Cmax observed in sheep plasma for OZ78, 
and two-fold higher than the Cmax of MT04. Adult 
worms recovered from cattle livers were incubated in 
triplicate in medium containing bile, haemoglobin or 
haemin and the peroxides. Their viability was assessed 
after 72 h incubation using a motility scale ranging 
from 3 (perfectly healthy) to 0 (dead).  
Surprisingly, the worms were already greatly affected 
when incubated with bile or haemin without the 
addition of peroxides. It is interesting to observe such 
deleterious effects of incubating worms with only 5% 
bile, considering that bile is their usual environment. 
Haemoglobin, on the other hand, is not as reactive as 
haemin, however a moderate effect on the worms was 
also observed. Worm viability in a haem-containing 
medium was not more compromised when peroxides 
were added. As observed by Keiser and Morson, 2008, 
haemin did not accelerate worm death when in contact 
with synthetic peroxides. In bile-containing medium, 
however, 10 µg/ml MT04 contributed to a slightly 
faster death of the worms. As previously mentioned, 
the presence of bile is clearly deleterious to the worm 
and adding peroxides to this incubation medium 
results in an earlier fasciocidal action. To summarize, 
MT04 at a concentration of 10 µg/ml, a two-fold 
higher concentration than the observed Cmax in sheep 
plasma, was not able to significantly act on the worms 
without the contribution of additional factors, such as 
haemin or bile. Repeating the experiment using much 
higher concentrations of peroxides, i.e. 100 µg/ml, 
might help to estimate whether the effect of bile is 
simply additive or synergistic. The help of scanning 
electron microscopy would also contribute to 
characterise the specific effects of bile with and 
without peroxides on the worm tegument, as it was 
done for haem. 
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Fig. 1 Comparison of motility values of worms incubated in bile-free medium vs. medium with 5% bile and the effect on worm motility of 
adding peroxides to the medium. 
 
 
Fig. 2 Comparison of worm motility between normal medium vs. medium containing different haem forms and effect of the addition of 
peroxides on worm motility 
Infection with liver flukes produces a tremendous 
reaction in the liver of the host, with a diminution of 
antioxidant enzymes and an increase in free radical 
production (Karsen et al., 2011; Bahrami, 
Esmaeilzadeh and Oryan, 2014). Hepatic fibrosis and 
biliary cholestasis can develop and have been shown 
to exacerbate the oxidative stress of the host (Bahrami, 
Esmaeilzadeh and Oryan, 2014). The liver and bile 
ducts become therefore a hostile environment for 
flukes, which have developed a collection of 
antioxidant enzymes as protection. They release these 
enzymes in great quantities in their excretory-
secretory (ES) products. Since they burrow deep in the 
bile duct tissues to reach blood vessels, the 
surrounding epithelium provides them with a 
protective pouch where they create a micro-
environment with high concentrations of antioxidant 
enzymes. When in contact with synthetic peroxides or 
artemisinin derivatives, the gut function of worms is 
greatly disturbed, impeding the absorption of essential 
nutrients to keep pace with their high metabolic rate 
(Halferty et al., 2009; O’Neill et al., 2015). Hence 
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starvation conditions might decrease the release of ES 
products, which might primarily affect the most 
posterior end of the parasite, the furthest to the mouth 
and most exposed to fresh bile. The starvation of the 
worm might also interfere with the natural renewal of 
the tegument, and here again the posterior end of the 
worm is less exposed to the protective effect of ES 
products. Considering all of the above, synthetic 
peroxides are therefore highly dependent on external 
factors, as haemin and bile, to achieve their fasciocidal 
effect. The exact mechanism of action however still 
needs further confirmation. 
6.1.4 What is the validity of MT04 as a drug candidate against trematodes? 
Due to their broad spectrum of activity, ranging from 
malaria and trematodes to herpes and cancer (Ho et al., 
2014), synthetic peroxides can present problems with 
toxicity. It was observed on several occasions that 
tetraoxanes are more problematic than trioxolanes 
(Kirchhofer, 2012; Cowan et al., 2015). Studies with a 
hepatic cell line demonstrated a limited toxicity of 
OZ78 but a higher toxicity of MT04, however still 
lower than observed for artesunate (Kirchhofer, 2012). 
In an experiment assessing the effect of artesunate on 
naturally infected sheep, two deaths were recorded. In 
the two studies using OZ78 in sheep, no lethal cases 
were observed with this compound (Keiser et al., 
2010; Meister et al., 2013). However, when treating 
naturally infected sheep with 100 mg/kg MOT04 
intramuscularly, one sheep (sheep number 4, one out 
of five) died 1 h after administration (not reported in 
Chapter 2). We were able to retrieve 3 blood samples 
from this individual between 25 min and 1 h post-
injection. The PK analyses revealed an extreme 
concentration of MT04 in plasma from the first sample 
on.  
 
 
 
Fig. 3 Log mean pharmacokinetic profile of MT04 in sheep after an intramuscular dose of 100 mg/kg with PK values of the sheep that displayed 
fatal toxicity (sheep 4) 
 
The most plausible explanation is a complete 
shutdown of the liver, which was not able to display a 
baseline detoxification/elimination of MT04. This 
event stresses the fragile condition of a chronically 
infected liver, probably not compatible with MT04 
treatment, at least at the concentration of 100 mg/kg. 
A way to decrease the risk of developing deleterious 
effects due to MT04 treatment would be to supplement 
the animal diet with antioxidants. For example, a diet 
consisting of flaxseed oil displayed a clear 
amelioration of the liver pathology and an appreciable 
WBR (Martinez-Perez et al., 2014). It still needs to be 
demonstrated that antioxidants would not interfere 
with MT04 activity. However, a protection of the liver 
with antioxidants would be greatly beneficial to 
fasciocidal therapy and would promote a faster 
recovery. Another solution would be to combine 
MT04 with other drugs of different mechanisms of 
action to lower the quantity of MT04 administered, as 
already tested with C. sinensis (Keiser et al., 2009). In 
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the case of F. hepatica, triclabendazole, acting on 
microtubules, could be a good candidate in regions 
with a low prevalence of phenotypes resistant to 
triclabendazole. A third alternative would be to 
combine MT04 with closantel, a flukicide marketed 
for veterinarian use that targets the parasite gut. It 
would be interesting to see whether these drugs would 
act synergistically since they target differently the 
same organ, the worm gut. Additionally, closantel is 
active only on biliary stages of the parasite (Hanna et 
al., 2015), while MT04 is also as well effective against 
migrating larvae (Kirchhofer et al., 2011). In 
conclusion, the fatal case of toxicity encountered with 
MT04 treatment in sheep should not cause its 
withdrawal as a fasciocidal drug candidate. Due to its 
double peroxidic bond, MT04 is already more potent 
than any trioxolane (Kirchhofer et al., 2011). Scaling 
down the treatment to 50 or 70 mg/kg would probably 
reduce its toxicity without compromising its activity, 
if indeed a rate-limiting phenomenon was present with 
the 100 mg/kg dose. An oral treatment combined with 
a sustained-release applicator placed in the rumen 
could also be an alternative to explore.
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6.2 Praziquantel 
6.2.1 Key findings  
Investigations on PZQ occupy a consequent part of my 
thesis (Chapters 3 to 5). The focus was to elucidate the 
role of each PZQ enantiomer and its main metabolite 
on trematocidal activity. The in vitro and in vivo 
activity assays were conducted on S. mansoni and the 
PK studies on Opisthorchis-infected patients. The use 
of S. mansoni over liver flukes for the activity assays 
is, besides from practical reasons (it is very difficult to 
obtain O. viverrini, since there are no labs maintaining 
its life cycle), that the scientific interest towards 
schistosomiasis is much higher. These activity results 
will be of great importance when performing PK 
studies on schistosomiasis, patients, currently 
undergoing in our team.  
The outcomes of the in vitro and in vivo assay 
designate R-PZQ as the eutomer, the enantiomer 
displaying the therapeutic effects, while S-PZQ does 
not seem to play any schistocidal role. The R 
configurations of the cis and trans main 
monohydroxylated metabolites of PZQ displayed 
some activity but at much higher concentrations than 
for R-PZQ. Their significance in the schistocidal 
activity of PZQ should be evaluated using PK studies 
in patients. The development of an enantioselective 
analytical method for PZQ is the first step in this 
direction. When validating the use of DBS technology 
as a PK tool, we analysed the PK profile of 9 patients 
infected with O. viverrini and treated orally with 3x 25 
mg/kg PZQ. We were surprised to observe that 
concentrations of R-trans-4-OH-PZQ were much 
higher than expected. Therefore, it is paramount to 
investigate the respective part of the metabolite and R-
PZQ in clearing trematode infections. Since the most 
detailed investigations on PZQ activity were done in S. 
mansoni, the first question that comes to mind is 
whether other PZQ-sensitive parasites would react to 
PZQ enantiomers and metabolites in the same way as 
S. mansoni. Then, in the second part of the discussion 
about PZQ, I would like to consider the main current 
challenges and limitations of PZQ.
6.2.2 Are investigations on PZQ activity transposable to other PZQ-sensitive parasites? 
PZQ is the standard treatment against most of 
flatworms. Aside from schistosomiasis and 
opisthorchiasis, PZQ cures other trematodes 
infections, such as the liver fluke C. sinensis, the lung 
flukes Paragonimus spp., and the intestinal flukes 
Fasciolopsis buksi, Echinostoma spp., Heterophyes 
heterophyes and Metagonimus spp. Interestingly, 
Fasciola spp. is the only known trematode genus 
refractory to PZQ therapy. PZQ is also highly efficient 
against most of the cestode species (Andrews, 1985; 
Cioli and Pica-Mattoccia, 2003).  
The investigation performed on the in vitro and in vivo 
activity of PZQ enantiomers and its main metabolites 
against S. mansoni (please see Chapter 3) were in line 
with the general opinion that R-PZQ was the main 
effector molecule. However, Irie et al., 1989, as well 
as Tanaka et al., 1989 found a clear effect of R-PZQ 
against S. japonicum, while for S. mansoni S-PZQ was 
driving most of the effects. The results obtained with 
S. mansoni are in complete disagreement with 
simultaneous and later publications (Xiao and Catto, 
1989; Staudt et al., 1992), but should not be given 
much importance as the experimental design and some 
inconsistencies in the result tables might be the cause 
of the confusion. Results with S. japonicum, on the 
other hand, are consistent with other publications, 
where a treatment with R-PZQ could cure S. japonica-
infected patients at half the dose of PZQ racemate (Wu 
et al., 1991; Liu et al., 1993). With the exception of 
studies with S. mansoni and S. japonicum, no further 
investigations of the activity of each PZQ enantiomer 
were conducted in other parasites. Since S. mansoni 
and S. japonicum display a clear agreement regarding 
enantiomer activity, we can postulate that a similar 
pattern occurs for all Schistosoma spp., and by 
extension to all PZQ-sensitive parasites. It actually 
seems very likely that the essential and specific 
receptor that PZQ targets conserved its chiral direction 
over evolution. In vitro investigations on R-PZQ 
activity with O. viverrini and E. caproni as 
representatives of trematode diversity would help in 
assessing the validity of this hypothesis. Of note, 
studies with S. haematobium and different S. mansoni 
isolates have been launched in our laboratories.  
The relative trematocidal activities between parent and 
metabolite enantiomers, and their comparison to PK 
values are also essential to understanding the 
modalities of PZQ action. Here again, investigations 
on the activity of PZQ metabolites are lacking in 
parasites other than S. mansoni. Although the polarity 
of the worm receptor to PZQ is not expected to change, 
different sensitivities to parent and metabolite 
molecules might be observed in PZQ-sensitive 
parasites. It would be very valuable to assess 
metabolite activity in O. viverrini, since we are 
performing an extensive population PK study in O. 
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viverrini-infected patients. The comparison of efficacy 
outcomes with PK data from the dose-finding study 
currently under analysis could be strengthened by the 
support of in vitro observations. 
6.2.3 Praziquantel, new challenges, same limitations? 
Since its advent on the market in the 1980s, PZQ 
treatment is based on kinetic and efficacy data 
collected in adults, while small children do not benefit 
from carefully tailored dosages. After decades of mass 
drug treatments in endemic countries, there is a strong 
incentive to include children, and especially pre-
school children, in targeted treatment programs. This 
population, although neglected by treatment programs, 
displays extremely high infection rates. Moreover, 
infections in the early age can compromise a child’s 
development and lead to an increased risk of 
irreversible chronic complications already at an early 
age (Stothard et al., 2013; Mutapi, 2015). The main 
drawbacks of PZQ when treating children are the tablet 
size and its very bitter taste. Tablets are manufactured 
as 600 mg tablets, which are difficult to swallow. To 
circumvent this difficulty, tablets are crushed to 
powder. However, the repulsive bitter taste of PZQ 
represents a challenge to swallow for many children, 
even mixed in very sweet and flavoured syrup. In 
2012, a public-private partnership including Merck, 
Astellas and the SwissTPH was created to develop a 
paediatric formulation of PZQ for pre-school children. 
This collaboration focuses on 3 main points: adapting 
the treatment dose to acceptable efficacy and safety 
levels, finding a way to mitigate the bitter taste and 
decreasing tablet size. These two last points rely on an 
enantiomeric formulation of PZQ. A tablet containing 
only the eutomer R-PZQ would be half as big as the 
racemic tablet for a most likely equivalent therapeutic 
potential. In a clinical trial in adults infected with S. 
japonicum, a treatment with R-PZQ achieved similar 
efficacy and fewer side effects than a conventional 
PZQ treatment (Wu et al., 1991). Moreover, removing 
S-PZQ from the tablets would ameliorate the overall 
taste (Meyer et al., 2009). The efforts invested for a 
paediatric formulation could ultimately be beneficial 
for other patients suffering from trematodiases if an 
enantiomeric formulation of PZQ would reduce the 
adverse events to nearly zero. Obviously, evidence of 
the relationship between S-PZQ and the type of 
adverse events (allergy, nausea, drowsiness) still needs 
to be collected. The challenge for the enantiomeric 
preparation compared to the original formulation is its 
cost. The additional steps to obtain pure R-PZQ are not 
so straightforward and efforts to optimise this process 
are underway (Woelfle et al., 2011). Chiral switch, i.e. 
switching from a racemic drug to an enantiomeric 
formulation, is of high interest for many modern drugs, 
because of the possibility to extend or present a new 
drug patent (Agranat, Caner and Caldwell, 2002). 
Although patenting is not in the scope of NTD drugs, 
the enormous knowledge currently generated for cost-
effective strategies to produce enantiomeric drugs 
would also be valuable for PZQ. A competitive price 
for the enantiomeric formulation is the cornerstone to 
a sustained effort against schistosomiasis.  
Resistance against PZQ is the subject of worries since 
the first report of PZQ treatment failure in Senegal in 
1994. For example, the refractory juvenile worms that 
survived a PZQ treatment later produce offspring with 
a decreased susceptibility to PZQ. However, since 
decades of intensive use and drug pressure in Africa 
and Asia, PZQ resistance does not appear to be 
occurring as fast as for other drugs (Caffrey, 2007; 
Wang, Wang and Liang, 2012). Actually, it seems that 
PZQ-resistant phenotypes are disadvantaged in terms 
of fitness compared to susceptible strains. As a 
consequence, traits conferring PZQ resistance are not 
able to fix permanently in the genome (Greenberg, 
2013). Some authors have proposed that 
schistosomiasis control instead of elimination 
programs hinders the emergence of resistance by 
maintaining foci of highly competitive PZQ 
susceptible strains. They anticipate that when 
implementing steps towards elimination and later 
perhaps even eradication of schistosomiasis, resistant 
phenotypes would then be able to take and hold the 
niche left by susceptible isolates. Monitoring 
resistance development becomes a difficult task when 
discussing PZQ. The mechanism of action of this drug 
remains a mystery, at least in part (Greenberg, 2005, 
2013). After exposure to PZQ, worms suffer a rapid 
influx of Ca2+ ions followed by muscular paralysis and 
tegumental damage, exposing parasite antigens to 
immune response. The identification of Ca2+ channels 
as PZQ receptors is however disputed. For example, 
cytocholasin D antagonises the effect of PZQ but does 
not block the influx of Ca2+ in the worm. Moreover, 
the expression of Ca2+ channel genes is not different 
between the refractory juveniles and the susceptible 
adults (Doenhoff, Cioli and Utzinger, 2008; Aragon et 
al., 2009; Greenberg, 2013). It seems that ABC 
transporters are involved in the uptake of PZQ and that 
a P-glycoprotein could be used as an efflux mechanism 
to evacuate PZQ (Messerli et al., 2009). Elucidating 
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the mode of action of PZQ would allow for predicting 
parasite’s strategies to develop resistance to PZQ. The 
identification of the target of PZQ, the means by which 
it accesses its receptor and the clarification of the 
downstream cascade of reactions would be highly 
valuable to generate new lead structures and new drug 
combinations minimising the resistance risks. It is not 
enough to stress out the importance of gathering more 
PK data in the target populations and link them to 
treatment efficacy. A thoroughly determined dosage is 
key against the emergence of resistance.  
For liver flukes, the situation is slightly more 
encouraging than for schistosomiasis, as clinical trials 
using the novel drug tribendimidine display equivalent 
results to PZQ trials (Soukhathammavong et al., 
2011). For chlonorchiasis and opisthorchiasis, a 
combination of social interventions and chemotherapy 
would in theory prevent new infections. Changes in 
eating habits are however extremely difficult to induce 
in regions where raw or fermented fish consumption is 
a strong cultural component (Sithithaworn and 
Haswell-Elkins, 2003; Sripa et al., 2010; Grundy-Warr 
et al., 2012). Interventions as health education 
demonstrated their efficacy but a sustained and more 
generalised effort is warranted. Until a strong societal 
change can occur, mass chemotherapy with PZQ or 
eventually later tribendimidine is vital to avoiding 
chronic complications, especially the 
cholangiocarcinoma. There are signs that PZQ 
treatment induces a transient increase in oxidative 
stress in hamsters (Pinlaor et al., 2008), but evidence 
needs to be collected for patients and its significance 
on the onset of cholangiocarcinoma should be 
evaluated. A comparative study of the adverse events 
of PZQ and tribendimidine with an emphasis on liver 
oxidative stress level should contribute to ameliorating 
the mass drug administration programs. 
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6.3 Technical Considerations 
As part of the general discussion of my thesis, it seems 
to me important to address some of the techniques I 
had the privilege to work with and to collaborate in 
developing in our research group, as for example the 
dried blood spot (DBS) technology. I would also like 
to give an outlook on the enantioselective analysis of 
chiral drugs and its relevance to drug development for 
neglected tropical diseases. Finally, the evaluation of 
the population PK analysis as a tool for drug 
development seems essential, as it is the next logical 
step of my investigations.  
6.3.1 Chiral analysis 
The enantioselective LC-MS/MS analysis of drugs 
faces significant challenges, such as the choice of the 
right chiral selector, sensitivity issues at the desired 
LLOQ, price or available column dimensions. For the 
chiral method development of PZQ, the major pitfall 
was to run plasma and blood samples. In contrast to 
traditional C18 columns that are relatively robust to 
sample impurities, the chiral columns used in our 
method display enlarged and split peaks after a few 
weeks of running blood or plasma samples extracted 
with acetonitrile. The implementation of a column 
switching system and regular column washes were not 
sufficient to give chiral columns a lifespan comparable 
to traditional ones. With respect to these observations, 
the choice of more sophisticated extraction methods, 
such as liquid-liquid extraction or solid phase 
extraction, should be weighed regarding handling time 
and respective costs of column and extraction material. 
Although some experience will still be gained over the 
next months, it seems that DBS extracts are much more 
compatible with chiral analysis than other acetonitrile-
extracted biofluids. This weakness of chiral columns, 
combined with a price twice as high as for traditional 
columns, encourages us to carefully consider the 
choice of chiral analysis.  
Enantioselective analysis can however bring valuable 
data, as it should be the case for our PZQ method. The 
possibility to study the kinetic disposition of each 
enantiomer of a drug gives a more detailed insight for 
adapting dosing strategies and for understanding 
factors ruling plasma concentrations. For example, 
albendazole (ABZ), the main drug against round 
worms, might be a good candidate. ABZ is 
metabolised by the CYP450 to ABZ-sulfoxide (ABZ-
SO), possessing a chiral center on the sulfure atom. 
ABZ-SO is further metabolised to ABZ-sulfone 
(ABZ-SO2) (Virkel et al., 2004). It seems that activity 
is shared between the parent ABZ and the ABZ-SO. 
For example, in neurocysticercosis, the R-form of 
ABZ-SO is the effective enantiomer (Paredes et al., 
2013). The conditions in which drug metabolism 
generates a particular enantiomeric ratio would be an 
additional point to investigate. Moreover, an 
enantioselective LC-MS/MS method is already 
available (del Nozal et al., 2002). 
6.3.2 DBS technology 
Dried blood spots are a remarkable technology for PK 
sampling. In the last decade, their use spread from 
metabolic disease screening to pharmacokinetic 
studies, therapeutic drug monitoring, immunoassays 
and epidemiological disease surveillance (Demirev, 
2013). The first challenge for DBS analysis is the 
evidently smaller amount of sample that can be 
extracted. For plasma, usually 100 µl are extracted 
with 300 µl organic solvent. In our DBS method, the 
typical volume of a blood spot is 20 µl. From this spot, 
only a portion of maximum 15 µl is punched out and 
further extracted with 300 µl organic solvent. There 
are many strategies to optimise analyte concentrations 
in the extract, such as evaporation and reconstitution 
or the pooling of samples, but the fact is that the 
starting amount of sample is nearly 10 times lower 
than in conventional plasma extraction. Even with the 
improvement of instrumentation and column quality, it 
is difficult to reach the same sensitivity as for plasma-
based methods; hence, when translating a plasma 
method to DBS, a 10 times higher LLOQ would be a 
reasonable starting point.  
The second major issue with DBS is the hematocrit. 
Blood viscosity alters the spread of the blood drop on 
the DBS card and therefore influencing the analyte 
concentration over the spot area (Xu et al., 2013). 
There have been several attempts to overcome this 
difficulty, by monitoring the blood spot potassium 
content (correlating with hematocrit) (De Kesel et al., 
2014), or by using pre-cut DBS cards (Meesters and 
Hooff, 2013) or the newcomer microsampling device 
(Spooner et al., 2015). Aside from blood viscosity 
problems caused by hematocrit, there are inherent 
caveats in switching from plasma to DBS. First, the 
drug partition might not be equivalent between plasma 
and blood or DBS. For example, some drugs, such as 
caffeine, do not bind to plasma proteins but have a high 
affinity for erythrocytes. Therefore, switching from 
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traditional plasma measurements to DBS would make 
the direct comparison between DBS-generated PK 
profiles and previously published studies more 
difficult. The kinetic profile measured in plasma will 
then be very different from the one observed in whole 
blood or DBS. In other cases, some drugs can have an 
equal affinity for plasma proteins and for erythrocytes. 
If the blood-cell partition remains constant across 
concentrations, the implications of switching to DBS 
are minimal. However, if there is a saturation of the 
binding sites of erythrocytes at high drug 
concentrations, PK measurements in plasma could be 
altered with plasma haemolysis. In this case, the use of 
blood or DBS over plasma is actually warranted. For 
PZQ, the drug is highly bound to plasma (80% 
(Gonzalez-Esquivel et al., 2005)) and does not display 
an affinity for erythrocytes. In this situation, the 
haematocrit value will influence the concentrations 
observed: the higher the number of erythrocytes, the 
higher the “dilution” of the drug will occur (Emmons 
and Rowland, 2010; Xu et al., 2013). When setting up 
a new DBS method for drugs in current use, most of 
the aforementioned parameters are already known. For 
new drugs or drug candidates, a drug partition assay 
could be easily implemented if needed.  
6.3.3 Population PK 
When dealing with patients with impaired liver 
function, as is the case for trematodiases, it is essential 
to understand the driving factors behind drug 
disposition. To address this issue, we worked in close 
collaboration with PK/PD modelists from the Swiss 
TPH to implement population PK clinical trials with 
tribendimidine and praziquantel in O. viverrini 
infected patients in Laos (currently being analysed). 
With population PK, in contrast to traditional PK 
analysis, it is possible to handle PK data originating 
from sparse sampling schemes, and at the same time to 
integrate and identify important factors influencing 
kinetic disposition in patients. The focus of this 
approach is to estimate PK parameters in the target 
population under field conditions, and to identify and 
quantify sources of kinetic variability, i.e. genetic, 
demographic, environmental or pathophysiological. 
This method generates a model describing PK 
parameters and integrating significant covariates. This 
model can later be applied and refined in further PK 
investigations. The advantage of this method is its 
great flexibility for handling sparse PK data, as well as 
pooling different trials together, as long as the raw data 
are available (Food and Drug Administration, 1999; 
Ette and Williams, 2004). Also, a tangible advantage 
of population PK is to optimise the sampling time 
points to meet field limitations, as the number of 
samples taken per patient or the specific time windows 
where sampling is difficult or impossible. This was the 
case for our tribendimidine study, where modelists 
provided us with optimised sampling time points 
according to previously generated PK data. Hence, we 
could only sample 5 time points per patient, instead of 
the conventional 8-10 time points used in traditional 
PK studies, without a significant loss of resolution. 
With the experience that is currently gained with these 
two trials, I am convinced that population PK will soon 
become a fundamental tool to assess PK data in 
diseased patients, especially in combination with the 
DBS technology. 
  
 
 
 
 
80 
6.4 References 
Agranat, I., Caner, H. and Caldwell, J. (2002) ‘Putting 
chirality to work: the strategy of chiral switches’, Nat 
Rev Drug Discov. 1(10), pp. 753–768.  
Andrews, P. (1985) ‘Praziquantel: mechanisms of 
anti-schistosomal activity’, Pharmacol Ther. 29(1), 
pp. 129–156.  
Aragon, A. D., Imani, R. A., Blackburn, V. R., Cupit, 
P. M., Melman, S. D., Goronga, T., Webb, T., Loker, 
E. S. and Cunningham, C. (2009) ‘Towards an 
understanding of the mechanism of action of 
praziquantel’, Mol Biochem Parasitol. 164(1), pp. 57–
65.  
Bahrami, S., Esmaeilzadeh, S. and Oryan, A. (2014) 
‘Role of oxidative stress in concomitant occurrence of 
Fasciola gigantica and leiomyoma in cattle’, Vet 
Parasitol. 203(1–2), pp. 43–50.  
Caffrey, C. R. (2007) ‘Chemotherapy of 
schistosomiasis: present and future’, Curr Opin Chem 
Biol. 11(4), pp. 433–439.  
Cioli, D. and Pica-Mattoccia, L. (2003) ‘Praziquantel’, 
Parasitol Res. 90 Supp 1, pp. S3-9.  
Cowan, N., Yaremenko, I. A., Krylov, I. B., Terent’ev, 
A. O. and Keiser, J. (2015) ‘Elucidation of the in vitro 
and in vivo activities of bridged 1,2,4-trioxolanes, 
bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides, 
silyl peroxides, and hydroxylamine derivatives against 
Schistosoma mansoni’, Bioorgan Med Chem, 23(16), 
pp. 5175-5181.  
Demirev, P. A. (2013) ‘Dried blood spots: analysis and 
applications’, Anal Chem. 85(2), pp. 779–789.  
Doenhoff, M. J., Cioli, D. and Utzinger, J. (2008) 
‘Praziquantel: mechanisms of action, resistance and 
new derivatives for schistosomiasis’, Curr Opin Infect 
Dis. 21(6), pp. 659–667.  
Emmons, G. and Rowland, M. (2010) 
‘Pharmacokinetic considerations as to when to use 
dried blood spot sampling’, Bioanalysis. 2(11), pp. 
1791–1796.  
Ette, E. I. and Williams, P. J. (2004) ‘Population 
pharmacokinetics I: background, concepts, and 
models’, Ann Pharmacother. 38(10), pp. 1702–1706.  
Gonzalez-Esquivel, D., Rivera, J., Castro, N., Yepez-
Mulia, L. and Jung Cook, H. (2005) ‘In vitro 
characterization of some biopharmaceutical properties 
of praziquantel’, Int J Pharm. 295(1–2), pp. 93–99.  
Greenberg, R. M. (2005) ‘Are Ca2+ channels targets 
of praziquantel action?’, Int J Parasitol. 35(1), pp. 1–
9.  
Greenberg, R. M. (2013) ‘New approaches for 
understanding mechanisms of drug resistance in 
schistosomes’, Parasitology. 140(12), pp. 1534–1546.  
Grundy-Warr, C., Andrews, R. H., Sithithaworn, P., 
Petney, T. N., Sripa, B., Laithavewat, L. and Ziegler, 
A. D. (2012) ‘Raw attitudes, wetland cultures, life-
cycles: Socio-cultural dynamics relating to 
Opisthorchis viverrini in the Mekong Basin’, Parasitol 
Int, 61(1), pp. 65–70.  
Halferty, L., O’Neill, J. F., Brennan, G. P., Keiser, J. 
and Fairweather, I. (2009) ‘Electron microscopical 
study to assess the in vitro effects of the synthetic 
trioxolane OZ78 against the liver fluke, Fasciola 
hepatica’, Parasitology. 136(11), pp. 1325–1337.  
Hanna, R. E., McMahon, C., Ellison, S., Edgar, H. W., 
Kajugu, P. E., Gordon, A., Irwin, D., Barley, J. P., 
Malone, F. E., Brennan, G. P. and Fairweather, I. 
(2015) ‘Fasciola hepatica: a comparative survey of 
adult fluke resistance to triclabendazole, nitroxynil and 
closantel on selected upland and lowland sheep farms 
in Northern Ireland using faecal egg counting, 
coproantigen ELISA testing and fluke histology’, Vet 
Parasitol. 207(1–2), pp. 34–43.  
Ho, W. E., Peh, H. Y., Chan, T. K. and Wong, W. S. 
(2014) ‘Artemisinins: pharmacological actions beyond 
anti-malarial’, Pharmacol Ther. 142(1), pp. 126–139.  
Irie, Y., Utsunomiya, H., Tanaka, M., Ohmae, H., 
Nara, T. and Yasuraoka, K. (1989) ‘Schistosoma 
japonicum and S. mansoni: ultrastructural damage in 
the tegument and reproductive organs after treatment 
with levo- and dextro-praziquantel’, Am J Trop Med 
Hyg. 41(2), pp. 204–211. 
Jefford, C. W. (2007) ‘New developments in synthetic 
peroxidic drugs as artemisinin mimics’, Drug Discov 
Today, 12(11), pp. 487–495.  
Karsen, H., Sunnetcioglu, M., Ceylan, R. M., 
Bayraktar, M., Taskin, A., Aksoy, N. and Erten, R. 
(2011) ‘Evaluation of oxidative status in patients with 
Fasciola hepatica infection’, Afr Health Sci. 11 Suppl 
1, pp. S14-8. 
Keiser, J., Kirchhofer, C., Haschke, M., Huwyler, J., 
Dong, Y., Vennerstrom, J. L., Vanhoff, K., Kaminsky, 
R. and Malikides, N. (2010) ‘Efficacy, safety and 
pharmacokinetics of 1,2,4-trioxolane OZ78 against an 
experimental infection with Fasciola hepatica in 
sheep’, Vet Parasitol. 173(3–4), pp. 228–235.  
Keiser, J. and Morson, G. (2008) ‘Fasciola hepatica: 
Surface tegumental responses to in vitro and in vivo 
treatment with the experimental fasciolicide OZ78’, 
Experimental Parasitology, 119(1), pp. 87–93.  
Keiser, J., Utzinger, J., Tanner, M., Dong, Y. and 
Vennerstrom, J. L. (2006) ‘The synthetic peroxide 
OZ78 is effective against Echinostoma caproni and 
Fasciola hepatica’, J Antimicrob Chemother. 58(6), 
pp. 1193–1197.  
Keiser, J., Utzinger, J., Vennerstrom, J. L., Dong, Y., 
Brennan, G. and Fairweather, I. (2007) ‘Activity of 
artemether and OZ78 against triclabendazole-resistant 
Fasciola hepatica’, Trans R Soc Trop Med Hyg, 
101(12), pp. 1219–1222.  
Keiser, J. and Vargas, M. (2010) ‘Effect of artemether, 
artesunate, OZ78, praziquantel, and tribendimidine 
alone or in combination chemotherapy on the 
81 
tegument of Clonorchis sinensis’, Parasitol Int. 59(3), 
pp. 472–476.  
Keiser, J., Xiao, S. H., Dong, Y., Utzinger, J. and 
Vennerstrom, J. L. (2007) ‘Clonorchicidal properties 
of the synthetic trioxolane OZ78’, J Parasitol. 93(5), 
pp. 1208–1213.  
Keiser, J., Xiao, S. H., Smith, T. A. and Utzinger, J. 
(2009) ‘Combination chemotherapy against 
Clonorchis sinensis: experiments with artemether, 
artesunate, OZ78, praziquantel, and tribendimidine in 
a rat model’, Antimicrob Agents Chemother. 53(9), pp. 
3770–3776.  
De Kesel, P. M., Capiau, S., Lambert, W. E. and Stove, 
C. P. (2014) ‘Current strategies for coping with the 
hematocrit problem in dried blood spot analysis’, 
Bioanalysis. 6(14), pp. 1871–1874.  
Kirchhofer, C. (2012) ‘Elucidation of the activity, 
pharmacokinetics,and toxicity profiles of fasciocidal 
drug candidates 1,2,4-trioxolane OZ78 and 1,2,4,5-
tetraoxane MT04’, PhD thesis, Faculty of Sciences. 
University of Basel.  
Kirchhofer, C., Vargas, M., Braissant, O., Dong, Y., 
Wang, X., Vennerstrom, J. L. and Keiser, J. (2011) 
‘Activity of OZ78 analogues against Fasciola hepatica 
and Echinostoma caproni’, Acta Trop. 118(1), pp. 56–
62.  
Liu, Y. H., Qian, M. X., Wang, X. G., Quan, Y. Z., 
Yan, S. H., Chen, B. Y., Li, J. S. and Qiu, Z. Y. (1993) 
‘Levo-praziquantel versus praziquantel in 
experimental and clinical treatment of schistosomiasis 
japonica’, Chin Med J (Engl). 106(8), pp. 593–596. 
Martinez-Perez, J. M., Robles-Perez, D., Benavides, 
J., Moran, L., Andres, S., Giraldez, F. J., Rojo-
Vazquez, F. A. and Martinez-Valladares, M. (2014) 
‘Effect of dietary supplementation with flaxseed oil or 
vitamin E on sheep experimentally infected with 
Fasciola hepatica’, Res Vet Sci. 97(1), pp. 71–79.  
Meesters, R. J. and Hooff, G. P. (2013) ‘State-of-the-
art dried blood spot analysis: an overview of recent 
advances and future trends’, Bioanalysis. 5(17), pp. 
2187–2208.  
Meister, I., Duthaler, U., Huwyler, J., Rinaldi, L., 
Bosco, A., Cringoli, G. and Keiser, J. (2013) ‘Efficacy 
and pharmacokinetics of OZ78 and MT04 against a 
natural infection with Fasciola hepatica in sheep’, Vet 
Parasitol, 198(1), pp. 102–110.  
Messerli, S. M., Kasinathan, R. S., Morgan, W., 
Spranger, S. and Greenberg, R. M. (2009) 
‘Schistosoma mansoni P-glycoprotein levels increase 
in response to praziquantel exposure and correlate with 
reduced praziquantel susceptibility’, Mol Biochem 
Parasitol. 167(1), pp. 54–59.  
Meyer, T., Sekljic, H., Fuchs, S., Bothe, H., 
Schollmeyer, D. and Miculka, C. (2009) ‘Taste, a new 
incentive to switch to (R)-Praziquantel in 
schistosomiasis treatment’, PLoS Negl Trop Dis. 3(1), 
p. 357. 
Moore, C. M., Hoey, E. M., Trudgett, A. and Timson, 
D. J. (2011) ‘Artemisinins act through at least two 
targets in a yeast model’, FEMS Yeast Res. 11(2), pp. 
233–237.  
Mutapi, F. (2015) ‘Changing policy and practice in the 
control of pediatric schistosomiasis’, Pediatrics. 
135(3), pp. 536–544.  
del Nozal, M. J., Toribio, L., Bernal, J. L., Nieto, E. M. 
and Jiménez, J. J. (2002) ‘Separation of albendazole 
sulfoxide enantiomers by chiral supercritical-fluid 
chromatography’, J Biochem and Bioph Meth, 54(1), 
pp. 339–345.  
O’Neill, J. F., Johnston, R. C., Halferty, L., Brennan, 
G. P. and Fairweather, I. (2015) ‘Ultrastructural 
changes in the tegument and gut of adult Fasciola 
hepatica following in vivo treatment with artesunate’, 
Exp Parasitol. 154, pp. 143–154.  
Paredes, A., de Campos Lourenco, T., Marzal, M., 
Rivera, A., Dorny, P., Mahanty, S., Guerra-Giraldez, 
C., Garcia, H. H., Nash, T. E. and Cass, Q. B. (2013) 
‘In vitro analysis of albendazole sulfoxide enantiomers 
shows that (+)-(R)-albendazole sulfoxide is the active 
enantiomer against Taenia solium’, Antimicrob Agents 
Chemother. 57(2), pp. 944–949.  
Pinlaor, S., Prakobwong, S., Hiraku, Y., Kaewsamut, 
B., Dechakhamphu, S., Boonmars, T., Sithithaworn, 
P., Pinlaor, P., Ma, N., Yongvanit, P. and Kawanishi, 
S. (2008) ‘Oxidative and nitrative stress in 
Opisthorchis viverrini-infected hamsters: an indirect 
effect after praziquantel treatment’, Am J Trop Med 
Hyg. 78(4), pp. 564–573.  
Sithithaworn, P. and Haswell-Elkins, M. (2003) 
‘Epidemiology of Opisthorchis viverrini’, Acta Trop, 
88(3), pp. 187–194.  
Soukhathammavong, P., Odermatt, P., Sayasone, S., 
Vonghachack, Y., Vounatsou, P., Hatz, C., 
Akkhavong, K. and Keiser, J. (2011) ‘Efficacy and 
safety of mefloquine, artesunate, mefloquine-
artesunate, tribendimidine, and praziquantel in patients 
with Opisthorchis viverrini: a randomised, 
exploratory, open-label, phase 2 trial’, Lancet Infect 
Dis. 11(2), pp. 110–118.  
Spooner, N., Denniff, P., Michielsen, L., De Vries, R., 
Ji, Q. C., Arnold, M. E., Woods, K., Woolf, E. J., Xu, 
Y., Boutet, V., Zane, P., Kushon, S. and Rudge, J. B. 
(2015) ‘A device for dried blood microsampling in 
quantitative bioanalysis: overcoming the issues 
associated blood hematocrit’, Bioanalysis. 7(6), pp. 
653–659.  
Sripa, B., Kaewkes, S., Intapan, P. M., Maleewong, W. 
and Brindley, P. J. (2010) ‘Food-borne trematodiases 
in Southeast Asia epidemiology, pathology, clinical 
manifestation and control’, Adv Parasitol. 72, pp. 305–
350.  
Staudt, U., Schmahl, G., Blaschke, G. and Mehlhorn, 
H. (1992) ‘Light and scanning electron microscopy 
studies on the effects of the enantiomers of 
82 
praziquantel and its main metabolite on Schistosoma 
mansoni in vitro’, Parasitol Res. 78(5), pp. 392–397. 
Stothard, J. R., Sousa-Figueiredo, J. C., Betson, M., 
Bustinduy, A. and Reinhard-Rupp, J. (2013) 
‘Schistosomiasis in African infants and preschool 
children: let them now be treated!’, Trends Parasitol. 
29(4), pp. 197–205.  
Tanaka, M., Ohmae, H., Utsunomiya, H., Nara, T., 
Irie, Y. and Yasuraoka, K. (1989) ‘A comparison of 
the antischistosomal effect of levo- and dextro-
praziquantel on Schistosoma japonicum and S. 
mansoni in mice’, Am J Trop Med Hyg. 41(2), pp. 198–
203. 
Toutain, P. L., Ferran, A. and Bousquet-Melou, A. 
(2011) ‘Species differences in pharmacokinetics and 
pharmacodynamics’, Handb Exp Pharmacol. (199), 
pp. 19–48.  
U.S. Department of Health and Human Services, Food 
and Drug Administration. (1999) ‘Guidance for 
industry on Population Pharmacokinetics’. Food and 
Drug Administration Fed Regist. 64(27), pp. 6663–
6664. 
Vennerstrom, J. L., Arbe-Barnes, S., Brun, R., 
Charman, S. A., Chiu, F. C., Chollet, J., Dong, Y., 
Dorn, A., Hunziker, D., Matile, H., McIntosh, K., 
Padmanilayam, M., Santo Tomas, J., Scheurer, C., 
Scorneaux, B., Tang, Y., Urwyler, H., Wittlin, S. and 
Charman, W. N. (2004) ‘Identification of an 
antimalarial synthetic trioxolane drug development 
candidate’, Nature. 430(7002), pp. 900–904.  
Virkel, G., Lifschitz, A., Sallovitz, J., Pis, A. and 
Lanusse, C. (2004) ‘Comparative hepatic and 
extrahepatic enantioselective sulfoxidation of 
albendazole and fenbendazole in sheep and cattle’, 
Drug Metab Dispos. 32(5), pp. 536–544.  
Wang, W., Wang, L. and Liang, Y. S. (2012) 
‘Susceptibility or resistance of praziquantel in human 
schistosomiasis: a review’, Parasitol Res. 111(5), pp. 
1871–1877.  
Woelfle, M., Seerden, J. P., de Gooijer, J., Pouwer, K., 
Olliaro, P. and Todd, M. H. (2011) ‘Resolution of 
praziquantel’, PLoS Negl Trop Dis, 5(9), p. e1260. 
Wu, M. H., Wei, C. C., Xu, Z. Y., Yuan, H. C., Lian, 
W. N., Yang, Q. J., Chen, M., Jiang, Q. W., Wang, C. 
Z., Zhang, S. J. and et al. (1991) ‘Comparison of the 
therapeutic efficacy and side effects of a single dose of 
levo-praziquantel with mixed isomer praziquantel in 
278 cases of schistosomiasis japonica’, Am J Trop Med 
Hyg. 45(3), pp. 345–349. 
Xiao, S. H. and Catto, B. A. (1989) ‘Comparative in 
vitro and in vivo activity of racemic praziquantel and 
its levorotated isomer on Schistosoma mansoni’, J 
Infect Dis. 159(3), pp. 589–592. 
Xiao, S. H., Keiser, J., Chollet, J., Utzinger, J., Dong, 
Y., Endriss, Y., Vennerstrom, J. L. and Tanner, M. 
(2007) ‘In vitro and in vivo activities of synthetic 
trioxolanes against major human schistosome species’, 
Antimicrob Agents Chemother. 51(4), pp. 1440–1445.  
Xu, Y., Woolf, E. J., Agrawal, N. G., Kothare, P., 
Pucci, V. and Bateman, K. P. (2013) ‘Merck’s 
perspective on the implementation of dried blood spot 
technology in clinical drug development - why, when 
and how’, Bioanalysis. 5(3), pp. 341–350.
 
 
83 
 
 
 
 
Chapter 7 
 
 
General conclusion 
 
 
 
 
84 
The aim of this thesis was to contribute to drug development against trematodiases, with an emphasis on 
pharmacokinetic studies. Analytical methods were developed to study kinetic disposition of praziquantel in 
Opisthorchis-infected patients and of lead peroxide candidates in sheep suffering from fascioliasis. In the former 
case, PK studies aimed to elucidate the disposition of each enantiomer of a drug, while in the latter, PK 
investigations intended to understand problems with drug efficacy. Also, in vitro and in vivo studies of PZQ 
enantiomers on different parasitic stages will be an appreciable support for a future paediatric formulation of PZQ. 
Finally, the implementation of DBS is a critical step for performing large-scale PK trials in rural settings, as 
population PK studies, and allowing future PK investigations in small children, where the amount of blood to be 
sampled is strictly limited.  
Investigating on one hand the gold standard PZQ and on the other hand two lead candidates, offers an excellent 
occasion to stress out the importance of gaining knowledge on existing drugs while promoting the advent of new 
drugs. In the same direction, as much as human and veterinary medicine are independent disciplines, drug 
development actively profits from investigation in either field to find new drug candidates. Even with the recent 
progress in genomics and proteomics, the biology of helminths is still poorly understood, which makes the 
endeavour of finding new targets extremely difficult and time-consuming. This is urgent matter, as resistance risks 
are increasing with time and only very few drug candidates are being developed to provide alternatives to existing 
drugs. The burden of the neglected tropical diseases is extremely high, especially among children, hence 
jeopardizing efforts towards future social and economic progresses. The growing awareness of the public and 
private sector towards neglected tropical diseases however gives some hope to see trematode infections step 
backwards.  
